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ABSTRACT 
Events at embryonic implantation play a key role in the establishment of 
successful pregnancy. Not only is delayed implantation associated with an 
increased incidence of early pregnancy loss, but may also be associated with 
impaired trophoblastic invasion and uteroplacental insufficiency. Furthermore, 
uteroplacental vascular mal-adaptation may also be affected by pre-existing 
maternal cardiovascular function and associated with maternal cardiovascular 
maladaptation during pregnancy. There is limited understanding of events 
surrounding human implantation because of the difficulties in conducting 
prospective studies from prior to pregnancy and an inability to study events at 
the trophoblast-decidual interface in vivo. 
The primary objective of this study was to test the feasibility of being able to 
conduct and complete a prospective study from prior to pregnancy to the 
postpartum period combining measures of ovulation, implantation, ultrasound 
measurements of fetal size and cardiovascular changes during pregnancy. 
The secondary objective was to investigate ovulation and implantation timing 
using digital home ovulation and pregnancy test kits along with cardiovascular 
changes in relation to various pregnancy complications and fetal growth to 
determine the power for a future prospective study. 
This was a prospective cohort feasibility study of 143 women planning to 
conceive. Pre-pregnancy cardiovascular function was investigated in all 
women. We observed ovulation, implantation timing in 101 pregnancies and 
investigated the relationship between implantation timing, embryonic and fetal 
growth, birthweight and length of gestation in the 69 viable pregnancies. 
Longitudinal cardiovascular changes in viable pregnancies were examined in 
relation both to previous obstetric history and index pregnancy outcome.  
Normal pregnancy was associated with profound cardiovascular changes, 
beginning from 6 weeks of gestation. Delayed implantation was associated 
with early pregnancy loss and a smaller first trimester fetal size. The 
incremental rise in cardiac output from before pregnancy to its peak in the 
second trimester was associated with birthweight.  
 iii 
It is feasible to conduct and complete a prospective study from prior to 
pregnancy to the postpartum period. Larger prospective studies of this nature 
will enable an understanding of the events surrounding implantation including 
the ‘cause and effect’ relationship of cardiovascular function with pregnancy 
complications such as preeclampsia and fetal growth restriction. 
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1.1  Background of the study 
Pregnancy complications range from those arising in early pregnancy such as 
miscarriage, to late pregnancy complications such as preeclampsia (PE) and 
intrauterine growth restriction (IUGR). Increasingly, the role of events around 
implantation is being highlighted in the etiology of recurrent early pregnancy 
loss1,2 and in placental insufficiency in PE3,4 and/or IUGR.  
Normal implantation is the key step for the establishment of a successful 
pregnancy. The process of implantation is a result of a complex interaction 
between endometrium and the blastocyst, regulated by numerous endocrine, 
paracrine and autocrine signals.5 Lack of endometrial preparedness, impaired 
communication between the embryo and the endometrium at the time of 
implantation and impaired trophoblastic invasion are likely to be pivotal in the 
disease process of recurrent miscarriage (RM).2 This hypothesis is supported 
by an increased incidence of early pregnancy loss in cases with delayed 
implantation6 and the association of RM with an increased risk of PE or IUGR 
in subsequent successful pregnancies.7-9 
Although PE and IUGR are different pregnancy specific complications with 
varied maternal manifestations, both have underlying abnormalities of 
placental function.10-12 Impaired trophoblastic invasion of the spiral arterioles, 
beginning around the time of implantation, and leading to impaired spiral 
artery remodelling and abnormal placentation is implicated in the aetiology of 
PE and IUGR.3,13 Impaired trophoblastic invasion is seen even in women with 
spontaneous miscarriage.14,15 This might explain the higher incidence of PE in 
women with unexplained sub fertility or recurrent miscarriage.16,17 Therefore, it 
is plausible that impaired placentation and pregnancy complications such as 
PE and IUGR are also accompanied by delayed implantation.  
Furthermore, pre-existing maternal cardiovascular function and maternal 
hemodynamic forces may also affect implantation events, trophoblastic 
invasion and uteroplacental vascular remodelling. This hypothesis is 
supported by the association of abnormal maternal cardiovascular 
parameters18-20 and uterine artery Doppler (reflecting uteroplacental 
impedance) early in pregnancy in women who go on to develop PE or 
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IUGR.21-23 Therefore, it is plausible that maternal systemic cardiovascular 
maladaptation may occur as early as at the time of implantation.  
Profound maternal cardiovascular changes are seen as early as 5-6 weeks in 
normal pregnancy.24-26 Pregnancies complicated by IUGR are associated with 
deficient plasma volume expansion very early in pregnancy.19 Those 
complicated by preeclampsia are associated with higher cardiac output as 
early as 10-14 weeks, much before the fetal and maternal manifestations of 
the syndrome.27,28 The relationship between implantation and cardiovascular 
changes is poorly understood in both normal and pregnancies complicated by 
uteroplacental insufficiency. Moreover, there are few prospective studies of 
maternal cardiovascular adaptation during normal pregnancies and pregnancy 
complications beginning from prior to conception.  
Women with a history of both early and late pregnancy complications are also 
at increased risk of subsequent cardiovascular disease (CVD).29-33 It has been 
suggested that this could be due to the deleterious effect of cardiovascular 
maladaptation in pregnancy complications but endothelial dysfunction, 
vascular disease or cardiovascular risk profile may already exist.34 This may 
predispose these pregnancies to altered embryo-endometrial interaction, 
abnormal trophoblastic invasion and placental disease.  
Our understanding of the events around natural human conception and 
implantation is very limited due to difficulties in conducting prospective studies 
of pregnancy where conception, implantation timing can be identified and the 
embryo-endometrial interaction can be studied in vivo. A prospective pre-
pregnancy to postpartum study of comprehensive cardiovascular function 
combining markers of ovulation, implantation and ultrasound measures of fetal 
size and growth, would be an ideal study design to understand the biological 
process of pregnancy, identify the cause and effect relationship between 
implantation, cardiovascular function and pregnancy outcomes.  
Improved understanding of the events around implantation, pre-pregnancy 
cardiovascular function and dynamics of the early pregnancy changes in 
maternal cardiovascular function may help to provide indirect insight into the 
pathophysiology of placentation. This may improve the ability to treat disorders 
related to implantation and placentation such as early pregnancy loss, PE or 
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IUGR, improve screening for PE and may lead to the development of new 
interventions in the pre-pregnancy period to prevent PE. An improved 
understanding of changes in the postpartum period may also enable to 
understand mechanisms of cardiovascular disease and prevention of CVD by 
controlling postpartum risks and early treatment opportunities.  
The problems of conducting prospective studies from prior to pregnancy have 
been highlighted in the past.35 Most pregnancies are uncomplicated and 
therefore, a large cohort of healthy women will need to be recruited to have 
sufficient power for pregnancy complications. A percentage of women may not 
conceive during the period of the study and amongst those who conceive, one 
third will miscarry.36 Moreover, there may be a significant “drop out” rate, 
quoted to be about 3 out of 4 in a large pre-pregnancy study.37  
The primary objective of this study was to test the feasibility of being able to 
recruit, conduct and complete a prospective pre-pregnancy to postpartum 
study, using digital home ovulation and pregnancy test kits to determine 
ovulation, implantation timing, serial ultrasound measures of embryonic and 
fetal growth and investigating changes in maternal cardiovascular function 
from prior to pregnancy using non-invasive tests. The secondary objective was 
to identify the trends in ovulation, implantation timing along with the pattern of 
cardiovascular changes in normal pregnancies, in women with previous 
history of RM, PE/IUGR and in those with PE/IUGR in their current pregnancy 
to provide information in order to enable us to determine power for a future 
prospective study. 
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1.2 Implantation  
The process of implantation is as a result of interaction between the 
developing embryo and a receptive endometrium. There is a 25-30% 
probability of clinical pregnancy in a given menstrual cycle.38 About a third of 
pregnancies are lost even before being recognized as clinical pregnancies.36 
The events that lead to the formation of a conceptus involve ovulation followed 
by fertilization. The conceptus then develops into a morula and reaches the 
endometrial cavity and is implanted in a primed endometrium. The exact 
process of human conception, implantation, the timing of implantation and 
factors affecting the process of implantation in spontaneous conception are 
not well understood in humans. Much of the understanding of early human 
development comes from animal models, which may not be exactly 
representative of the steps in the process of human implantation.39  
 
1.2.1 Ovulation 
Ovulation is considered as a marker of ovarian function.40 Determination of the 
ovulation day is important in longitudinal epidemiological studies of menstrual 
and reproductive function and to help in understanding the biological 
processes of pregnancy. The World Health Organization (WHO) Task Force 
on methods for the determination of the fertile period determined the temporal 
relationships between ovulation and changes in the concentration of plasma 
estradiol-17ß, LH, FSH and progesterone where ovulation was determined by 
morphological examination and biopsy of ovaries at laparotomy.41 Ovulation 
could be predicted in 90% of cases within -3(±5) hours and 36(±5) hours of 
plasma LH surge.41 Various other methods have been used to estimate 
ovulation such as, patient-performed charting of basal body temperature, 
cervical mucus scoring and daily mid-cycle sonographic monitoring of follicle 
development.42-44 These methods may not be very reliable, are time-
consuming and expensive.  Estimation of ratio of urinary estrone-3-
glucuronide and pregnanediol-3-glucuronide, is concordant with the day of 
peak urinary LH, with marked reduction of this ratio suggestive of the luteal 
phase transition, which can be reliably used in epidemiological studies.40,45 
Daily urinary LH testing is a reliable, simple and useful predictor of ovulation 
within 20 ± 3 hours [95% confidence intervals (CI);14-26] of LH surge with a 
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positive predictive value for ovulation within 0 to 24 hours being 73%(95% CI; 
70.9%-74.7%) and 92%(95% CI; 89.8-93.6%) at 48 hours.46 
1.2.2 Fertilization 
The process of fertilization, involves interaction between sperm and oocyte. 
Neither do we know much about events around human conception nor do we 
have a reliable marker of detecting conception in vivo. Most of the 
spermatozoa may reach the mature oocyte within 1 hour after 
insemination.47,48 A population of viable spermatozoa then becomes 
established in the isthmus of the fallopian tube and fertilizing potential is 
maintained by being stabilized by interaction between the isthmic epithelium 
and the spermatozoa.49-51 The spermatozoa undergo the process of complex 
changes over a few hours, followed by the fusion of the acrosomal membrane 
of the sperm to the zona pellucida. This allows a series of events involving 
various receptors and mediators resulting in fusion of the male and female 
pronucleus to form a two-cell zygote.47 The zygote undergoes a series of 
mitotic divisions and after three to four divisions the zygote is known as the 
morula, which then enters the uterus at 12 to 16 cell stage.52  
Fertilization can occur only around the time of ovulation and is likely if 
intercourse occurs within 5 days before and on the day of ovulation itself 
(Figure 1.2).53 In the North Carolina study,53 the probability of conception 
progressively increased from about five days before ovulation to the day of 
ovulation, followed by a rapid drop after ovulation.53 The drop in probability of 
conception after ovulation may be due to short survival time for ova believed 
to be about 12-24 hours after ovulation54 or perhaps a change in the cervical 
mucus after ovulation that obstructs entry of other sperm. The sperm retains 
the ability to fertilize an ovum for about five days in the female reproductive 
tract.  
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Figure 1.2 Probability of conception in relation to the ovulation day. The highest 
probability of conception is if the day of intercourse is 24 or 48 hours before the day of 
ovulation. The bold black line represents all the pregnancies and the red line 
represents the day of ovulation. (Adapted from Wilcox A.J. et al Post-ovulatory aging 
of the human oocyte and embryo failure. Human Reproduction. 1998;13:2:394-
397)
54,55
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1.2.3 Pre-implantation conceptus 
After fertilization the two-cell zygote develops into a 12 to 16 cell mass, known 
as the morula. The morula reaches the uterine cavity about 2 to 3 days after 
fertilization. Approximately five days after ovulation, the morula differentiates 
into a blastocyst with the appearance of a fluid-filled inner cavity and cellular 
differentiation of surface cells into trophectoderm, which contributes to 
development of the placenta, and the inner cell mass which gives rise to the 
embryonic structures. The embryo (blastocyst) undergoes a sequence of 
events to enhance its ability to implant in a receptive endometrium by about 6 
days following fertilization.5  
 
 
 
 
 
Figure 1.3: Timescale of events leading to implantation: Ovulation, fertilization 
and implantation (Adapted from Internet: google images by Alexis Dixis 2003) 
 
Fertilization: 
12-24 hours 
Ovulation 
Implantation: By 
6 days post-
ovulation 
Blastocyst: About 5 
days post-ovulation 
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1.2.4 Implantation 
The human endometrium undergoes histological, biological and physiological 
changes during the menstrual cycle, which enable the endometrial tissue to be 
receptive for blastocyst adhesion.56 The maximum endometrial receptivity is 
acquired during the mid-secretory phase about one week after ovulation and 
lasts for about 2 to 7 days in humans.57,58 Further changes continue during the 
process of implantation, which include proliferation, differentiation of epithelial 
cells, structural changes, enhanced secretory activity of the endometrial 
glands, and increased vascularity. As a result of this the endometrial cells in 
the vicinity of the implantation site are transformed into decidual cells.  
Regulation of events: The molecular mechanisms regulating the events 
around human implantation remain elusive. Hormones such as 17ß estradiol, 
progesterone and human chorionic gonadotrophin (hCG), maternally-derived 
growth factors secreted by uterine glands such as leukemia inhibiting factor 
(LIF), cytokines and growth factors secreted by the trophoblastic cells are 
examples of factors associated with implantation and maintenance of early 
pregnancy.5  
Measures of implantation: The precise measures of implantation are not 
simple. The best in vivo measure of human implantation is hCG hormone. It is 
produced by the trophoblast surrounding the blastocyst and is secreted into 
the maternal circulation at the time of implantation.59 It has a luteotrophic 
action and rescues the corpus luteum to produce increasing quantities of 
steroid hormone and thus maintain the pregnancy.  
HCG subunits are already transcribed in six to eight-cell embryos,60 and hCG 
becomes first detectable in the maternal circulation about 6 to 8 days 
postconception.61 The first detection of hCG in the urine or maternal plasma 
may indicate successful implantation and the exponential rise in the maternal 
serum or urine hCG represents successful invasion of the maternal tissue by 
the conceptus although this may not be the earliest step in implantation.61 The 
urinary hCG pattern during the first week following implantation may reflect the 
efficacy of placentation process.62 Absolute hCG values in maternal serum 
and urine, the rates of rise in hCG hormone levels in the maternal serum and 
urine have been associated with the embryo’s genetic quality, site of 
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implantation i.e. intrauterine pregnancy or ectopic pregnancy63,64 and 
development of the pregnancy. 
Ovulation to implantation (O-I) interval: The average timing between estimated 
day of ovulation to estimated day of implantation in spontaneous conception 
ranges from 6 to 12 days (mean 9.1± 1.12 days) using changes in urinary 
excretion of estrone 3-glucoronide and pregnanediol 3- glucuronide as 
indicator of ovulation and first detection of urinary hCG as indicator of 
implantation.6  
Factors affecting O-I interval: It is plausible that the O-I interval is affected by 
the quality of the conceptus or endometrial receptivity. Later implantation is 
associated with increased risk of early pregnancy loss less than 6 weeks.6 The 
time to implantation is also a significant predictor of the pattern of hCG rise in 
the first week after conception, when the process of placentation occurs.65 
Early implantation is associated with lower hCG levels on the day of 
implantation but higher rates of increase during the first week whereas late 
implantation is associated with a slower rise of hCG: an association that may 
suggest that time to implantation is related to embryo quality.65 Since, the 
process of placentation begins in the first week as well, it is plausible that 
delayed implantation is also accompanied by less successful placentation and 
may be associated with conditions such as PE/IUGR. 
Timing to implantation is also affected by a number of maternal factors. 
Current smoking and longer time between oocyte release and fertilization are 
associated with late implantation and increased incidence of early pregnancy 
loss.66 A steeper rise in hCG is noted in the first week of pregnancy in women 
older than 29 years of age.66  
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1.3 Placentation  
The process of placental development (placentation) begins following 
trophoblastic invasion of the endometrium at implantation.  The human 
placenta is haemochorial because there is direct contact between maternal 
blood and chorionic (fetal) villi in the intervillous space. Therefore, 
establishment of optimal uteroplacental blood flow is a crucial step of human 
placentation.  
As the blastocyst penetrates into the uterine epithelium, the trophoblastic cells 
differentiate into outer syncytiotrophoblast and inner cytotrophoblast. Lacunae 
in the syncytium form the intervillous spaces of the definitive placenta after 
establishment of the uteroplacental circulation. The trabeculae of 
syncytiotrophoblast develop into primary villi protruding in the intervillous 
spaces and later form secondary and tertiary villi. 
Subsequently, both the trophoblastic cells differentiate further into villous and 
extravillous trophoblast. Those in contact with maternal blood are known as 
villous trophoblast and are involved in the transport of nutrients, oxygen to the 
fetus and secretion of hormones and proteins. The extravillous trophoblast 
forms placental anchoring villi, which anchor the fetal trophoblastic cells to the 
underlying decidua. These extravillous trophoblastic cells also invade the 
spiral arteries and make up the endovascular trophoblast. This extravillous 
trophoblastic invasion occurs as a two-wave phenomenon in the human:3,67-69 
the endovascular trophoblast appears in the decidual parts of the spiral 
arteries early in pregnancy upto the deciduo-myometrial junction, and 14-15 
weeks onwards the myometrial spiral arteries are invaded by the endovascular 
trophoblast. 
1.3.1 Histiotrophic embryonic nutrition 
Although the process of endovascular invasion begins at about 7 to 8 weeks 
of gestation, maternal blood flow to the placenta is only fully established at 
about 10-12 weeks.70,71 The low oxygen environment, facilitated by plugs of 
cytotrophoblastic cells may protect the developing embryo from free radical 
mediated damage.72 Loss of these trophoblastic plugs has been shown to be 
associated with early miscarriage, or, dependent upon the timing, associated 
with preeclampsia.72,73 The first trimester embryonic growth and development 
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is dependent upon nutrition derived from the endometrium and uterine glands, 
which is known as ‘histiotrophic’ nutrition.74 
 
Figure 1.4 Schematic diagram of histiotrophic nutrition of the embryo till 8 to 10 
weeks followed by haemotrophic nutrition after first trimester in human 
placenta. (Figure adapted from lecture notes on: Implantation, pregnancy loss and 
development of extra embryonic membranes from Human Reproduction module of 
Gonville and Caius College, Cambridge) 
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1.3.2 Haemotrophic nutrition 
After the first trimester uteroplacental blood flow is an important determinant of 
fetal growth and development.75 Maternal uterine spiral artery remodelling 
leads to a low resistance uteroplacental circulation and is the crucial step of 
human placentation.11 The remodelling and dilatation of the uteroplacental 
arteries is believed to be a result of pregnancy-induced activation of the local 
decidual artery renin-angiotensin system leading to disorganized vascular 
smooth muscle and lumen dilatation followed by direct invasion of the smooth 
muscles of uteroplacental arteries by extravillous trophoblastic cells.76 Figures 
1.6 A and B describe spiral artery remodeling.11 
              
Figures 1.5 A) Representation of endovascular trophoblastic invasion before 6 
weeks of pregnancy and B) shows after 20 weeks of gestation in normal 
pregnancy. Blue: fetal tissues, Red: Maternal tissues. Ps: zone of placental 
separation, where the basal plate separates from the placental bed (Adapted from 
Kaufmann P et al. Biology of Reproduction. 2003;69: 1-7)
11
 
Assessment of placentation: There are several approaches of assessing 
placental function in vivo. These include assessing biochemical markers: 
circulating trophoblast derived proteins such as pregnancy-associated plasma 
protein-A (PAPP-A) and free ßhCG and ultrasound markers: first and second 
trimester uterine artery blood flow indices21 and placental volume.77 All are 
indirect measures of placental function and are affected by various maternal 
and fetal parameters making them less reliable as surrogate markers of 
placental function. Uterine artery Doppler is often used to assess placental 
function along with maternal cardiovascular adaptation78,79 and in screening 
high-risk women for preeclampsia clinically and for research purposes. We 
therefore used second trimester uterine artery Doppler to assess 
uteroplacental blood flow in this study. 
A B 
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1.4 Determination of gestational age 
Gestational age (GA) assessment forms the basis for interpreting early 
pregnancy ultrasound scans and diagnosing fetal growth restriction. GA is 
routinely established by ultrasound measurement of fetal crown-rump length 
(CRL).80-82 Fetal CRL charts were constructed from observed first trimester 
CRL measurements in relation to GA calculated from the LMP in women with 
regular menstrual cycles assuming that ovulation occurs mid-cycle.80 
Emphasis has been focused on a single first trimester CRL measurement in 
determining fetal growth.77 However, there is a lack of prospective studies 
exploring the impact of biological variability due to ovulation and implantation 
timing on first trimester CRL. We have prospectively observed ovulation and 
implantation timing along with ultrasound measures of first trimester CRL in 
order to explore if this biological variability affects fetal CRL, fetal growth, 
birthweight or length of gestation.  
 
Figure 1.6 Schematic representation of timeline of events and variability that 
can contribute to the crown rump length measurement at 10-14 weeks from the 
first day of menstrual cycle (LMP): ovulation, conception, ovulation to implantation 
(O-I) interval (North Caroline Study)
6
 and first trimester growth 
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1.5 Embryonic and fetal growth 
Intrauterine growth restriction (IUGR) is defined as the failure of the fetus to 
achieve its genetic growth potential in utero and implies placental dysfunction 
due to various causes originating in the mother, placenta or the fetus and 
occurs in about 4-7% of births.83 The diagnosis of intrauterine growth 
restriction depends on the correct establishment of gestational age based on 
the fetal CRL at 10-14 weeks. In addition to the assumptions about ovulation 
and implantation timing, it is also assumed that growth is uniform in the first 
trimester.84 However, first trimester growth is affected by age, smoking, 
ethnicity, maternal body mass index and fetal factors.85 A relationship between 
a small first trimester embryonic measurement and low birth weight has been 
shown in IVF pregnancies86 and in natural conceptions.87,88 Fetal growth itself 
is a dynamic process and is controlled by maternal, fetal, placental and 
environmental factors. Fetal size at birth is a result of the interaction of all 
these factors. Fetal nutrition is provided by the placental and uterine vascular 
system and hence implantation, trophoblastic invasion, placentation are 
necessary for normal fetal growth. Maternal factors such as age89, BMI, 
smoking, medical diseases and cardiovascular function can affect fetal growth 
and fetal size at birth.90,91 
There are few prospective studies of serial ultrasound measurements in the 
first trimester exploring longitudinal embryonic and fetal growth along with 
biological variation in ovulation, implantation timing and late pregnancy growth 
and cardiovascular changes. In this study, we have explored the relationship 
between first, second, third trimester fetal growth, implantation timing, 
placental function using second trimester uterine artery Doppler, maternal 
characteristics and maternal cardiovascular changes. 
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1.6 Early pregnancy loss 
Early pregnancy loss can have significant impact on woman’s psychological 
wellbeing. Common causes of early pregnancy loss are: miscarriage or 
ectopic pregnancy. Most of the loss in early pregnancy is a result of impaired 
embryo-endometrial interaction and impaired trophoblastic invasion.14 It is 
plausible that delayed implantation in early pregnancy loss less than 6 weeks 
is due to impaired trophoblastic invasion.5 
1.6.1 Miscarriage and recurrent miscarriage 
Miscarriage is the most common complication of pregnancy.1 One third of 
embryos are lost prior to implantation92 and a further third of early pregnancy 
loss occurs even before the pregnancy is recognized as a clinical pregnancy.36 
Recurrent miscarriage (RM) is defined as three consecutive miscarriages and 
affects about 1% of couples. Eighty five percent of cases of RM are 
unexplained93 and heterogeneous in etiology.2 RM is also associated with 
thrombophilia and antiphospholipid antibody syndrome. 
1.6.2 Ectopic pregnancy 
It occurs in about 1-2% of pregnancies. An ectopic pregnancy is characterised 
by the presence of an extra uterine gestational sac with or without a yolk sac 
or an adnexal mass or extra uterine sac like structure in the absence of an 
intrauterine pregnancy. It may compromise woman’s health and future 
fertility.94 
1.6.3 Pregnancy of unknown location 
Women with a positive pregnancy test with no evidence of an intrauterine or 
extrauterine pregnancy on transvaginal ultrasound scan (TVS) are classified in 
the group to have pregnancy of unknown location. These women may either 
have an intrauterine pregnancy, miscarriage or ectopic pregnancy.95   
We explored the relationship of ovulation, implantation timing and O-I interval 
in women who miscarried in the study population. 
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1.7 Impaired placentation and uteroplacental insufficiency: 
Preeclampsia and intrauterine growth restriction 
Preeclampsia (PE) and intrauterine growth restriction (IUGR) are both 
common pregnancy complications and have different manifestations, but both 
are associated with underlying abnormalities of placental function. This 
association is supported by the presence of abnormal uterine artery Doppler 
and abnormal umbilical artery Doppler.10,12 
1.7.1 Preeclampsia 
It remains the second leading cause of maternal mortality in both developing 
and developed countries with the absolute numbers being higher in 
developing countries.96 In the most recent report of confidential enquires into 
maternal deaths in the UK- PE and hypertensive disorders are responsible for 
22/107 direct deaths.97 PE affects about 3-5% of all pregnancies and is 
responsible for significant maternal and neonatal mortality and short and long-
term morbidity.98,99 Women with a history of PE are at increased risk of CVD 
later in life.29,100 PE is associated with 15% of preterm births and a four-fold 
increase in the incidence of IUGR and is responsible for long-term health 
consequences such as obesity, cardiovascular disease, hypertension and 
diabetes later in life for the growth restricted newborns born to hypertensive 
mothers.101-105  
Preeclampsia is commonly defined as a diastolic blood pressure (BP) of ≥ 110 
mm of Hg on one or more occasions or ≥ 90mm of Hg on two or more 
occasions at least 4 hours apart, in combination with significant proteinuria (≥ 
300mg/ 24hours or 2+ dipstick) developing after 20 weeks of gestation, in a 
previously normotensive woman.106 PE is classed as severe if the systolic and 
diastolic BP rise above 160mmHg or 110mmHg respectively.106  
1.7.2 Intrauterine growth restriction 
IUGR even in the absence of PE is responsible for significant short term and 
long term neonatal morbidity and mortality.103,104 It contributes to iatrogenic 
prematurity and short and long term complications associated with 
prematurity. Moreover, growth restricted neonates are likely to be at an 
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increased risk of hypertension, coronary heart disease and metabolic 
syndrome in adulthood.104,107,108 
Although it is believed that fetal growth restriction begins in the first trimester, 
is associated with uteroplacental insufficiency and is associated with 
cardiovascular maladaptation,91 there is lack of prospective studies of naturally 
conceived pregnancies, assessing the impact of biological variability in 
ovulation and implantation on measures of fetal size along with longitudinal 
ultrasound measures of fetal growth alongside maternal cardiovascular 
adaptation.109 We have explored all these aspects in this feasibility study. 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Evidence of abnormal placentation in preeclampsia (PE) and 
intrauterine growth restriction (IUGR) by uteroplacental Doppler (Doppler images 
have been obtained from Fetal Medicine Foundation website – online Doppler 
module) 
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1.8 Cardiovascular adaptation in pregnancy 
1.8.1 Cardiovascular changes in normal pregnancy 
Normal pregnancy is associated with profound cardiovascular adaptation in 
order to optimize uteroplacental perfusion without compromising maternal 
function and to ensure optimal conditions for fetal growth and development.110 
Lindhard first reported maternal cardiovascular function in pregnancy in 1915 
using invasive investigations by dye-dilution techniques.111 With development 
of newer, non-invasive and more accurate techniques it is now possible to 
determine patterns in maternal cardiovascular changes such as the time of 
onset of changes, the time of maximum changes, magnitude of change and 
behavior during and after pregnancy.112 Understanding the nature and extent 
of cardiovascular adaptation in normal pregnancy enables assessment of 
cardiovascular changes associated with maternal complications such as PE or 
IUGR113 and possible prediction of these pregnancy complications.  
The haemodynamic changes in normal pregnancy start even before a fully 
functional placenta is formed.26 Most of the current studies of maternal 
cardiovascular adaptation in pregnancy are cross-sectional and they may not 
account for individual variation during pregnancy. Existing longitudinal studies 
are small in number and most of them begin from late first trimester and use 
either first trimester or postpartum data as baseline data. However, it is known 
that significant cardiovascular changes begin as early as 5 to 6 weeks in 
pregnancy (Summary of longitudinal pre-pregnancy to postpartum studies in 
Table 1.1).24-26 Moreover, certain cardiovascular parameters e.g. cardiac 
changes, may take longer to return to normal and may not return to 
baseline.114  
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Table 1.1 Summary of longitudinal studies investigating maternal 
cardiovascular changes in pregnancy 
 Parameters studied Study population 
(number and 
parity) 
Timings of Research 
Visit 
Atkins AFJ. 
1981 
BP, HR and SV using a 
Minnesota Impedance 
Cardiograph, PVR and 
CO 
8 
(Mixed parity) 
Preconception, then 
monthly until delivery 
and on 3
rd
 postpartum 
day, 6weeks and 4 to 16 
months postpartum 
Capeless E. 
1989 
 
M- mode echocardiograph 
left ventricular 
measurements, CO, 
ejection fraction, SV, 
MAP, systemic vascular 
resistance  
8 
(5 Nulliparous/ 3 
multiparous) 
 
Preconception within 3 
months before 
conception, 6-8, 14-16, 
22-24 weeks. 
Robson SC. 
1989 
 
 
HR, BP, CO and SV using 
cross-sectional 
echocardiography and 
Doppler methods 
13   
(6 Nulliparous, 7 
multiparous) 
 
Preconception, early 
pregnancy at mean 35 
days after the LMP and 
then monthly from 8 to 
36 weeks and finally at 
38 weeks 
Chapman 
AB. 
1998 
MAP, CO, renal functions 10 
7 normal/ 3 (one 
with PE, one with 
severe asthma and 
one with twins) 
Preconception, 6, 8, 10, 
12, 24 and 36 weeks 
Ogueh O. 
2009 
Echocardiography for CO, 
SV, left ventricular 
measurements and BP 
28 (Four groups):  
(Spontaneous and 
IVF pregnancies) 
13 normal 
singleton, 5 
singleton IVF, 4 
singleton ovum 
donation, 6 multiple 
pregnancies 
Preconception, at 6, 10, 
16, 26, 36 weeks and 6 
weeks postpartum. 
 
Changes in Brachial blood pressure: Blood pressure (BP) is the most 
commonly measured clinical variable. It is well accepted that brachial blood 
pressure (BP) falls by about 10% in the midtrimester.115,116 At least half of this 
fall in BP occurs in the first trimester, beginning very early in pregnancy at 
about 6weeks in pregnancy (13 ± 2.6 mmHg/ 20%), as observed in 
longitudinal studies from the pre-conception period26, followed by a further 
drop in the midtrimester (Figure 1.9).25,26,116,117 This is followed by an increase 
in BP towards term. These initial studies recorded BP using a 
sphygmomanometer. A cross-sectional study of automated BP in a large 
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cohort of pregnant women at various gestations has derived the 5th and 95th 
centiles of mean arterial pressure (MAP) values as 90/50mmHg and 130/80 
mmHg respectively between 5 to 42 weeks of gestation (Figure 1.9).118 The 
data regarding postpartum return of BP to normal are inconclusive because of 
lack of pre-pregnancy to postpartum follow up in most of the studies. It is 
suggested in a study from prior to conception that there is no difference at BP 
at 6 and 12 weeks postpartum and the MAP at 12 weeks returns to 
baseline.114 Studies beginning during pregnancy have shown that SBP and 
DBP values are higher at up to 12 weeks postpartum compared to 36 
weeks.119 There is no difference in postpartum BP due to breastfeeding.119 BP 
in Caucasians during pregnancy is affected significantly by parity, age and 
body mass index (BMI). BP is slightly lower in Asian and black women.118 This 
could be because of lower BMI in Asian women and multiparity in black 
women. In addition, BP shows circadian rhythm and variability over a 24-hr 
time interval during pregnancy of 21-25 mmHg. The pattern of mean BP 
changes is maintained even after accounting for variability in normotensive 
pregnancies (Figure 1.8).120,121 
60
65
70
75
80
85
90
M
A
P
, 
m
m
 H
g
Gestation, Weeks
 
 
Figure 1.8 Changes in mean arterial pressure (MAP) during pregnancy. ** P<0.05 
at that gestation in relation to Mid-Follicular  MAP. (Adapted from Chapman AB et al. 
Kidney International. 1998;54:2056-63)
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Figure 1.9 Reference ranges for A) Systolic BP and B) Diastolic BP during 
pregnancy (5-42 weeks) using automated BP. (Adapted from Ochsenbein-Kolble N 
et al. BJOG. 2004;111:319-25)
118
 
A) Systolic BP 
B) Diastolic BP 
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Changes in Central (aortic) BP: Brachial artery BP is routinely used in day-to-
day clinical practice and in research. However, brachial BP does not reflect BP 
changes in the central (aortic) BP. Central BP differs from brachial BP due to 
differences in the arterial stiffness and pulse wave reflections in the arterial 
tree and can differ by up to 20mmHg in young women.122 Central BP is 
considered to be more relevant in understanding the pathophysiology of 
cardiovascular diseases than peripheral pressures due the proximity of aorta 
to the kidney, brain and heart123 and also has superior prognostic value in 
prediction of cardiovascular disease later in life compared to brachial BP.124 
Due to proximity of the aorta to the uteroplacental bed central BP may 
represent the effects of pregnancy associated cardiovascular changes better 
than brachial BP. Central BP values during pregnancy in cross-sectional 
studies indicate that central systolic BP (SBP) is lower in pregnant than non-
pregnant women (Figure 1.10) and lower in the second trimester during 
pregnancy.125,126 Moreover, longitudinal data using late first trimester 
measurements as ‘baseline’ show that central SBP decreases in mid 
pregnancy127,128 and to a greater extent than brachial SBP.128 There is a lack 
of studies describing longitudinal changes in central SBP from prior to 
pregnancy to postpartum. It is plausible that the extent of changes during 
pregnancy is underestimated by using late first trimester measurements as 
‘baseline’ measurements. 
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Figure 1.10 Difference between central BP in pregnant and non-pregnant women 
(Adapted from Macedo ML et al. Hypertension. 2008:51;4)
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Changes in cardiac function (cardiac output, stroke volume), morphology of 
the heart and heart rate: In normal pregnancy, there is an increase in cardiac 
output (CO), cardiac index (CI), heart rate (HR) and intravascular volume 
(Figure 1.11).24,112,113  
The first cardiovascular change during pregnancy seems to be a rise in heart 
rate (HR).129 Previous small prospective studies from prior to pregnancy have 
demonstrated that this rise starts between two and five weeks and continues 
well into the third trimester and plateaus after 32-34 weeks.24-26,113   
In the last three decades, changes in CO, stroke volume (SV) and structural 
changes in the heart during pregnancy have been determined using the non-
invasive, validated technique of M mode echocardiography.112,130 Although 
there are a number of studies describing changes in heart during pregnancy, 
there is still controversy regarding left ventricular performance and global 
cardiac function.131  
CO increases in pregnancy, with most of the increase being described in the 
first trimester.132,133 This increase in CO is first seen by five weeks after the 
last menstrual period and a maximum increase of about 43-48% occurs (~ 2.5 
L) by about 24 weeks.24-26,129 The initial increase in CO is due to the increase 
in HR, followed by an increase in SV starting a little later than 8 weeks, with a 
maximum rise at about 20weeks.24,113 The later increase of SV from 8 weeks 
onwards is believed to be a result of left ventricular remodelling, an increase in 
the left ventricular (LV) mass index and adaptation of the heart in response to 
physiological changes in the preload and afterload secondary to systemic 
vasodilatation.129,134 The size, timing and mechanism of changes in CO and 
SV in the third trimester remain variable between different studies. Studies 
using dye dilution methods and impedance echocardiography have described 
a fall in CO due to a reduction in SV by 35 weeks, with heart rate remaining 
constant.28,135 However, studies using echocardiography have reported that 
CO, SV and HR after 32 weeks plateau with a slight fall after 38 weeks and a 
further reduction back to pre-pregnancy levels by 2 weeks postpartum.24,113,136 
The increase in CO and SV in the third trimester are associated with structural 
changes in the heart such as progressive increase of LV end-diastolic and 
end-systolic diameters and volumes, increased LV muscle mass and 
septal131,137,138 thickness and eccentric LV hypertrophy. These changes are 
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similar to those seen in athletes as a result of chronic adaptation of heart to an 
increased preload. 
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Figure 1.11 Changes in A) cardiac output, alongside changes in B) heart rate 
and C) stroke volume during normal pregnancy. (Adapted from Robson SC et al. 
Br Heart J. 1992;68:540-3)
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Changes in arterial and venous compliance, aortic stiffness, pulse wave 
reflection:  
There is a growing awareness of the importance of large artery function in the 
understanding of the pathophysiology of CVD. Large artery stiffness, 
measured as the aortic pulse wave velocity (aPWV), and wave reflections, 
quantified by augmentation index (AIx) independently predict cardiovascular 
outcome later in life.124 There is an increasing interest in the understanding the 
pregnancy related changes in the structural properties of large arteries such 
as the aorta, which can be measured using aortic compliance. Aortic 
compliance is affected by aortic vessel wall stiffness, its structural properties 
and wave reflections in the aorta.139 Vessel wall stiffness and pulse wave 
reflections also have significant impact on central BP.123  
Central BP, AIx and aPWV are higher in the preclinical140 and clinical phases 
of pregnancies complicated by PE and IUGR.126,141,142 However, in order to 
understand the extent and timing of changes in pregnancies complicated by 
PE/IUGR, it is important to understand changes in normal pregnancy from a 
pre-pregnancy baseline.  
AIx is lower in pregnant than non-pregnant women and lower in mid 
pregnancy compared to the first trimester in cross-sectional studies125 
however there are few longitudinal studies of changes in AIx beginning from 
late first trimester.126-128 The extent and relationship of maternal vascular 
function changes as reflected by arterial stiffness and arterial wave forms 
along with central haemodynamics in very early pregnancy from a pre-
pregnancy baseline, their relationship to the process of implantation and 
pregnancy outcomes at the time of profound cardiovascular adaptation has 
not been reported before. 
It is believed that aortic compliance increases during normal pregnancy with 
maximum increase in the third trimester, associated with a decrease in 
aPWV.143,144 This change in aortic compliance and vessel compliance helps to 
regulate the cardiac output, accommodate the volume overload and the 
circulatory changes during pregnancy and maintain blood pressures.139,143 
However, it is difficult to interpret the existing evidence because of the limited 
numbers in the longitudinal studies performed, different parameters and 
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methods used to measure aortic compliance (or aortic distensibility) and 
varied times of performing the measurements (Summary of the existing 
longitudinal studies of aortic compliance is described in Table 1.2).126,143-145 
Table 1.2 Summary of longitudinal studies assessing changes in maternal aortic 
compliance during pregnancy 
 
Changes in renal haemodynamics: Pregnancy requires volume expansion for 
meeting the demands of maternal pregnancy adaptation and to meet the extra 
fluid demands of the growing conceptus.146 This is met by changes in the 
osmoregulatory system and renal haemodynamics. Renal plasma flow and 
glomerular filtration rate is increased and renal vascular resistance decreases 
significantly by 6weeks. Maximum renal plasma flow, maximum glomerular 
filtration rate (about 45% above the follicular phase of the menstrual cycle) 
and minimum renal vascular resistance are seen at the eighth week of 
gestation.129,146,147 The increase in the glomerular filtration rate remains until 
36weeks with the peak glomerular filtration rate in the second trimester. 
Although still higher than the pre-pregnancy levels, there is a decline in later 
 
Parameter  
Technique used 
Population 
Timing of tests 
Changes during 
pregnancy 
Edouard 
D.A., 1998 
Aortic PWV 
Carotid-femoral, 
pulse transducers 
9 normal pregnancies, 
First, third trimester and 
postpartum control 
Decrease from first 
to third trimester 
Mersich B., 
2005 
Aortic PWV, 
SphygmoCor® 
system (SCOR; 
PWV Medical, 
Sydney, Australia) 
12 normal pregnancies, 
First, second, third 
trimester and 
postpartum control 
Decrease from first 
to second to third 
trimester 
Oyama-Kato 
M., 2006 
Brachial-ankle PWV   
BP-203PRE, Colin 
Inc, Komaki, Japan 
167 normal and 16 with 
hypertensive 
pregnancies 
First, second, third 
trimester and 
postpartum  
Decrease from first 
to second with non-
significant further 
decrease and 
increase in third 
trimester.  
No decrease in 
hypertensive 
pregnancies 
Robb A., 
2009 
Carotid-femoral 
PWV 
SphygmoCor 
system (AtCor 
Medical) 
 
22 normal pregnancies 
16, 24, 32 and 37 weeks 
of gestation. 
15 preeclamptic women 
at diagnosis and 7 
weeks postpartum 
An increase from 24 
weeks to 7 weeks 
postpartum. Increase 
more in those with 
PE 
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pregnancy, which may be attributed to an increase in measurement errors in 
late pregnancy.148 Renal function tests were performed in this study in the late 
first trimester in order to have an indirect estimate of the contribution of renal 
haemodynamics to pregnancy induced changes in early pregnancy and to 
assess if uteroplacental insufficiency was associated with reduced volume 
expansion modulated by renal haemodynamics. 
Mechanisms: The initial cardiovascular changes in pregnancy are those of 
peripheral vasodilatation with a specific renal vasodilating effect and these 
lead to secondary changes in HR, CO followed by SV.26,129 Normal human 
pregnancy is characterized by increased plasma renin concentration and 
activity149, increased angiotensin II (A-II) and aldosterone however, an 
increased resistance to the pressor effects of infused A-II. Although the 
mechanisms for renal changes in normal human pregnancy are unclear, it is 
proposed that peripheral vasodilatation in very early pregnancy could be due 
to reduced sensitivity to A-II, and norepinephrine secondary to modulation of 
the renin-angiotensin-aldosterone system150, increased nitric oxide 
production151, a primary volume expansion129 or relaxin mediated changes in 
arterial compliance.152,153 It is unclear if the changes in large arteries later in 
pregnancy with minimal changes in blood pressure are due to passive 
changes in vessel wall properties due to exposure to enhanced preload 
following volume expansion, reduced distending pressure, vascular 
remodeling154 or reduced smooth muscle tone mediated through estrogen 
receptors.139  
Although we believe we know more about the sequence of cardiovascular 
adaptation we are nonetheless no wiser in determination of the mechanisms 
behind these changes. For decades it was believed that one or more feto-
placental hormones such as sex steroids initiated a decrease in vascular 
reactivity, tone, systemic haemodilution, renal function and thus changes in 
effective circulating volume to trigger other hemodynamic changes.155 The 
temporal relationship between cardiovascular, renal and hormonal changes 
from pre-pregnancy to very early in pregnancy also suggests that significant 
systemic and renal vasodilatation along with vasopressor activation occurs 
very early in pregnancy prior to full placentation.26,129 Therefore, it is plausible 
that conceptus-derived factors may play a key role rather than maternal 
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hormones.156 Unfortunately, due to the inability to perform in vivo studies at 
the trophoblast-decidual interface, complete understanding of these 
mechanisms may remain impossible.110,112 
1.8.2 Cardiovascular changes in preeclampsia/intrauterine growth 
restriction 
Recognition of changes in normal pregnancies has highlighted that 
pregnancies complicated by gestational hypertension, PE and/or IUGR are 
characterized by failure of normal cardiovascular adaptation.  
Reduced volume expansion and insufficient CO changes very early in 
pregnancy are believed to precede later fetal growth restriction.19 
The exact nature and timing of haemodynamic mal-adaptation in PE is unclear 
because of heterogeneity of various studies. The discrepancy between the 
results may be because of the heterogeneity in the study population, small 
cohorts of mixed parity and varying pre-existing risk factors or medical 
problems. Not only is the severity of PE varied in the various studies, but 
women may be already treated with intravenous fluids or vasoactive 
medications. Moreover, most studies are cross-sectional and have described 
maternal central haemodynamics during the clinical phase of PE. Most of 
these studies do not differentiate between early and late onset PE and it is 
now believed that early onset (<34weeks) PE (preterm PE) and late onset PE 
(34weeks) are two different disease entities157 and therefore there is a 
difference in cardiovascular changes in both these conditions.  
Changes in BP in PE and gestational hypertension (GH): Whilst it is known 
that BP reduces in pregnancy until 18-20 weeks of gestation, followed by a 
rise till delivery,26,115,158,159 it is known to be higher in hypertensive disorders of 
pregnancy and BP of  140/90mmHg has been used as a cut off for the 
diagnosis of hypertension in pregnancy.106 Higher BP prior to pregnancy,18,158 
and in late first trimester (11-14 weeks)160,161 are associated with increased 
risk of developing hypertensive disorders of pregnancy. Women who develop 
PE/GH not only have a higher BP very early in pregnancy but also have a 
reduced initial first and second trimester drop in SBP and a faster elevation in 
BP from 18weeks onwards, with women likely to develop PE having a further 
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marked rise in BP from 30 weeks.162 There is overall reduced variability within 
24-hour ambulatory blood pressure readings in hypertensive pregnancies 
compared to good variability seen in normotensive pregnancies, although the 
overall pattern of change (such as the overall increase from 18 weeks 
onwards) in brachial SBP and DBP is maintained.120,121  
Although the symptoms of PE resolve a few weeks after delivery, it is known 
that these women have higher BP at 2 yrs postpartum and also several years 
following the pregnancy.163,164 
Changes in central haemodynamics- arterial, venous system and CO, SV and 
HR in preclinical phase, clinical phase of preeclampsia and postpartum: It 
remains debatable if PE is characterized by a high-output, low resistance 
haemodynamic state or a low output and high resistance hemodynamic 
state.28,165-167 Easterling and Benedetti suggested that PE is characterized by 
an elevated CO,28 which occurs early in pregnancy, before the development of 
hypertension and persists during the clinical phase of PE followed by elevated 
vascular resistance. Whereas a large, study of invasive haemodynamics in 
untreated preeclamptic women supports the concept of PE being associated 
with low CO in the presence of an increased left ventricular afterload.167 Bosio 
PM in a longitudinal cohort study of 400 primigravidae proposed an initial 
hyperdynamic disease model characterized by elevated CO earlier in 
pregnancy but a subsequent hemodynamic crossover to low CO and high 
vascular resistance circulation coinciding with the onset of the clinical 
syndrome in PE and persistence of high CO and vascular resistance in 
gestational hypertension.27  
Early PE (<34weeks) is associated with higher total vascular resistance 
(difference of  866 ± 248 dyn.s.cm-5); lower CO (difference of  4.47 ± 1.09 
L) and systemic under perfusion compared to late onset PE.168 Both preclinical 
and clinical phases of PE are characterized by low plasma volume and low 
venous reserve capacity.146,169  
Although not much is known about the temporal relationship between vascular 
resistance and cardiac function in PE, it is proposed that increased systemic 
vascular resistance and decreased vascular compliance leads to an increased 
systemic afterload in PE. This leads to left ventricular concentric remodeling in 
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order to minimize myocardial oxygen demand and thus preserve left 
ventricular performance.137 This may lead to mild-moderate left ventricular 
global diastolic dysfunction, seen in both term and preterm PE. Preterm PE is 
associated with significant impairment of myocardial contractility and left 
ventricular systolic dysfunction.170 Left atrial remodeling is only seen in cases 
of severe, preterm PE, due to increased left-sided chamber filling pressures 
following left ventricular global diastolic dysfunction from prolonged exposure 
to higher afterload.134 Right ventricular hypertrophy and systolic dysfunction 
are only evident in severe preterm PE with advanced left ventricular 
impairment as a result of increased right ventricular afterload.170 It is believed 
that 56% of women with preterm PE will have asymptomatic left ventricular 
dysfunction at about 2 years postpartum.134,170  
Thus, PE and IUGR are associated with cardiovascular dysfunction, which is 
seen even in the pre-clinical phases. However, because of lack of pre-
pregnancy data in all these studies, the baseline cardiovascular impairment in 
women with PE/IUGR remains unknown. 
Aortic compliance, pulse wave reflection and aortic stiffness in the preclinical 
and clinical phase of pregnancy complications and postpartum: PE and IUGR 
are associated with impaired vascular function characterized by increased 
arterial stiffness during the clinical disease and even prior to the clinical 
disease, in the second trimester.140,142,171 Both, AIx and aPWV are higher in 
women with PE as shown in cross-sectional and longitudinal studies.126,172 It 
has recently been shown that the reduction in pulse pressure and vascular 
compliance from pre-pregnancy to very early in pregnancy is different in 
pregnancies complicated with hypertension and PE.20 Most of the reports on 
AIx and aPWV in PE are from cross-sectional studies however, the 
longitudinal studies begin from late first or second trimester. There is lack of 
any information about arterial stiffness in women with PE or hypertension 
either prior to pregnancy or in very early pregnancy. 
Mechanisms of cardiovascular changes in PE: The pathogenesis of 
cardiovascular maladaptation in PE is still unclear. It was first shown by Gant 
et al in 1973 that the pathophysiologic process of preeclampsia begins months 
before the onset of overt disease, may be present as early as 18-22nd weeks in 
pregnancy and is characterized by increased sensitivity to A-II.173  
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It was also hypothesized that imbalance between prostacyclin and 
thromboxane created a positive feedback loop of endothelial damage, platelet 
activation and increased endothelial damage in PE however their role in 
pathogenesis was not established because this imbalance is only seen in the 
clinical phase of PE. Women who develop uteroplacental insufficiency 
demonstrate hyperdynamic circulation prior to the development of PE to 
compensate for a lower degree of volume expansion and relatively under filled 
circulation.174 Hypertension is the primary and ultimate manifestation of PE 
however this is in fact the end result of the inability of the various 
autoregulatory mechanisms to adapt to the pregnancy induced maternal 
cardiovascular changes.  
It is believed that elevated CO precedes the development of hypertension175. 
An elevated CO during the latent phase before development of hypertension 
could result in compensatory vasodilatation to maintain near-normal blood 
pressure. Profound vasodilatation combined with significant BP changes may 
lead to damage of the endothelium of capillary beds and exhaust the 
vasodilatory rescue functions of the endothelium resulting in a damaging, fixed 
vasoconstricted state of severe PE and the absence of endothelial damage 
leading to persistently high CO and vascular resistance in gestational 
hypertension.27 It is clear that the final cross over from high CO, normal BP to 
low CO, high BP and high peripheral vascular resistance (PVR) occurs before 
the clinical phase however the exact mechanism and timing of the initial CO 
increase remains poorly understood.  
The elevated CO could be due to either primary chronic sympathetic 
overactivity176 or failure of the vascular system to fill and increase in preload 
(primary failure of volume expansion in early pregnancy).174 This could lead to 
compensatory higher CO which leads to compensatory vasodilatation, 
increased sensitivity to Angiotensin II and further reducing the vasodilatory 
reserves and ultimate decompensation leading to a low CO state in 
development of PE. 
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1.8.3 Metabolic changes in normal pregnancy 
Pregnancy is characterized by transition to a catabolic state using lipids as 
energy sources and sparing glucose and amino acids for the fetus. The fetus 
requires maternal lipids, such as cholesterol for fetal use in building cell 
membranes, for cell proliferation, development of the growing body, and as a 
precursor of bile acids and steroid hormones. Thus, lipid metabolism is 
important for fetal growth but maternal hypertriglyceridaemia poses a stress to 
the maternal metabolic system, and appears to increase the risk of 
preeclampsia and preterm birth in predisposed women.177 Not only do these 
changes predispose a woman to pregnancy complications, but also contribute 
towards increased maternal cardiovascular risk later in life.178,179 
 
 
 
 
 
 
 
 
Figure 1.12 Schematic representation of mechanisms of hyperlipidaemia in 
pregnancy 
Longitudinal and cross sectional studies of lipids in pregnancy from first 
trimester onwards and postpartum have shown that following initial first 
trimester decrease in HDL cholesterol and increase in LDL cholesterol, both 
LDL, HDL cholesterol and TG increase in the second trimester and maximum 
increase in total cholesterol (43%), LDL (36%), TC:HDL ratio and TG (about 
60%) occurs at the end of third trimester.180,181 Following an initial reduction, 
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there is increase in plasma lipids after 8 weeks of pregnancy due to increased 
intake, estrogen stimulation and insulin resistance leading to increased 
maternal fat accumulation. Lipoprotein lipase (LPL) in the extrahepatic tissues 
hydrolyses triglycerides (TG). Various maternal tissues such as the adipose 
tissues take up the fatty acids and glycerol produced as a result of this 
hydrolysis. This favors lipid metabolism thus sparing glucose and amnio acids 
for the fetus.182,183 This is necessary for fetal metabolism, fetal growth 
especially brain and retinal development in the first trimester and then in the 
synthesis of steroids and bile acids via the placenta in later pregnancy.  
In later pregnancy the increased lipolysis in the adipose tissues results in 
substantial increase in free fatty acids (FFA) and TG in the circulation, both of 
which cannot freely cross the placenta. As a result of which they are converted 
in the maternal liver to release very low -density lipoprotein (VLDL). These, 
along with increased insulin resistance lead to increased gluconeogenesis and 
ketogenesis. This results in increased maternal TG, phospholipids and 
cholesterol levels in the third trimester representing a pool of easily available 
energy source for the mother in fasting situations in order to spare glucose for 
the fetus.182 Following delivery there is increased LPL expression and activity 
in the mammary glands to enable increased milk synthesis for subsequent 
lactation.182 
It is known that the elevated TG and hypercholesterolemia in the third 
trimester predispose the mother to develop gestational diabetes and have 
atherogenic potential however the crucial levels for TG or cholesterol in order 
to predict this risk are not clear yet. Pregnancies complicated by preeclampsia 
are associated with significantly higher plasma lipids during the clinical phase 
of PE and it is believed that this hyperlipidaemia is responsible for endothelial 
injury and the systemic manifestations of PE.  
1.8.4 Changes in platelet function in normal pregnancy 
Pregnancy is believed to be a hypercoagulable state with an increase in 
clotting factors secondary to an increased estradiol. Platelet activation is 
increased in pregnancy and increases with increase in gestation; however this 
is not believed to be a feature of established PE.184 There is limited evidence 
about the sequence of events that lead to platelet activation during normal 
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pregnancy due to a lack of prospective studies and variation in the methods 
for the assessment of platelet function in pregnancy. 
Circulating platelets play a role in contributing towards the thrombotic 
tendency. The process of platelet activation involves stimulation of platelets 
following endothelial injury due to blood flow changes. Activated platelets 
change shape and express dendritic extensions. These changes mediate 
release of ADP from secretory granules within the platelets promoting platelet 
aggregation and coagulation, and mediate secretion of von Willebrand factor 
and platelet factor 4 from  granules.  Platelet membrane glycoprotein 
receptors mediate initial platelet adhesion to the sub endothelial tissue 
followed by subsequent aggregation to form a haemostatic plug.185   
It is plausible that the haemodynamic changes during pregnancy lead to 
platelet activation, which may lead to increased platelet aggregation as 
pregnancy advances. Platelet aggregation in very early pregnancy at the time 
of maximum cardiovascular changes has not been explored before. 
8.5 Metabolic and hematological changes in preeclampsia/intrauterine 
growth restriction 
Pregnancies complicated by IUGR are associated with the placental pathology 
similar to PE however without the systemic manifestations. It is proposed that 
gestational hyperlipidaemia should compensate for the placental insufficiency 
to provide nutrition to the fetus.186 However, cross sectional studies in the third 
trimester have shown lower cholesterol, LDL cholesterol and VLDL mass in 
pregnancies complicated by IUGR compared to normal pregnancies.186 If 
implantation and first trimester growth are related to both: placentation and 
birth weight then the changes in serum lipids by the end of the first trimester 
may reflect this. In this study we explore lipid changes in the end of first 
trimester and its relationship with first trimester fetal growth and pregnancy 
complications. 
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1.9 Recurrent miscarriage, placental insufficiency and 
cardiovascular disease later in life 
PE and/or IUGR are associated with an increased maternal risk of 
cardiovascular disease (CVD) later in life.29,31,100 Although the symptoms of PE 
resolve a few weeks after delivery, there is evidence of persistence of 
postpartum maternal endothelial dysfunction,187 cardiac dysfunction in the 
form of asymptomatic left ventricular hypertrophy170 and hypertension188 for 
several months to years following the pregnancy. Physiological changes in the 
maternal cardiovascular system together with metabolic and hematological 
changes during a normal pregnancy predispose women to an increasingly pro-
atherogenic metabolic state.189 The cardiovascular dysfunction in women with 
PE/IUGR may therefore predispose them to long term CVD. 
RM has also been inconclusively associated with hypertensive disorders in 
subsequent pregnancies. It is therefore possible though not proven that RM is 
also associated with cardiovascular dysfunction similar to PE. A previous 
study has suggested endothelial dysfunction and altered cardiovascular risk 
profile in women with RM, however this study included women with 
antiphospholipid antibody syndrome.190 However, there is paucity of 
information on detailed cardiovascular function in women with unexplained 
RM. 
It is known that RM, PE, IUGR and CVD share common risk factors. It is 
therefore, plausible that preexisting cardiovascular risk factors in women with 
RM or PE/IUGR may predispose them to impaired implantation, abnormal 
trophoblastic invasion and failure of the cardiovascular adaptation in 
pregnancy. Whether cardiovascular risk factors are the cause or effect of 
impaired cardiovascular adaptation in pregnancy is not yet determined. Only a 
prospective study from prior to pregnancy to the postpartum period could 
provide an insight into the cause and effect relationship of cardiovascular risk 
and pregnancy complications such as RM, PE or IUGR. 
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1.10 Feasibility study 
In order to conduct a prospective pre-pregnancy to postpartum study powered 
to answer the questions related to ovulation, implantation timing, embryonic 
and fetal growth and cardiovascular adaptation in pregnancy complications, a 
large cohort of healthy women will need to be recruited. This would involve 
huge resources. A percentage of women may not conceive during the study 
period, a further third may miscarry and a significant number may drop out37 
and most women would have normal pregnancies.  
A feasibility study is defined as a trial study carried out before a definitive 
study to assess the feasibility of the processes involved in the study and its 
management, resources needed, all of which are important for the success 
and add to the scientific value of the main study.191 For a pre-pregnancy study 
the key processes are recruitment, retention and refusal rates, success rates 
of conception, rates of pregnancy loss, non-compliance rates, assessment of 
eligibility, time taken for the study and resources involved and pregnancy 
follow up rates. The scientific information regarding demographics, accuracy 
of the tests and extent of pregnancy changes using a pre-pregnancy baseline, 
usefulness and value of the non-invasive tests, blood tests, variability in the 
measurements from a feasibility study would enable establishing power for a 
future prospective study. This is the rationale behind this prospective feasibility 
study of ovulation implantation interval and maternal haemodynamics. 
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1.11 Hypotheses 
1. Recurrent miscarriage is associated with delayed implantation and an 
adverse pre-conception cardiovascular risk factor profile 
2. Women with a history of late complications in a previous pregnancy have 
delayed implantation in a subsequent pregnancy and an adverse pre-
conception cardiovascular risk profile. 
3. The timing of implantation is related to the maternal haemodynamic 
adaptation to pregnancy 
Objectives 
Primary: To assess the feasibility of both recruiting to and completing a future 
study of sufficient power to be able to test the hypotheses proposed above 
prospectively, using a cohort design.  
Secondary: To be able to investigate the following relationships to help 
establish power calculations. 
1. To establish whether a relationship exists between ovulation-implantation 
interval and subsequent pregnancy outcome. 
2. To compare time from ovulation to implantation between women who have 
recurrent miscarriages, those with a previous late complication of pregnancy, 
and control healthy women.  
3. To compare the pre-conception cardiovascular risk profile and 
cardiovascular changes in pregnancy between women who have recurrent 
miscarriage, those with a previous placental insufficiency, and control healthy 
women.  
4. To characterize the changes in cardiovascular and metabolic function 
during pregnancy in relation to pregnancy outcome, using pulse wave 
reflection, aortic stiffness, central haemodynamics. 
5. To compare the postpartum persistence of haemodynamic changes and 
changes in cardiovascular risk profile in relation to pregnancy outcome
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2.1 Design 
This was a prospective cohort feasibility study combining measures of 
ovulation, implantation timing, fetal growth and maternal cardiovascular 
function from preconception to postpartum period.  
2.1.1 Subjects  
One hundred and forty three women planning to conceive were recruited in 
three groups: nulliparous women (70) or those with previous normal 
pregnancies who were healthy (35) (normal controls), history of unexplained 
recurrent miscarriages (RM) (26) and those with previous preeclampsia 
(PE)/intrauterine growth restriction (IUGR) (12). Additionally, three women 
were recruited in the PE/IUGR group for pre-pregnancy assessment but as 
they were not trying to conceive, they were not included within the cohort of 
143 women for longitudinal study.  
Unexplained recurrent miscarriage was defined as three or more consecutive 
miscarriages at less than 12 weeks, where investigations such as 
thrombophilia screen, cytogenetic examination of products of conception, 
pelvic ultrasound and parental peripheral blood karyotyping were negative and 
no specific problem was detected.192  
PE was defined as diastolic blood pressure (BP) ≥ 110 mm Hg on ≥ one 
occasion, or ≥ 90mm Hg on ≥ two occasions at least 4 hours apart, in 
combination with significant proteinuria (≥ 300mg/ 24hours or 2+ dipstick; 
International Society for the Study of Hypertension in Pregnancy).106 
IUGR was defined as birth weight below 3rd percentile,193 in the absence of 
congenital infection or aneuploidy with abnormal umbilical artery Doppler, 
defined as umbilical artery pulsatility index (PI) of greater than 95th centile194 
and/or either absent or reversed end diastolic flow. 
Participants were between 18-50 years of age and were not known to have 
thrombophilia or diabetes. One out of 15 women with previous PE/IUGR and 
one multiparous woman in the control group were known to be previously 
hypertensive and their hypertension was well controlled on antihypertensive 
medication.  
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Women with PE/IUGR in previous pregnancies have a higher recurrence rate 
of PE and IUGR in a subsequent pregnancy195-197 and women with RM are 
also believed to have an increased risk of uteroplacental insufficiency in 
subsequent pregnancy.7-9 We included both these subgroups of women in 
order to identify differences in their pre-pregnancy cardiovascular function and 
cardiovascular adaptation during pregnancy. 
2.1.2 Recruitment of the participants (Figure 2.1) 
Recruitment was achieved by advertisements over a period of 11 months from 
July 2010 to June 2011. Seventy nulliparous and 35 multiparous women with 
previous normal pregnancies (controls) were recruited prospectively in the 
study when they started trying to conceive. Study posters were put up in 
various wards and corridors in the Addenbrooke’s hospital, in 95 GP surgeries 
in Cambridgeshire, on the Rosie hospital website, in the local newspapers, 
BLISS and APEC website (See Appendix 2). Furthermore, the study was 
advertised in preschool groups, NCT newsletter and in local GP newsletter. 
Information about the study was conveyed to GPs via the hospital GP liaison 
team and to the staff on the early pregnancy unit. The advertisements had the 
direct contact details of the lead research fellow and women who were 
interested to find more information would contact the research fellow by phone 
or email. Participants were given information about the visit by email or over 
the phone prior to each visit in advance. 
One hundred and twenty five women with unexplained recurrent miscarriage 
were identified from the clinic lists and 250 women with previous PE and IUGR 
delivered in the past 4 years were identified from the delivery database and 
hypertension clinic & were invited to participate in the study. These women 
were sent invitation letters with reply slip to be returned (See Appendix 3) or to 
contact the lead research fellow by email or phone.  
All 184 women who approached the research fellow were given the participant 
information sheet (See appendix 4) and detailed explanation about the study 
either by email, personally or over the phone. 146/184 were suitable and 
consented to participate in the study. Three women who were not actively 
trying in the PE/IUGR group were only included for their pre-pregnancy data 
but were not included in the prospective study. Women who were not pregnant 
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at the end of 6 cycles of the study were re-recruited if they wished to continue 
with the study. The total number of women including the women who were re-
recruited following their first 6 unsuccessful cycles (n=27) or following an early 
pregnancy loss in their first pregnancy (n=11) in the study was 184.  
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3- Included for pre-
pregnancy assessments 
not trying during the 
study period so 
excluded from planning 
to conceive 
Assessed for eligibility (n=184) 
88 Nulliparous, 43 multiparous (Advertisement, Friends, GPs) 
23 PE/IUGR (18/250 who replied to invitation letter/5 via advertisement) 
30 RM (26/125 who replied to invitation letters/4 via advertisement) 
Total recruited planning to conceive (n=143) 
 
Out of 184 eligible: 38 did not proceed with the study 
31 Declined to consent: transport issues, not trying, 
not wanting to use tests, did not want scans 
7 unsuitable: 6 pregnant, 1 with previous stillbirth 
70 Nulliparous 35 healthy multiparous 
with previous normal 
pregnancy 
12 with previous 
PE/IUGR  
26 with previous 
RM 
105 Healthy controls trying to conceive 
45 Nulliparous   
(51 
pregnancies) 
24 Multiparous 
(25 
pregnancies) 
15 RM (17 
pregnancies) 
7 PE/IUGR (8 
pregnancies) 
38 with previous pregnancy complication 
trying to conceive 
101 Total pregnancies 
 
 
Figure 2.1 Flow chart of recruitment to the study 
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2.2 Study Protocol (Figure 2.2)  
Women were recruited prior to conception and written consent was obtained 
at the time of recruitment or at the first research visit prior to any 
procedures/assessments. Baseline cardiovascular assessment and blood 
tests were performed as described below. They then performed digital home 
urine ovulation and pregnancy tests as described below. Women who became 
pregnant were followed up longitudinally with serial ultrasound scans and 
repeat cardiovascular assessments in very early pregnancy, second and third 
trimester and 3 to 4 months postpartum. Women who were re-recruited 
following a miscarriage or an ectopic pregnancy did not undergo repeat 
baseline cardiovascular assessments.  
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Figure 2.2 Summary of the study protocol 
 
 (At least a month after stopping hormonal contraception) 
 Age, Ethnicity, Menstrual, obstetric, Cardio-vascular History 
 Height, weight and body mass index (BMI) 
 Cardiovascular assessment 
 Blood tests: biochemistry and platelet function 
 Provided digital home urine ovulation detection kits and pregnancy test 
kits (Swiss Precision Diagnostics, GmbH, Bedford, UK) 
 
Daily ovulation testing (day 6 to detection of LH surge) 
Daily pregnancy testing (day of LH surge till three consecutive positive 
pregnancy tests) 
At 6-7 weeks gestation by LMP, at least 2-3 weeks after the first positive 
pregnancy test:  
 Ultrasound scan to confirm pregnancy viability and measure embryonic 
size using crown- rump length (Two scans, two weeks apart to check 
serial first trimester growth) 
 Cardiovascular assessment and blood tests for platelets 
 
 Ultrasound scan: Fetal growth scan/ maternal uterine artery doppler 
scan 
 Cardiovascular assessment 
 
 Growth scan with Umbilical artery Doppler  
 Cardiovascular assessment 
Pregnancy outcome: Gestation, birth weight, preeclampsia, intrauterine growth 
restriction 
 Cardiovascular assessment and blood tests (biochemistry and platelets) 
 
Pre-conception 
 
Early pregnancy 
visit 
 
Home digital urine 
testing for 6 cycles 
or till pregnant 
2nd Trimester 
(22-24 weeks) 
 
3rd Trimester 
(32-34 weeks) 
   
Post-partum 
4 months 
END OF PROTOCOL 
Delivery 
Re-recruited if not 
pregnant after 6 cycles 
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2.2.1 Setting  
The study was undertaken at Addenbrooke’s Hospital. The cardiovascular 
assessments and blood tests were performed in the vascular research clinic in 
the University of Cambridge and the ultrasound scans during the pregnancy 
were performed in the Rosie Ultrasound Department, Maternal Fetal 
Assessment Unit or on Daphne ward (Early Pregnancy Unit) in the Rosie 
Hospital. Participants were provided with car park tickets and travel expenses 
when necessary.  
2.2.2 Ethics and data governance 
The study received ethical approval from the Cambridgeshire 1 Research 
Ethics Committee (REC Ref. no. 10/H0304/28) (Appendix 1). The data 
collected from the study was anonymized to study numbers, the key to the 
study numbers from patient hospital numbers was kept in a paper diary 
marked as ‘IMPOST’ and locked in a safe non-clinical filing cabinet within 
Fetal Medicine Department. All data was entered on an access 2007 
database, which was accessible on a password protected secure hospital 
server. 
2.2.3 Pre-pregnancy visit 
The first pre pregnancy visit was conducted at least a month after stopping 
contraception and in the luteal or follicular phase of the cycle. After taking 
written informed consent from these women personal details such as maternal 
age, ethnic group, smoking, detailed menstrual, obstetric and cardiovascular 
history, height, weight, body mass index (BMI) were recorded using a 
participant’s questionnaire (Appendix 6). A copy of the consent form and the 
questionnaire were stored securely in the hospital in the research files.  
2.2.4 Cardiovascular tests 
Cardiovascular measurements were performed after 10 minutes rest in the 
supine left lateral position with arms relaxed and by their side with their head 
supported and legs uncrossed. All measurements were performed in a quiet, 
temperature-controlled room (21C to 23C). Participants were requested to 
abstain from caffeinated drinks for 4 hours before the visit and be fasted for at 
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least 4 hours before the first visit to enable performing blood tests for lipids 
and cholesterol. Cardiovascular function was assessed non-invasively by 
measuring brachial blood pressures (BP), central blood pressures (BP), pulse 
wave reflection quantified by augmentation index (AIx) (described later), aortic 
stiffness measured by carotid femoral (aortic) pulse wave velocity (aPWV), 
cardiac output (CO), cardiac index (CI) and stroke volume (SV).  
Peripheral Blood pressures: Brachial BP and heart rate (HR) were measured 
in the non-dominant arm using an automated BP measuring device (Omron-
M7) that has been validated for use in pregnancy using standard cuff size 
according to the arm circumference of the woman.198  
 
Pulse wave reflection and central haemodynamics using pulse wave analysis: 
Central BP and arterial stiffness were investigated using pulse wave analysis 
with the SphygmoCor device (AtCor Medical, Sydney, Australia) (Figure 2.3). 
This technique of pulse wave analysis developed by Michael O’Rourke,199 
utilizes applanation tonometry to record high fidelity waveforms from 
peripheral arteries. The principal behind this is that when the curved surface of 
a cylinder is flattened, circumferential pressures are equalized and intraluminal 
pressures can be recorded accurately (Figure 2.4).  
This device consists of a hand-held tonometer with a high-fidelity 
micromanometer located on its tip (SPC-301; Millar Instruments, USA); Radial 
artery waveforms were recorded by placing the tonometer on the wrist of the 
non-dominant arm (Figure 2.4)  
 
 
 
 
Figure 2.3: SphygmoCor device (AtCor Medical, Sydney, Australia) (From AtCor 
Medical website/ SphygmoCor technology /www.atcormedical.com/sphygmocor.html) 
 Tonometer 
Sphygmocor 
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Figure 2.4 Recording of the radial artery waveform by placing the hand-held 
tonometer on the radial artery and using the principal of applanation tonometry 
(shown in the box on the right corner) 
 
The recorded waveforms were calibrated by using the brachial systolic and 
diastolic BP, measured as above. A corresponding central waveform is 
generated with a validated transfer function (SphygmoCor; AtCor Medical, 
Sydney, Australia) (Figure 2.5).199,200 Central systolic and diastolic BPs, mean 
arterial pressure (MAP), aortic augmentation index (AIx) were determined 
using the integrated software.  
 
 
 
Figure 2.5: Pulse wave analysis using radial artery waveform. The green graph is 
the radial artery waveform and the dotted black graph is the aortic waveform derived 
by the computerized software using the generalized transfer function 
 
Radial artery waveform 
Derived aortic waveform 
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Central BP can be measured non-invasively using applanation tonometry. A 
transcutaneous pressure transducer at the end of a probe is held against an 
artery to flatten the artery in order to equalize circumferential pressures and 
obtain pressure waveforms, which are identical to those obtained by intra-
arterial measurements.123,201 From these waveforms, central BP is estimated 
non-invasively either by using the carotid waveform as a surrogate for that of 
the aorta or by using a generalized transfer function where using a 
mathematical formula, an aortic waveform is derived from a radial 
waveform.200 The second method is the most commonly used method 
because it is easy to use and has been shown to have repeatability.  
Augmentation index (AIx), is a method of quantifying pulse wave reflection and 
it is the difference between the second and first systolic peaks (also known as 
augmentation pressure AP), expressed as a percentage of aortic pulse 
pressure.  
AIx =100 x AP/PP (Figure 2.6). 
The first systolic peak is the maximum pressure created by the forward going 
pressure wave and the second is a composite of forward and backward-going 
waveforms. Since the amplitude and velocity of wave reflection depends on 
the large artery stiffness, AIx provides an indirect measure of large artery 
stiffness.202 Figure 2.6 is the schematic representation of derivation of AIx.  
All measurements were performed at least twice and a third reading taken if 
the difference between two consecutive readings was more than 5 units and 
for waveforms derived using the SphygmoCor device operator index of at least 
more than 80 (quality control contained within the software) was considered 
acceptable. The average of the two or three readings was used for 
subsequent analysis.  
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Figure 2.6 AIx representation and derivation of AIx: A typical central aortic 
pressure waveform- AIx= PP/P. Augmentation index (AIx) is calculated as the 
difference between systolic peaks: P1 and P2 (P), expressed as a percentage of the 
pulse pressure (PP). Ejection duration is calculated as the time between the foot of 
the wave (TF) and the incisura, and TR defined as the time between TF and the 
inflection point. (Schematic figure adapted from Wilkinson I.B. Thesis title: Arterial 
stiffness, endothelial function and cardiovascular disease. Green College, Oxford. 
2003)
203
 
 
Aortic stiffness assessed by Carotid-femoral pulse wave velocity: Carotid-
femoral PWV is the ‘gold standard’ measurement for arterial stiffness and has 
the largest amount of epidemiological evidence for its predictive value for 
cardiovascular events.204 Carotid-femoral PWV was recorded non-invasively 
using SphygmoCor device (AtCor Medical, Sydney). For each subject the 
carotid-femoral distance was measured using calipers. ECG electrodes were 
attached to the participant to measure HR. After palpating the maximum 
palpable carotid artery pulse and femoral artery pulse the carotid-femoral path 
length was calculated using calipers. The carotid femoral path length = Distal 
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(distance in mm between the supra-sternal notch and the femoral artery site) – 
proximal distance (distance in mm between the supra-sternal notch and the 
carotid artery site). Two good quality and steady waveforms were obtained 
giving duplicate readings using the tonometer at the carotid and femoral site 
for at least 15 seconds. If readings differed by >0.5m/s then a third reading 
was taken & the two closest readings were averaged. The recording was 
obtained as shown in Figure 2.7.  
 
Figure 2.7 Measuring aPWV by placing the tonometer on the carotid followed by 
the femoral pulse 
 
The carotid-femoral PWV was derived by the SphygmoCor from the carotid-
femoral distance and the time delay between the foot of the carotid waveform 
and that of the femoral waveform obtained from the pressure waveforms at the 
carotid and the femoral site as shown in Figure 2.8. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Recording of aortic pulse wave velocity: screen showing the recording 
of carotid waveform at the top and femoral waveform at the bottom part of the screen 
alongside an ECG analysis of heart rate 
Carotid 
waveform 
Femoral 
waveform 
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Cardiac output measurement: Cardiac output (CO) was assessed using a non-
invasive, inert gas re-breathing technique known as Innocor, Innovision A/S, 
Denmark. (Figure 2.9) CO is the volume of blood pumped by the heart per unit 
of time (litres/minute). Innocor utilises pulmonary gas exchange as a means of 
measuring the pulmonary blood flow using a mixture of soluble and insoluble 
gases- some of which may be absorbed across the lungs.  
Briefly, while resting, the subject continuously re-breathes a gas mixture: 1% 
sulphur hexafluoride (SF6), 5% nitrous oxide (N20) and 94% oxygen (O2) over 
20 seconds, with a breathing rate of 15/min (Figure 2.9). Expired gases were 
sampled continuously and analyzed by an infrared photoacoustic gas analyzer 
(InnoCor, Innovision A/S, Denmark), for the determination of CO and SV. The 
rate of disappearance of nitrous oxide (N2O) is proportional to the pulmonary 
blood flow. Hence, the higher the cardiac output, the higher the disappearance 
rate of this gas. The inert/insoluble gas in the bag is sulphur hexafluoride and 
as it does not cross the lungs; it is used to quantify the lung volumes from 
which the N2O is removed. A pulse oximeter simultaneously determines the 
HR from which SV (i.e. the volume of blood ejected per heartbeat) is 
computed by the machine. The machine also deduced cardiac index (CI). It is 
non-invasive, simple and easy to use- using the touch screen. This method 
has been validated against thermodilution in patients with cardiac failure.205 
 
 
 
 
 
Figure 2.9 Innocor Gas re-breathing device (The top figure shows the device and 
the bottom one demonstrates the usage of the device) 
Mouthpiece and Filter 
Pulse oximeter 
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Peripheral vascular resistance: Peripheral vascular resistance (PVR) was 
calculated from the formula:  
PVR (dynes.s-1.cm-5) = MAP (mmHg) x 80/ CO (L/min) 
Variability of cardiovascular measurements: All measurements were 
performed in duplicate by a single, trained investigator (AAM), and the mean 
values were used in subsequent analyses. The within observer measurement 
reproducibility values for the AIx and aPWV described below were in 
agreement with previously published data.206 The arterial wave reflections are 
believed also to have moderate reproducibility during the different phases of 
menstrual cycle (within subject absolute differences of AIx upto 10% between 
the different phases of menstrual cycle).207 It has been shown that AIx is lower 
in the luteal compared to the ovulatory phase however overall the wave 
reflections and all other indices including central BP do not appear to vary 
significantly during the menstrual cycle.126,207 Therefore, pre-pregnancy 
cardiovascular assessments were performed at any time in the menstrual 
cycle to make recruitment more flexible. 
 
Intra-observer variability for AIx measurements: In 15 women (combination of 
pregnant and non-pregnant), the overall mean AIx was 13% ± 9% (95%CI: 8%, 
18%). The mean difference between the readings was -0.5 ± 1.7% with no 
significant difference between the two readings (P=0.3) as has been shown 
before.206 
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Figure 2.10 Within observer variability for AIx measurements using a Bland-Altman 
plot 
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Intra-observer variability for aPWV measurements: In 15 women (combination 
of pregnant and non-pregnant), the overall mean aPWV was 5.07 ± 0.44 m/s 
(95%CI: 4.8, 5.3). The mean difference between the readings was -0.01 ± 
0.27m/s with no significant difference between the two readings (P=0.9) as 
has been shown before.206 
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Figure 2.11 Within observer variability for aPWV measurements using a Bland-
Altman plot 
 
CO measurements: In 43 women (13 non-pregnant i.e. prior to pregnancy or in 
the postpartum period, 20 in second trimester and 10 in third trimester). The 
overall mean CO was 6.2 ± 0.4 L/min (range: 4.5-8.7 L/min), mean CI was 3.4 
±0.2 L/min per m2 (range: 2.5-5 L/min per m2) and mean SV was 83 ± 5 ml 
(range: 56-110 ml). There was no trend of the values to vary with any of the 
analyses. The within-observer differences (mean ± 2SD) were 0.10 ± 0.5 L/min 
for CO (95% CI of mean differences: -0.9,1.1) (Figure 2.12a), 0.07 ± 0.3 L/min 
per m2 for CI (95% CI of mean differences:-0.5, 0.6)(Figure 2.12b) and for SV 
were 0.9 ± 7ml (95%CI: -12.9, 14.7) (Figure 2.12c). There was no difference in 
the values for reproducibility between the two readings of CO (P=0.2), CI (P=0.1) 
and SV (P =0.4) and the coefficient of variation between the two readings of CO, 
CI and SV was <6%. 
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Figure 2.12a Within observer reproducibility of CO measurements using a Bland-
Altman plot 
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Figure 2.12b Within observer reproducibility of CI measurements using a Bland-
Altman plot 
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Figure 2.12c Within observer reproducibility of SV measurements using a Bland-
Altman plot 
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2.2.5 Metabolic and kidney function assessment- blood and urine tests 
In order to investigate the presence of unfavourable cardiovascular and 
metabolic risk profiles prior to pregnancy which may predispose to both 
preeclampsia and cardiovascular disease- baseline lipid profile, renal function, 
HbA1c were performed and the urine was tested to assess urine albumin 
creatinine ratio (UACR) (Urine Albumin-to-Creatinine Ratio (UACR).208-210  
Blood samples were collected in accordance to the Addenbrooke’s Hospital 
venepuncture guidelines: 5 millilitres (ml) in plain bottle, 2.5ml in yellow top 
fluoride bottle, 2.5ml in pink top EDTA bottle and 5ml in hirudin tube.  The clotted 
blood was tested for total cholesterol, High-density lipoprotein (HDL) cholesterol, 
Low-density lipoprotein (LDL) cholesterol and total triglycerides (TG); for renal 
function tests such as serum creatinine, estimated glomerular filtration rate 
(eGFR), urea and electrolytes. Blood sample in EDTA was tested for HbA1c and 
the sample in the fluoride bottle was analysed for serum glucose. These 
biochemistry tests were performed and results interpreted as per standard 
hospital protocols.(Table 2.1) The blood sample in hirudin tube was analysed for 
platelet aggregometry (described below).  
These blood tests were performed at the first pre-pregnancy visit and repeated 
at 3 to 4 months postpartum. The platelet aggregation was repeated separately 
at 6 to 7 weeks in early pregnancy to investigate changes following implantation. 
The lipid profile and renal function tests were repeated separately at 10-14 
weeks along with the routine blood tests to investigate changes in lipids and 
renal function in the first trimester. 
Table 2.1 Reference ranges for blood biochemistry results (Addenbrooke’s Hospital 
biochemistry ranges and BNF for lipid/cholesterol profile) 
Test Reference range (N adult female >18yrs)  
 
Full Lipid Profile:  
Serum cholesterol 
HDL 
LDL 
TG 
 
<6mmol/L- normal 
Se. cholesterol ≥ 6mmol/L then refer to non-smoker/ 
under 50yrs chart of TC: HDL ratio (BNF-Cardiovascular 
risk prediction charts- see below figure 1) and inform GP  
Serum creatinine 
Serum Urea 
eGFR 
Na
+
 & K
+
 
35-12µmol/L 
<7.5mmol/ L 
≥ 60ml/min/1.73m
2 
Na
+
: 135-145mmol/L & K
+
: 3-4 to 5mmol/L 
HbA1c 
Random Glucose 
4.9-6.3% (non-diabetic)  
3.5-5.5 mmol/L (Fasting) 
3.5-9.0 mmol/L (Non-Fasting) 
>7mmol/L – Inform GP 
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Figure 2.13 Cardiovascular risk prediction charts based on Total cholesterol:HDL 
cholesterol ratios. (Adapted from Wood D.A. Heart 2005; 91(supplement V: V1-V52)
211
) 
 
Urine test: Urine was tested for albumin/ creatinine ratio using urine dipstick 
(Siemens microalbustix). Spot protein creatinine ratio (UPCR) has good 
correlation with 24-hour urine protein excretion in kidney disease however urine 
albumin creatinine ratio (UACR) is useful to diagnose and monitor 
microalbuminuria. It is also used as a cardiovascular risk predictor.208,209 The 
NKDEP (National Kidney Disease Education Program) suggests that albuminuria 
is present when UACR is greater than 30mg/g and is a marker of CKD (Chronic 
kidney disease) (Urine Albumin-to-Creatinine Ratio (UACR). (NKDEP factsheet; 
March 2010) 
Table 2.2a Urine Microalbustix interpretation of albumin and creatinine 
depending on the colour on the strip (Adapted from Siemens Microalbustix Label. 
Product ref no. 04960872 (2087) 
Creatinine (60 sec) 
mg/dl  
mmol/L 
g/dL 
 
10 
0,9 
0.01 
 
50 
4,4 
0.05 
 
100 
8,8 
0.1 
 
200 
17,7 
0.2 
 
300 
26,5 
0.3 
Albumin (50 sec) 
mg/L 
mg/dL 
 
10 
1 
  
30 
3 
 
80 
8 
 
150 
15 
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Table 2.2b Urine Microalbustix interpretation of results (Adapted from Siemens 
Microalbustix Label. Product ref no. 04960872 (2087) 
Albumin 
mg/L 
                                            Creatinine 
10 
 
50 100 200 300 
10 Recollect specimen  Normal Normal Normal Normal 
30 Slight abnormal Abnormal Abnormal Normal Normal 
80 Medium abnormal Abnormal Abnormal Abnormal Normal 
150 High abnormal High abnormal Abnormal Abnormal Abnormal 
 
Table 2.3 Calculated value of Urine Albumin-to-Creatinine Ratio (UACR) in 
mg/g= Albumin excretion in mg/day 
Albumin 
mg/dL 
                                         Creatinine (g/dL) 
0.01 0.05 0.1 0.2 0.3 
1 100 20 10 5 3.33 
3 300 60 30 15 10 
8 800 160 80 40 26.7 
15 1500 300 150 75 50 
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2.2.6 Platelet function assessment212,213  
Platelet function was assessed by whole blood aggregation using Multiple 
Electrode Aggregometry (MEA) on a new generation impedance aggregometer 
(Multiplate Analyzer, Dynabyte Medical, Munich) (Figure 2.14).  
 
   
Figure 2.14 Multiplate® Analyzer, Dynabyte Medical, Munich (Adapted from 
multiplate® international marketing, Multiplate Services, GmbH, Munich, Germany-
company information leaflet) 
Test cell 
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The blood platelets are non-thrombogenic in their resting state, but have 
exposed receptors on their surface which when activated, allow them to attach 
on the vascular injury and artificial surfaces. This system detects the electrical 
impedance change due to the adhesion and aggregation of platelets on two 
independent electrode-set surfaces in the test cuvette or test cells (Figure 2.15). 
 
Figure 2.15 Aggregation of platelets on the electrodes in the test cells (Adapted 
from multiplate® international marketing, Multiplate Services, GmbH, Munich, Germany-
company information leaflet) 
  
The blood sample was collected in the hirudin tube, containing recombinant 
hirudin; which anticoagulates blood by direct inhibition of thrombin and allows 
platelet function analysis under physiological calcium concentration. Adenosine 
diphosphate (ADP) was used as an agonist for platelet activation. ADP was 
prepared by addition of 1ml purified water to ADP test vial and stored at 2-8°c for 
7 days or at -80c for 4 weeks.  
A 1:2 dilution of whole blood anticoagulated with hirudin and 0.9% NaCl was 
stirred and incubated at 37c for 3 minutes in the test cells. After addition of ADP 
agonist in serial dilution (10µl, 5µl, 2µl, 1µl and diluted ADP 1µl) to the incubated 
blood in the test cells, the increase in electrical impedance was recorded 
continuously for 6 minutes. The increase in impedance upon addition of ADP 
and platelet aggregation is transformed into arbitrary aggregation units (AU) and 
plotted against time. The most important parameter is the area under the 
aggregation curve (AUC). It is affected by the total height of aggregation curve 
as well as by its slope and is best suited to express the overall platelet activity 
(Figure 2.16). The other parameters reported are the aggregation as represented 
by the height of the curve and the velocity, which is the maximum slope of the 
curve. The internal quality control in the software gives the mean values of the 
curves from the two independent sensors in the Multiplate- test cell. 
Platelet 
aggregate 
 Test and control 
electrodes 
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Figure 2.16: Description of derivation of the area under curve for platelet 
aggregation (AUC) and Aggregation Vs Time (Adapted from multiplate® international 
marketing, Multiplate Services, GmbH, Munich, Germany-company information leaflet) 
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2.3 Use of home ovulation and pregnancy test kits 
Participants were given digital home ovulation and pregnancy test kits to 
identify the ovulation timing, implantation timing and ovulation to implantation 
interval (O-I interval). Tests were provided by Swiss Precision Diagnostics, 
GmbH (SPD), Bedford (Figure 2.17). They were instructed to use daily 
ovulation tests from the 6th day of their cycle until luteinizing hormone (LH) 
surge was detected in the urine identified by the ‘smiley face’ on the digital 
reader and perform daily pregnancy tests from 8 days after the LH surge 
(Figure 2.18) until they recorded three consecutive positive pregnancy tests or 
until their next period. These kits were provided with the menstrual diary and 
written instructions for initially three cycles (See appendix 5) and if the 
participants needed more for another three cycles then additional kits were 
sent either by post or personal collection. Participants were advised to contact 
the research fellow when they had three consecutive positive pregnancy tests 
to organize the early pregnancy visits and/or if they needed any more tests or 
any advice regarding the testing. Once pregnant the participants were 
followed up as described below however if they were not pregnant at the end 
of 6 cycles they were offered re-recruitment for another 3 to 6 cycles 
depending on the feasibility of the study time limits. 
 
Figure 2.17 Ovulation and Pregnancy test kit pack with menstrual diary and 
information sheets provided to the participants 
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Figure 2.18 Flow chart: Instructions regarding use of ovulation and pregnancy 
tests in each menstrual cycle (LMP= Day 1 of the cycle). (The test results as 
shown in the figure have been adapted from the Clearblue- company information 
sheet) 
 
A rise in urinary LH predicts ovulation at a mean of 20 hours from the initial LH 
rise. We therefore calculated the ‘LH surge + one day’ to define the day of 
ovulation as has been previously described.46,214 The day of the first positive 
pregnancy test using sensitive digital urine pregnancy test kits was reported 
as the ‘implantation day’ in a similar way to previously described.6 The 
ovulation-implantation (O-I) interval was calculated as the time interval 
between the presumed day of ovulation as indicated by the urinary LH test kits 
and the first positive pregnancy test.  
Establishment of Ovulation to implantation interval in pregnancies: Ovulation 
to “implantation” interval was estimated in these women using the day of LH 
surge and the first positive pregnancy test from their menstrual diary data. 
(See Appendix 6). This was recorded in the data collection form at the first 
early pregnancy visit or if the subject miscarried, they were offered the option 
of returning the data by post.  
LH surge +1 = 
Ovulation day 
First positive 
pregnancy test= 
implantation day  
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2.4 Ultrasound scans and pregnancy follow up 
All ultrasound scans were reported using the Astraia® database and all 
participants were informed of the results and given the written report of the 
scan. Any pregnancy complication diagnosed on the scan or any abnormal 
scan result was managed according to the Rosie Hospital protocol. 
2.4.1 Early pregnancy scans 
The first early pregnancy visit was arranged at 6 to 7 weeks gestation by LMP 
similar to previous pre-pregnancy studies,24,25 or from the ovulation day in 
case of irregular cycles. In order to demonstrate that we performed the 
cardiovascular measurements very early in pregnancy, at about 2 to 3 weeks 
after the first positive pregnancy test, representative of the ‘implantation day’ 
we have also reported the timing of the tests in days from the first positive 
pregnancy test. The purpose of the first scan was to assess gestational age, 
number, viability of the embryo and this gestational age was subsequently 
confirmed by the fetal crown rump length (CRL) measurement at 10-14 weeks. 
Ultrasound scans were performed at 6-7, 8-9 weeks, and 10-14 weeks of 
gestation from either the LMP or gestational age estimated by ovulation. At 
each pregnancy visit gestational age (GA) was reported from LMP (GALMP), 
GA adjusted by ovulation timing and implantation timing (GAOV and GAIMP) 
respectively. GA adjusted for ovulation timing (GAOV) was derived by 
subtracting 14 days from the predicted ovulation date (LH +1) to the effective 
LMP, as is convention for pregnancy dating.  The median implantation day was 
27 days and the GAIMP was derived by adjusting to day 27 implantation. In 
other words if implantation occurred later than day 27 then the GA adjusted for 
implantation timing (GAIMP) was obtained by subtracting the additional number 
of days from GALMP. Women with ongoing pregnancies at 10-14 weeks were 
followed up subsequently.  
Early pregnancy transvaginal scans: The transvaginal probe utilizes 
frequencies of 7.0-8.0 MHz and is the preferred method of pregnancy 
assessment in the first 9 weeks of gestation. Transvaginal ultrasound scans 
were performed using Toshiba Xario/SSA-660A, Siemens ACUSON Antares, 
Toshiba (Powervision-6000)/SSA -370A, Hitachi Aloka (ProSound Alpha 7) 
depending on the availability of the machines. A gestational sac was located 
CHAPTER 2: METHODS 
 65 
by examining the entire uterus in a true longitudinal view of the uterus, with 
optimal longitudinal view of the uterine cavity, endometrium and cavity line. 
The site, size, number of gestational sac along with the decidual reaction and 
contents of the gestational sac such as the yolk sac, embryonic pole and fetal 
heart beat were identified (Figure 2.19) 
 
Figure 2.19 Transvaginal scan at 6 weeks showing singleton pregnancy, yolk 
sac and embryo 
The mean gestational sac and crown rump length measurements were taken. 
As measurements of yolk sac do not correlate to the outcome of pregnancy 
only its presence or absence was reported. Mean gestational sac diameter 
was measured in three planes: the maximum longitudinal diameter (L) 
together with the maximum antero-posterior diameter (AP) was measured in 
the true longitudinal section and in a cross-sectional view maximum 
transverse diameter was obtained (Figure 2.20). The MSD (Mean Sac 
diameter = [L (cm) + AP (cm) + T (cm)]/ 3 was calculated from Astraia® once 
the measurements were inserted into the system. The values were recorded 
for the study as continuous variables and the mean gestational age derived 
from the charts by Grisolia et al (1993) 215  
 
 
 
 
Embryonic 
pole 
Yolk sac 
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Figure 2.20 Gestational sac measurements in saggital (longitudinal and antero-
posterior dimensions), and cross sectional (Transverse) view 
Crown Rump length measurement: Three CRL measurements of a true, 
unflexed, longitudinal section of the embryo or fetus were taken by obtaining a 
longitudinal section of the uterus and gestation sac. The viability of the 
pregnancy was ascertained by the presence or absence of embryonic heart 
pulsations at this stage. The CRL was measured transvaginally at 6-7 and 8-9 
weeks by placing the callipers at the outer side of the crown and rump of the 
embryo or fetus in a longitudinal, midsagittal section.216,217 Of three CRL 
measurements taken, the one that most closely conformed to the standard 
described above was used for the analysis.  
 
Figure 2.21 CRL measurements at 6 to 7 and 8 to 9 weeks on transvaginal scan 
Early pregnancy complications: A pregnancy loss of less than 6 weeks was 
defined as either miscarriage or no demonstrable viable pregnancy at the 6 
week scan followed by subsequent confirmation of missed miscarriage. Any 
early pregnancy problem that was suspected or detected had second observer 
Saggital 
view 
Cross 
sectional 
view 
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confirmation, and participants were referred to the early pregnancy unit (EPU) 
and managed according to the departmental protocols.  
Any small bleeding around the gestational sac was reported and 
measurements were taken in three dimensions - longitudinal, transverse and 
antero-posterior. Incidental findings such as a simple ovarian cyst <5 cm in 
size and free fluid in the pouch of douglas were also reported. 
 
Transabdominal dating scan (11-13+6 weeks routine scan): The participants 
had routine departmental dating scan, where the fetal CRL at 10-14 weeks 
was measured transabdominally in a midsagittal plane with the fetal spine 
longitudinally in view as per the standards of dating (Figure 2.22).218 The CRL 
measurements, results of the Down’s syndrome screening, nuchal 
translucency (NT) and biochemical markers were recorded in the research 
records. 
 
 
 
 
 
Figure 2.22 Measurement of fetal CRL in saggital plane and placement of 
calipers for gestational age assessment (Adapted from Fetal Medicine Foundation 
website) 
2.4.2 Second trimester scans (18-21 weeks anomaly scan and 20-24 weeks 
uterine artery Doppler) 
The participants had a routine departmental anomaly scan at 18-21 weeks in 
accordance with the National standards (FASP standards) and the findings of 
this scan including measurements of biometry and expected fetal weight 
(EFW) obtained using the computerized software (Astraia®) were recorded for 
longitudinal growth.  
Uterine Artery Doppler: An extra transabdominal scan was performed at 20-24 
weeks to assess uterine artery Doppler and fetal biometry using GE Voluson 
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E8 and GE Voluson 730 PRO ultrasound machines. Women with preexisting 
risk factors had this scan as a part of their routine antenatal care. 
Pregnancies complicated by PE or IUGR have been associated with impaired 
trophoblastic invasion and impaired physiological changes in the spiral 
arteries.219,220 Uterine artery Doppler has allowed non-invasive assessment of 
uteroplacental circulation by assessing the uterine artery waveform.221 There 
is an agreement that there is increased impedance to uterine blood flow on 
uterine artery Doppler waveforms in women preceding development of 
PE/IUGR and during the clinical phase of PE/IUGR and uterine artery Doppler 
is thus, being used in screening for PE/IUGR. However, the sensitivity and 
specificity varies according to the study population, technique and site of 
measurement, gestational age at assessment, indices of the waveform that 
have been used and most importantly the definition of outcomes of PE or 
IUGR.  
Technique of measurement of uterine artery Doppler: Transabdominally, the 
probe was placed longitudinally in the lower lateral quadrant of the abdomen 
angled medially.222 The uterine artery was identified, at the site where it 
appears to cross the external iliac artery by identifying the external iliac artery 
on B-mode ultrasound. Colour flow mapping was used to visualize the uterine 
artery waveform. Once the artery was visualized, the sample volume was 
placed 1 cm downstream to the crossover point or just before the bifurcation of 
the uterine artery. Pulse repetition frequency (PRF) or in other words the scale 
of colour Doppler was adjusted in such a way that there was no aliasing of 
blood flow. The PRF was increased if there was aliasing and decreased if 
blood vessels were not clearly seen. Once the uterine artery was visualized at 
the cross over with the iliac blood vessels then by making further probe 
adjustments the uterine artery was positioned on the screen at an oblique 
angle so that the sample volume was obtained by placing the sample gate in 
the middle of the blood vessel. By Poiseuille’s law the best estimation of the 
velocity of the blood flow would be obtained in the middle of the blood vessel. 
Once good quality, appropriate size waveforms with clear edges were 
captured using pulse wave Doppler, then the Doppler waveform indices are 
calculated either by manually placing the callipers on the waveform or by 
using the auto option. 
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Uterine artery Doppler indices:223,224 Different indices have different predictive 
values, sensitivity and specificity in the prediction of various abnormal 
pregnancy outcomes associated with placental insufficiency. Table 2.4 
describes the various Doppler indices, their advantages and disadvantages. 
 
 
 
 
 
 
Figure 2.23 Indices of Doppler waveform (Taken from Fetal Medicine 
Foundation website) 
 
Table 2.4 Explanation of the Doppler indices and their description 
Index Definition Pros/cons 
S/D ratio or 
A/B ratio 
Systolic
max
/Diastolic
max
 Does not account for the entire wave 
form 
RI  
(Resistance 
index) 
Systolic
max
 -Diastolic
max
/ 
Systolic
max
 
 Only accounts for the systolic and 
diastolic velocities not the entire 
waveform.  
 If notching or if absent EDF then 
does not account for the entire 
waveform 
PI  
(Pulsatility 
index) 
Systolic
max
 -Diastolic
max
/ 
Mean velocity over one 
cardiac cycle 
 Better as accounts for the entire 
waveform, mean velocity as well as 
the presence/absence of notch or 
EDF. 
 Determined by cardiac contraction 
force, heart rate, vessel 
compliance, blood viscosity and 
downstream impedance 
 
We used two consecutive readings of uterine artery PI values on both sides 
and took the best of the two as the final result and reported the presence of 
absence of unilateral or bilateral notching. The cut off values to interpret the 
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results and management of the abnormal results was in accordance with the 
departmental guideline (Uterine artery Doppler screening guidance- The Rosie 
Hospital 2010).225,226 
Table 2.5 Interpretation of Doppler results according to the Rosie Hospital 
protocol 
Uterine artery Doppler 
result 
Risk 
stratification 
Management 
Mean PI ≤1.3  
(Figure 2.24) 
Low risk-Normal Routine antenatal care as planned 
Mean PI > 1.3 Medium risk Serial growth scans at 28 and 34 
weeks and management as per the 
results 
Mean PI >95
th
 centile 
(1.45) or bilateral notches 
(Figure 2.25) 
High risk Three weekly growth scans/ 2 
weekly BP and urine monitoring 
 
 
Figure 2.24 Normal uterine artery waveform 
 
Figure 2.25 Abnormal uterine artery waveform 
Fetal biometry and wellbeing227,228 The measurements of biparietal diameter 
(BPD), head circumference (HC), abdominal circumference (AC), and femur 
length (FL) were performed to assess fetal size and growth. For each of the 
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parameters two measurements were obtained and the best of the two 
measurements was accepted. 
Biparietal diameter (BPD) and head circumference (HC): The BPD is the 
maximum diameter of a transverse section of the fetal skull at the level of the 
parietal eminences.  
Anatomical landmarks for obtaining BPD and HC on the thalamic view (Figure 
2.26): 
 A cross-sectional view of the fetal head was obtained at the level of the 
thalami. 
 “Rugby football” shape of the head 
 Centrally placed midline, the anterior midline presence of the cavum 
septum pellucidum (CSP) followed by the thalami interrupting the 
continuous midline echo of falx cerebri. 
 Visualization of the basal cisterns. 
Caliper placement (Figure 2.26):  
 For BPD, the calipers were placed from outer to inner edge of the skull 
at the widest part of the skull using an angle perpendicular to the 
midline falx. 
 For HC, the ellipse was placed around the skull bone echoes at the 
same thalamic view. 
 The measurements of BPD and HC were plotted on the Chitty charts229 
on Astraia to determine serial growth velocity. 
 
Figure 2.26 Measurement of BPD and HC by a thalamic view 
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Abdominal circumference (AC):  
Anatomical landmarks (Figure 2.27):  
 A circular section of the fetal abdomen with an unbroken and short rib 
echo of equal size on each side were taken.  
 A cross-section of one vertebra was visualized. 
 A short length of the umbilical vein was visible at the level of the portal 
sinus. 
 The stomach was visualized as an hypoechoic area in the left side of 
the abdomen. 
Caliper placement: The AC was measured by placing the calipers of the 
ellipse at the outer surface of the skin line (Figure 2.27) and then plotted on 
the Chitty charts.230 
 
Figure 2.27 Measurement of fetal AC 
Femur length (FL):  
Anatomical landmarks (Figure 2.28): The femur was obtained in as horizontal 
view as possible with both ends of the ossified metaphysis clearly visible.  
Caliper placement (Figure 2.28): Calipers were placed on either ends of the 
ossified diaphysis at the center of the ‘U’ shape of the bone without including 
the distal femoral epiphysis if it was visible and then measurements were 
plotted on the Chitty charts.231 
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Figure 2.28 Measurement of fetal FL  
Expected fetal weight (EFW): This was calculated using the Hadlock formula 
and reference charts used by Astraia® software. 
2.4.3 Third trimester scans (31- 34 weeks) 
Fetal biometry was performed along with amniotic fluid assessment using the 
ultrasound machines mentioned before. The biometry measurements were 
performed as described in the second trimester and EFW was calculated. Two 
measurements of each parameter were performed and the best of the two 
readings was accepted.  
Amniotic fluid volume was evaluated by measuring the amniotic fluid index. 
Using the maternal umbilicus as a reference point, the abdomen is divided into 
four quarters. The largest vertical pool depth in each quadrant was recorded 
by placing the ultrasound probe perpendicular to the floor on the maternal 
abdomen. The sum of the measurements in all four quadrants represented the 
amniotic fluid index (AFI). Amniotic fluid of >25 cm was classed as 
polyhydramnios and <5 cm as oligohydramnios.  
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2.5 Postnatal Follow up  
Women were followed up with the cardiovascular tests, blood biochemistry 
and the platelet function tests at three to four months postpartum. At this visit it 
was recorded if they were breast-feeding and if they were on any 
contraceptives. 
2.6 Definition of pregnancy outcomes in the study  
Table 2.6 Definitions of pregnancy outcomes in the study 
Outcome Definition 
Miscarriage 
<6weeks  
Early pregnancy loss of less than 6 weeks following a positive 
pregnancy test or no demonstrable viable pregnancy at the 6 
weeks scan followed by a ‘missed’ miscarriage. 
Miscarriage 
>6weeks  
Early pregnancy loss between 6 to 12 weeks of pregnancy 
after a viable pregnancy was confirmed at the 6 weeks scan. 
Ectopic pregnancy Pregnancy located outside the uterus confirmed on ultrasound 
scan or by histological examination after surgery. 
Preeclampsia Diastolic blood pressure (BP) ≥ 110 mm Hg on ≥ one 
occasion, or ≥ 90mm Hg on ≥ two occasions at least 4 hours 
apart, in combination with significant proteinuria (≥ 300mg/ 
24hours or 2+ dipstick; International Society for the Study of 
Hypertension in Pregnancy)
106
 
IUGR Birth weight below 3
rd
 percentile for a given gestational age
193
, 
in the absence of congenital infection or aneuploidy. 
 
*Fetal anomaly not leading to termination of pregnancy was included in the study. 
Only singleton pregnancies were included for pregnancy follow up. We have 
combined the PE and IUGR cases within the category of uteroplacental insufficiency, 
as the study is too small for them to be considered separately. 
 
 
2.7 Communication with Primary Care 
General practitioners were informed about the participation of their patient in 
the study with a standard letter approved by ethics committee (See Appendix 
7). If any abnormal blood results were identified then the GP was informed of 
the results with a copy of the GP letter and copy of the results.  
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2.8 Statistical analyses 
Statistical analyses were performed using the Statistical Package for Social 
Sciences (SPSS Version 18.0.0, 2009, SPSS Inc., Chicago, USA) and 
Medcalc software for windows (Medcalc Belgium, Version 11.6). The data on 
recruitment, conception, protocol adherence and outcome are presented in 
numbers and percentages. The data was assessed for normality of distribution 
by using frequency histograms and Kolmogorov-Smirnov test. Data are 
expressed as means ± standard deviation (SD) if normally distributed, and 
median ± inter-quartile range (IQR) or range if appropriate.  
One-way analysis of variance (ANOVA) test was used to determine 
statistically significant difference between the means of three or more 
independent groups. This test was used for normally distributed continuous 
variables with equality of variances between the independent groups. When 
the overall difference between all the means was significant a post-hoc 
Bonferroni test was used to identify which two means were significantly 
different.  
Kruskal-Wallis one-way analysis of variance was performed to determine 
statistically significant difference between non-normally distributed means of 
three or more independent groups. This test was also used when the groups 
were of unequal size. 
Univariate general linear model (GLM) was performed to determine 
statistically significant difference between the means of two independent 
groups when the continuous dependent variable was affected by two or more 
factors. The mean AIx and mean aPWV between the groups were compared 
accounting for the fixed factors and covariates affecting them. 
A repeated measures analysis of variance was performed to determine 
statistically significant difference between three or more observations of a 
dependent continuous variable in the same participant over time. When the 
overall difference between all the means was significant a post-hoc Bonferroni 
test was used to identify which two means were significantly different.  
Paired or independent sample t-test was performed to determine statistical 
significance between the means of two observations if the data was normally 
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distributed and Mann-Whitney U test was performed if the data was not 
normally distributed or if the sample size was small.  
The association between normally distributed variables was determined by 
Pearson’s correlation coefficient (r) and that between non-normally distributed 
or small sample size was determined by Spearman’s correlation coefficient 
rho (). The value of the correlation coefficient varies between -1 to +1, with 1 
being the strongest and 0 being no correlation between the variables. The sign 
“-“ is suggestive of inverse and “+” is suggestive of positive correlation.  
For all statistical tests P < 0.05 was determined as statistically significant. All P 
values were two-tailed. 
Z-Score is the probability of a score of data occurring within the normal 
distribution and was determined using the observed and expected values from 
the means and SD of the population as described for the CRL measurement 
at 10-14 weeks and birthweight.  
Bland Altman Plot232 is a statistical method of plotting and comparing 
measurements obtained by two different techniques. The scatter plot 
represents the correlation between the two different methods. The mean of the 
two measurements is plotted on the X-axis and the difference between the 
measurements is plotted on the Y-axis. The limits of agreement are the 95% 
confidence interval of the difference between the two methods (average 
difference ± 1.96 SD of the difference). A narrower the 95% confidence 
interval implies better agreement between the two techniques.  
2.8.1 Cardiovascular data 
Pre-pregnancy comparisons: The pre-pregnancy measurements of MAP, 
central SBP, HR, CO and PVR in the four groups were compared using one-
way analysis of variance (ANOVA) test and a post-hoc Bonferroni test was 
used to determine statistically significant differences between the groups. The 
AIx and carotid-femoral (aortic) aPWV between the groups were compared 
using ANOVA – generalized linear model univariate analysis using age, height 
and HR as covariates for AIx and MAP as a covariate for aPWV. The pre-
pregnancy measurements of cardiovascular tests were also compared 
between the two groups: those with normal pregnancy outcome and those 
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with PE and/or IUGR in their current pregnancy using independent student t- 
test or Mann-Whitney U-test. 
Longitudinal analysis: For the purpose of longitudinal analysis nulliparous and 
multiparous women with normal current pregnancies were considered as 
normal control group and the longitudinal changes were analyzed in this group 
separately as opposed to the other two groups- normal pregnancies in women 
with previous history of RM and normal pregnancies in women with previous 
IUGR/PE. 
Longitudinal data on cardiovascular assessment, blood biochemistry and 
platelet aggregation data were analyzed using repeated measures ANOVA 
with the post-hoc Bonferroni test for pair wise comparisons. For the cases 
where the cardiovascular data was missing the data was imputed by 
calculating the estimated value using the mean difference of changes at that 
time in the pregnancy.233  
2.8.2 Ovulation and implantation timing data  
The ovulation, implantation timing and O-I interval in the ongoing pregnancies 
at 10 weeks, pregnancies that miscarried at less than 6 weeks and 
pregnancies that miscarried after 6 weeks were compared using Kruskal-
Wallis Test.  
Bland-Altman plots were constructed to compare the GA predicted by CRL 
(GACRL), GA estimated by adjusting for ovulation timing (GAOV) and GA 
estimated by adjusting for implantation timing (GAIMP).232 The 95% confidence 
intervals (CI) were calculated of the differences between the gestational age 
estimated by single CRL measurement and that estimated based on 
adjustments for ovulation timing and implantation timing.  
2.8.3 Ultrasound scan and birth weight data 
Growth rate (mm/day) was calculated by dividing change in CRL by change in 
GA in the first trimester, changes in AC by change in GA in second and third 
trimesters respectively. The first trimester CRL growth rate was calculated as 
an average of the growth rate between scan 1 and 2 and the growth rate from 
scan 2 to 3. The second and third trimester growth rate was calculated as an 
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average of growth rate of AC between scan 1 and 2 in the second trimester 
and scan 2 to scan 3 in the third trimester.  
CRL z-score at the 10-14 week scan was calculated as (measured CRL – 
expected CRL)/standard deviation, with respect to the Robinson & Fleming 
curve.80 The birthweight z-score was calculated from the unstandardized 
residuals derived from the correlation between observed birthweight and 
observed GA at delivery. The relationship between implantation day, O-I 
interval, first-trimester growth, birthweight z-score, length of gestation and 
cardiovascular changes was investigated using spearman’s correlation 
coefficient for non-normally distributed data and Pearson’s correlation 
coefficient for normally distributed data. 
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CHAPTER 3: FEASIBILITY OF A PROSPECTIVE COHORT 
STUDY OF MATERNAL CARDIOVASCULAR CHANGES IN 
PREGNANCY FROM PRIOR TO CONCEPTION 
 
 
 
Summary points: 
 It is feasible to conduct a prospective study combining pre-pregnancy to 
postpartum study changes in cardiovascular function in relation to 
implantation events, fetal growth and pregnancy outcomes. 
 This information would allow the design of a study, powered for pregnancy 
complications such as preeclampsia, to enable investigation of the ‘cause and 
effect’ relationship between abnormal cardiovascular function and pregnancy 
complications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based on: 
Mahendru AA, Everett TR, McEniery CM, Wilkinson IB, Lees CC. The feasibility of 
prospectively studying maternal cardiovascular changes from before conception. 
Hypertension Research. 11 April 2013;doi:10.1038/hr.2013.24 
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3.1 Introduction 
There is compelling evidence that factors prior to pregnancy and around 
implantation may have a bearing on maternal cardiovascular adaptation to 
pregnancy, pregnancy outcome and cardiovascular function later in life. The 
questions related to the cause and effect relationship between pre-pregnancy 
factors and pregnancy complications such as PE can only be answered by 
prospective cohort studies from prior to pregnancy. However, studies from 
prior to pregnancy are associated with difficulties in recruitment, low 
conception rates (25-30% probability of conception in a given menstrual 
cycle),38 low retention of participants during pregnancy37 along with further 
reduction in total numbers as a result of early pregnancy loss in about a third 
of pregnancies.36 The incidence of pregnancy complications such as PE being 
3-5% means a large number of pregnancies will be required to investigate the 
cause and effect relationship between cardiovascular dysfunction and PE. 
Assessment of timing and events around human conception along with 
cardiovascular changes may also enable to provide insight into indirect 
evidence regarding the events around implantation. The objective of this study 
was to establish the feasibility of recruitment to and conducting and 
completing a prospective cohort study of ovulation, implantation timing and 
cardiovascular function from prior to pregnancy to the postpartum period.   
This chapter describes the feasibility of recruitment prior to pregnancy in 
healthy women and in those with previous pregnancy complications, the 
pregnancy, miscarriage and livebirth rates, follow up, study completion and 
retention rates and the incidence of pregnancy complications such as PE and 
IUGR. 
 
3.2 Methods 
This was a prospective feasibility study in a single center.  The study design, 
recruitment methods and the study protocol have been described in detail in 
chapter 2. There was no pre-existing data to help decide the sample size. The 
sample size for this study was a pragmatic choice rather than being based on 
a formal power calculation. We expected to recruit 80 participants in order for 
at least 20 pregnancies in each group to be followed up throughout the 
pregnancy. In this chapter the recruitment, conception, protocol adherence 
and outcome data are presented in numbers and percentages. 
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3.3 Results 
3.3.1 Feasibility of recruitment and study participation (Flow chart in 
Chapter 2, Figure 2.1) 
Out of the 184 women who responded to the advertisements/invitations, 
143(80%) women planning to conceive were recruited in the pre-pregnancy 
period. Two hundred and fifty women with severe PE/IUGR were identified 
from the delivery unit database and clinic lists of 2006 to 2010. One hundred 
and twenty-five women with unexplained RM were identified from the clinic 
lists of 2009 to 2010. These women were invited to participate in the study if 
they were trying to conceive. Only 18 women (7%) with previous PE/IUGR and 
26 women (21%) with unexplained RM replied to the invitation. Additionally, 5 
women with severe PE/IUGR and 4 with RM in their previous pregnancy 
responded to the advertisements, had heard about the study from friends or 
from GPs and contacted by either email or over the phone for study 
information. Healthy volunteers contributed to 72% (105/143) of the study 
cohort. Nulliparous women formed 49% of the cohort, followed by 24% of 
healthy multiparous women; women with RM contributed to 18% of the cohort, 
and those with PE/IUGR contributed to 9% of the cohort.  
 
3.3.2 Usage of home digital ovulation and pregnancy test kits as per 
protocol 
Amongst women, who conceived and had a viable pregnancy, ovulation 
and/or implantation data was unavailable in about 15 pregnancies (21% 
cases). One of them had amenorrhea so did not start using the LH tests and 3 
women did not detect LH surge in spite of using daily LH tests. Eleven women 
did not use LH and/or pregnancy tests as per protocol.  
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3.3.3 Conception rates (Figure 3.1) 
One hundred and forty three women were trying to conceive at the time of 
recruitment. Three additional women recruited to the previous PE/IUGR group 
were not trying to conceive so were not included in the calculation of 
pregnancy rates. Ninety-one of one hundred and forty three women, (64%), 
became pregnant in 18 months. There were a total of 101 pregnancies in 143 
women in 18 months including those who conceived twice during the study 
period. In those women who became pregnant, the median time to conceive 
(including the months they had been trying to conceive prior to participating in 
the research) was 5 (IQR 2 to 7) months and this constituted a median of 2 
cycles after the study entry (IQR 1 to 5).  
 
 
Figure 3.1: Number of participants who became pregnant in each group 
 
64% 
69% 
58% 
58% 
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3.3.4 Protocol adherence for cardiovascular tests (Table 3.1) 
The cardiovascular assessments were performed at a median of 13 days in 
the menstrual cycle during the pre-pregnancy period, at 6 weeks in early 
pregnancy, 23 weeks in the second trimester, 33 weeks in the third trimester 
and at 16 weeks postpartum. 93% of pregnant participants completed all the 
cardiovascular tests as per protocol. 90% of participants completed the 
protocol for blood biochemistry tests and 86% completed the protocol for the 
platelet aggregometry. 
Table 3.1 Protocol adherences for cardiovascular assessments, blood 
biochemistry and platelet aggregometry in 71 viable pregnancies  
 Timing of 
assessment * 
Cardiovascular 
assessments# 
Blood 
biochemistry# 
Platelet 
aggregometry# 
Pre-
pregnancy, 
days of 
menstrual 
cycle 
13 (6-21) 71 (100%) 69 (97%) 69 (97%) 
Early 
pregnancy, 
weeks of 
gestation 
6 (6-7) 69 (97%) - 66 (93%) 
Late first 
trimester, 
weeks of 
gestation 
12 (10-13) - 63 (89%) - 
Second 
trimester, 
weeks of 
gestation  
23 (23-24) 68 (96%) - - 
Third 
trimester, 
weeks of 
gestation 
33 (32-34) 67 (94%) - - 
Postpartum, 
weeks from 
delivery 
16 (14-17) 66 (93%) 64 (90%) 61 (86%) 
 
*Data are median (IQR).  #Data are number (percentage of total 71 viable 
pregnancies where data was complete) 
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3.3.5 Pregnancy outcomes (Figure 3.2) 
One third of pregnancies did not continue beyond the first trimester giving a 
pregnancy loss rate of 29/101 (29%) pregnancies. Early pregnancy loss 
included miscarriage<6 weeks (13%), miscarriage>6 weeks (12%) and ectopic 
pregnancy (4%). The miscarriage rate was higher in women with history of RM 
(53%) compared to all the other groups. Two participants were lost to follow 
up- one just after the pregnancy and another one in the middle of second 
trimester as she moved to another area.  Therefore, the “dropout rate” 
following recruitment was 2% and was 1/71 (1.5%) amongst the participants 
with a viable pregnancy. Overall there was a very good follow up rate and a 
small dropout rate. Two out of seventy one women (3%) had a fetal 
abnormality (one had a fetus with triple X chromosomes and had a termination 
of pregnancy at 14 weeks and another one had a baby born with hypertrophic 
cardiomyopathy, who subsequently died in the neonatal period). 
3.3.6 Pregnancy outcomes in live births (Figure 3.3) 
Out of 57 (88%) controls. 50 had a normal pregnancy, 3 (5%) women had 
uteroplacental insufficiency (1 early onset IUGR <34 weeks, 1 late onset 
PE>37 weeks, 1 late onset PE with IUGR). All three were nulliparous women. 
3 (5%) women had gestational diabetes. One fetus had hypertrophic 
cardiomyopathy and although the pregnancy was normal the baby died in the 
neonatal period. All women with RM had normal pregnancies (7). Amongst 
women with previous PE/IUGR, 2/6 (33%) had uteroplacental insufficiency 
(one had early onset PE and IUGR <34 weeks and the second one had late 
onset IUGR >37 weeks). Nulliparous women and those with previous healthy 
pregnancies were grouped together as controls and the cardiovascular 
changes in pregnancy have been described separately in normal pregnancies 
in this group. The pre-pregnancy cardiovascular function is different in women 
with previous PE/IUGR and they have been described separately.  
3.3.7 Complete data for implantation timing and ultrasound scans 
Amongst the 71 viable pregnancies, complete information on O-I interval was 
available in 56 (79%) pregnancies. Amongst these 56 pregnancies, first 
trimester growth rate was available in 45 (63%) pregnancies, second trimester 
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growth rate in 51 (72%) pregnancies, third trimester growth rate in 53 (75%) 
pregnancies and 54 (76%) cases had birthweight information. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Flow chart of number of pregnancies, miscarriage and viable 
pregnancy in each group (Out of 100 pregnancies there were 29 early pregnancy 
losses, 1 TOP after 14 weeks and 70 livebirths) 
 
Early pregnancy loss = 29 
Miscarriage <6 weeks = 13 
Miscarriage >6 weeks = 12 
Ectopic pregnancies = 4 
Total pregnancies 101 
Lost to follow up 1 
 
Total Livebirths= 70 
Nulliparous  
Total pregnancies = 50 
Early pregnancy loss = 14 
Livebirths = 36 
 
Multiparous  
Total pregnancies = 25 
Early pregnancy loss = 4  
Livebirths = 21 
Previous RM  
Total pregnancies = 17 
Early pregnancy loss = 10 
Livebirths = 7 
Previous PE/IUGR 
Total pregnancies = 8 
Early pregnancy loss = 1  
TOP for fetal abnormality = 1 
Livebirths = 6 
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Figure 3.3 Flow chart of late pregnancy outcomes in all pregnancies with 
livebirth 
 
 
Normal 
pregnancies: 7 
Total Livebirths 70 
Nulliparous 36 Multiparous 21 Previous RM 7 Previous PE/IUGR 6 
Normal 
pregnancies 31 
Pregnancy 
complications: 5 
Late onset PE (40wks): 1 
Late onset PE+IUGR 
(38wks): 1 
Early onset IUGR 
(<34wks): 1 
Gestational diabetes: 2 
 
 
Gestational diabetes: 02 
 
Normal pregnancies: 19 
Pregnancy complications: 1 
Gestational diabetes: 1 
 
Lost to follow 
up: 1 
Normal 
pregnancies: 3 
Pregnancy complications: 3 
Early onset PE+ IUGR (28+5): 
1 
Late onset IUGR (38wks): 1 
Gestational diabetes: 1 
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3.4 Discussion  
We have demonstrated that it is feasible to recruit, conduct and complete a 
study of implantation timing and cardiovascular function from prior to 
pregnancy. The feasibility of pre-pregnancy recruitment and prospect of a 
pregnancy follow up study has also recently been reported from a large 
prospective Chinese cohort study.234 
The conception rate was almost similar between healthy nulliparous and 
multiparous women (64% and 69%). The information on ovulation and 
implantation timing was missing in about 21% of cases. The incidence of PE 
and/or IUGR is higher in women with previous PE/IUGR (33%), followed by 
nulliparous women (4%), consistent with what has been shown before.3 The 
reported recurrence of PE in various studies varies between 6.8%196,197 to 
40%.195 The high incidence in this study could be due to a selected population 
and small numbers. Although the incidence of uteroplacental insufficiency is 
higher in women with previous PE/IUGR, this group was difficult to recruit due 
to difficulties in identification of the cases prior to pregnancy. Moreover, having 
had PE/IUGR would have already affected the cardiovascular function in these 
women. Therefore, these women may not be ideal to study the ‘cause and 
effect’ relationship between pre-pregnancy cardiovascular function and 
uteroplacental insufficiency. 
Complete data on O-I interval, embryonic and fetal growth and cardiovascular 
tests was available in 45(63%) cases. About 7% participants did not complete 
the entire study protocol for cardiovascular tests, 14% did not complete the 
entire study protocol for blood tests, 24% did not have entire O-I interval 
and/or cardiovascular test for a combination of reasons including moving 
away, inconvenience to attend postpartum visits, problems with equipment 
and transport of blood samples. A prospective study would have to account for 
the missing data as well as the incidence of uteroplacental insufficiency i.e. 
the outcome of interest in order to calculate the sample size. 
3.5 Conclusion 
It is possible to recruit women planning to conceive prospectively and 
conducting cohort studies using combination of measures of ovulation, 
implantation, fetal growth and cardiovascular function and provides estimates 
for a sample size for a definitive prospective cohort study from prior to 
pregnancy.
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CHAPTER 4: DEMOGRAPHIC DATA OF THE STUDY 
POPULATION AND DIFFERENCES IN PRE-PREGNANCY 
CARDIOVASCULAR FUNCTION, BIOCHEMICAL PROFILE 
AND PLATELET AGGREGATION 
 
 
 
Summary points: 
 Pre-pregnancy cardiovascular BP and PVR were higher in women with 
previous PE/IUGR compared to normal multiparous or nulliparous women.  
 Women who developed either PE and/or IUGR in their current pregnancy had 
a lower pre-pregnancy HR with higher PVR. 
 Women with unexplained RM had no difference in their pre-pregnancy 
cardiovascular function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based on: 
Mahendru AA, Everett TR, McEniery CM, Wilkinson IB, Lees CC. Cardiovascular 
function in women with recurrent miscarriage, preeclampsia and/or intrauterine growth 
restriction. J Matern Fetal Neonatal Med. 2013;26(4):351-356 
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4.1 Introduction 
RM, PE and/or IUGR share the same risk factors as those for CVD such as 
obesity, hyperlipidaemia, insulin resistance and hypertension.29,32,100,235 
PE/IUGR are also associated with maternal endothelial dysfunction,187,190 
cardiac dysfunction, remodeling236 and hypertension,163 which persist 
postpartum and may contribute to CVD in the long term. Presence of 
underlying thrombophilia may predispose women with RM to an increased 
long term risk of CVD, however there is limited data on cardiovascular risk and 
cardiovascular function in women with unexplained RM to explain their risk of 
CVD.33,190  
The knowledge of pre-pregnancy cardiovascular function and improved 
understanding of cardiovascular changes in normal pregnancies and 
pregnancy complications may enable us to understand the pathophysiology of 
long term CVD in these women. Early identification of cardiovascular risk 
factors may also enable primary prevention by controlling major CVD risk 
factors and early treatment opportunities to reduce morbidity and mortality.  
This chapter describes the demographic data of the entire study population 
and the differences in pre-pregnancy cardiovascular function using brachial 
and central BP, AIx and aPWV along with metabolic function and platelet 
aggregation between healthy nulliparous, multiparous controls and women 
with previous PE/IUGR and RM in the first part. The second part of results 
describes differences in the pre-pregnancy cardiovascular function between 
women who had normal pregnancy outcome and those who had 
uteroplacental insufficiency during their current pregnancy. 
4.2 Methods 
Statistical analyses were performed using the Statistical Package for social 
sciences (Version 18.0.0, 2009, SPSS Inc., Chicago, USA). The normally 
distributed data was expressed as means ± SD and the non-normally 
distributed data as median [IQR or range]. The mean differences between the 
cardiovascular parameters were described as means ± standard error of 
means (SE). The brachial and central pulse pressures were calculated by 
subtracting the diastolic BP from the systolic BP separately for brachial and 
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central BP. The pulse pressure amplification (PP amplification) was then 
calculated by the following formula: 
PP amplification = Brachial PP / Central PP 
The demographics, measurements of the cardiovascular tests, blood tests for 
lipid profile, renal function, electrolytes and platelet aggregation were 
compared in all the four groups using one-way ANOVA and post-hoc test if 
normally distributed; and Kruskal-Wallis test if not normally distributed. The 
estimated glomerular filtration rate (eGFR) was calculated based on the 
creatinine clearance using the following formulae: 
eGFR (ml/min/1.73m2)= 186 x (Creat/88.4)-1.154x Age0.203 x(0.742 if female) and 
1.210 if black. 
Previous studies have reported differences of 8 to 15 mm mmHg in SBP in 
women with previous PE and healthy controls.163,190 The sample size required 
to detect a difference of 10mm Hg in SBP between controls and PE/IUGR 
group with the ratio of 1.4:1 assuming an SD of 10 at 80% power and with 
type 1 error of 0.05, was 20 controls to 15 PE/IUGR and for a ratio of 1.8:1 for 
RM it was 24 controls versus 13 RM.  
The pre-pregnancy cardiovascular function in relation to the current pregnancy 
outcome was compared between those women who had a normal pregnancy 
(n=64) and those who had uteroplacental insufficiency (n=5) using Mann- 
Whitney U test. AIx and aPWV were compared after adjusting AIx for age, 
height and heart rate and aPWV for age and MAP using univariate logistic 
regression. A P value of <0.05 was considered significant. The estimated 
sample size to detect significant difference in SBP between normal pregnancy 
and PE/IUGR group assuming a standard deviation of 9 at 80% power and 
with type I error of 0.05 was at least 38 in each group.  
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4.3 Results 
4.3.1 Pre-pregnancy differences in relation to previous obstetric history  
Demographics of the study population (Table 4.1): Nulliparous women were 
significantly younger with a median age of 30 compared to multiparous women 
(healthy multiparous controls with a median age of 35 years and those with 
previous pregnancy complications with median age of 36 and 37 years 
respectively, P<0.001). The majority of women (125, 87%) were Caucasian in 
all groups, reflecting our local demographics.237 Although women with RM 
were taller, the average BMI across all groups was normal (24 kg/m2 in 
nulliparous women and 25 kg/m2 in the rest of the groups). All women were 
non-smokers, except 2 nulliparous women, 2 RM women and 1 parous 
woman. The median time interval of the pre-pregnancy visit from the index 
pregnancy was 8 months in women with RM compared to 28 months in 
controls (P<0.001) and 40 months in women with PE/IUGR. The number of 
total pregnancies was significantly higher in the RM group than controls 
(P<0.001). The birthweight and GA at delivery were significantly lower in the 
PE/IUGR group compared to the controls (P<0.001). Seventy-nine percent of 
women with history of PE/IUGR had a family history of CVD compared to 24% 
of controls (P<0.05). Forty-eight percent of those with RM had family history of 
CVD, which was not significantly different from the controls. Information 
regarding the income and education was not collected and therefore, it was 
not possible to comment on the differences in socio-economic status within 
the study population. 
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Table 4.1 Demographics and obstetric history in all the groups 
Characteristics Nulliparous 
(n=70) 
Healthy 
Multiparous 
(n=35) 
PE/IUGR 
(n=15) 
RM 
(n=26) 
Age, years 30(28-32) # 35(33-38) 37(32-38) 36(33-41) 
Caucasian 86% 91.4% 80% 88% 
Height, m 1.64(1.61-1.69) 1.63(1.59-
1.71) 
1.61(1.57-1.65) 1.67(1.62-
1.72)# 
Weight, kg 65(59-73) 68(59-76) 63(57-71) 71(61-86)  
BMI, kg/m
2
 24(22-28) 25(22-29) 25(22-29) 25(23-32) 
Previous 
pregnancies, n 
0(0-2) 
(3 had 
miscarriage in 
past) 
2(1-3) 2(1-3) 5(4-6)* 
Primiparous/ 
Multiparous, n 
- 27/8 11/4 19/2 
Interval from last 
(index) 
pregnancy, 
months 
- 28(15-38) 40(20-46) 8(5-15)* 
Previous first 
trimester 
miscarriages, n 
0(0-2) 
 
1 (0-1) 
 
1(0-2) 4(3-5)* 
GA at 
miscarriage, wks 
8(6-10) 9(6-10) 7(5-19) 8(6-10) 
GA at delivery, 
wks 
- 39(38-41) 36(32-38)* 40(38-41) 
Birth weight, g - 3560(3175-
3719) 
2259(1360-
2640)* 
3175(2721-
3629) 
 
Data are median (IQR), BMI= Body mass index, GA= gestational age, *P<0.05 Mann-
Whitney Test, #P<0.05 Kruskal-Wallis Test 
 
Differences in pre-pregnancy cardiovascular function in relation to previous 
obstetric history (Table 4.2, Figure 4.1): Differences in the cardiovascular 
parameters between the groups are described in Table 4.2. Women with 
previous PE and/or IUGR had significantly higher brachial diastolic pressure 
(DBP) by 7 ± 2 mm Hg (P = 0.03), central systolic pressure (CSBP) by 8 ± 3 
mm Hg (P = 0.01); and mean arterial pressure (MAP) by 8 ± 3mm of Hg (P = 
0.02) compared to the multiparous women with previous healthy pregnancies. 
There was no significant difference between brachial and central BP in women 
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with RM compared to multiparous controls (Figure 4.1, Table 4.2). compared 
to multiparous controls The pulse pressure amplification was higher in the 
nulliparous controls and RM group compared to the multiparous controls and 
women with previous PE/IUGR (1.4 ± 0.2 versus 1.3 ± 0.4, P = 0.004). 
Women with previous PE and/or IUGR had significantly higher PVR by 221 ± 
75 dynes.s-1.cm-5 than the multiparous control group of women (P = 0.02). The 
unadjusted AIx was higher in the women with PE/IUGR compared to 
nulliparous controls (P = 0.001), but after adjustment for age, height and heart 
rate (HR), there was no significant difference between the AIx in different 
groups. There were no significant differences between the CO, CI, HR and 
aPWV between the groups. The SV was higher by 15 ± 5 mL in the RM group 
compared to the multiparous controls (P =0.02).  
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Table 4.2: Differences in clinical characteristics of normal nulliparous and 
multiparous controls, with previous PE and/or IUGR and recurrent miscarriage 
(RM) 
Cardiovascular 
parameter 
Nulliparous 
(70) 
Multiparous 
(35) 
Previous 
PE/IUGR 
(15) 
RM 
(26) 
P 
Brachial SBP, 
mmHg 
109 ± 9 108 ± 9 115 ± 10 109 ± 12 0.1 
Brachial DBP, 
mmHg 
72 ± 7 71 ± 8* 78 ± 9* 72 ± 10 0.03* 
Brachial PP, 
mmHg 
36 ± 5 37 ± 6 37 ± 4 37 ± 7  0.9 
Central SBP, 
mmHg 
99 ± 9* 100 ± 9* 108 ± 10* 100 ± 11 0.01* 
Central PP, 
mmHg 
26 ± 5 28 ± 5 29 ± 4 27 ± 4 0.04* 
PP amplification 1.4 ± 0.2* 1.3 ± 0.1* 1.3 ± 0.1* 1.4 ± 0.1 0.001* 
MAP, mmHg 85 ± 8* 84 ± 9* 93 ± 9* 86 ± 10 0.02* 
Heart rate, 
beats/min 
69 ± 10 68 ± 9 68 ± 12 68 ± 12 0.9 
CO, L/min 5.7 ± 1.0 5.5 ± 0.9 5.2 ± 1.1 5.9 ± 1.2 0.2 
CI, L/min/m
2
 3.3 ± 0.6 3.2 ± 0.5 3.1 ± 0.6 3.3 ± 0.7 0.6 
SV, ml 80 ± 15 78 ± 12 68 ± 24 82 ± 14 0.02* 
PVR, dynes.s
-
1
.cm
-5
 
1223 ± 240* 1248 ± 216* 1468 ± 311* 1206 ± 232* 0.004* 
Unadjusted AIx, 
% 
18 ± 10* 23 ± 7 28 ± 5* 22 ± 9 0.001 
AIxa, % 19 ± 9 22 ± 8 25 ± 8 20 ± 9 0.2 
Unadjusted 
aPWV, m/sec 
5.3 ± 0.7 5.3 ± 0.7 5.7 ± 0.7 5.4 ± 0.7 0.1 
aPWVb , m/sec 5.3 ± 0.8 5.3 ± 0.6 5.4 ± 0.8 5.3 ± 0.5 0.9 
 
Data are means ± S.D. a=adjusted for age, height and heart rate. b=adjusted for age 
and MAP. (SBP= Systolic blood pressure, DBP= Diastolic blood pressure, PP= pulse 
pressure, MAP=Mean arterial pressure, CO=cardiac output, SV= stroke volume, 
PVR= peripheral vascular resistance) *P <0.05 using one way ANOVA. *P <0.05 for 
control versus PE/IUGR or RM is by post hoc comparison using Bonferroni test  
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Figure 4.1 Differences in Brachial SBP and Brachial DBP between women with 
PE/IUGR versus controls and those with RM versus control 
 
Differences in blood biochemistry and platelet aggregation between the 
groups (Table 4.3) Serum low-density lipoprotein concentration was higher in 
the RM group compared to the nulliparous group by 0.5 ± 0.2 mmol/l (P = 
0.04) and the cholesterol:high-density lipoprotein (HDL) ratio was higher in the 
previous PE/IUGR group compared to the nulliparous controls by 0.5 ± 0.2 
mmol/l (P = 0.06). However, there was no significant difference between the 
cholesterol, triglycerides, plasma glucose and platelet aggregation between 
the groups. Women with previous PE/IUGR had the lowest e-GFR, lower than 
the nulliparous women by 13 ± 5 ml/min/1.73m2, (P = 0.04). e-GFR was lower 
in the healthy multiparous women in comparison to the nulliparous women by 
9 ± 3 ml/min/1.73m2, (P=0.04). There was no difference in renal function 
between RM and the multiparous controls and in the serum creatinine 
between all the four groups. 
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Table 4.3: Metabolic risk factors, renal function and platelet aggregometry 
 
 
Nulliparous 
(70) 
Multiparous 
(35) 
Previous 
PE/IUGR 
(15) 
RM 
(25#) 
P
*
 
Total cholesterol, 
mmol/L 
4.5 ± 0.8  4.8 ± 0.9 4.8 ±0.9 5.0 ± 0.7 0.08 
Triglyceride, mmol/L 0.8 ± 0.8 1.0 ± 0.8 1.1 ± 0.9 1.2 ± 1.2 0.4 
HDL, mmol/L 1.6 ± 0.3 1.6 ± 0.3 1.5 ± 0.4 1.6 ± 0.3 0.5 
LDL, mmol/L 2.7 ± 0.7* 2.9 ± 0.7 2.9 ± 0.7 3.2 ± 0.6* 0.04* 
Cholesterol:HDL ratio 2.9 ± 0.6* 3.1 ± 0.6 3.4 ± 1.0* 3.3 ± 0.8 0.02* 
Plasma Glucose, 
mmol/L 
4.3 ± 0.4 4.4 ± 0.3 4.4 ± 0.3 4.3 ± 0.4 0.7 
HbA1c, mmol/L  34 ± 3 35 ± 3 36 ± 4 36 ± 4 0.1 
Creatinine, µmol/L 66 ± 13 68 ± 6 73 ± 20 66 ± 9 0.1 
eGFR, ml/min/1.73m
2
 101 ± 18* 92 ± 10* 88 ± 22* 96 ± 14 0.04* 
AUC with 10µl ADP  64 ± 22 63 ± 21 74 ± 22 71 ± 21 0.2 
AUC with 5µl ADP 58 ± 21 58 ± 22 61 ± 22 64 ± 23 0.7 
AUC with 2µl ADP 43 ± 23 44 ± 20 44 ± 21 48 ± 26 0.8 
AUC with 1µl ADP 31 ± 18 31 ± 20 31 ± 14 34 ± 21 0.9 
AUC with1µl Low ADP 17 ± 12 14 ± 9 18 ±17 23 ± 16 0.07 
 
HDL: High-density lipoprotein, LDL: Low density lipoprotein, HbA1c: haemoglobin 
A1c, eGFR: estimated glomerular filteration rate, AUC: Area under the curve on 
aggregometry, ADP: Adenosine diphosphate. *P < 0.05 significant by one-way 
ANOVA between the three groups. *P <0.05 for control versus PE/IUGR or RM is by 
post hoc comparison using Bonferroni test with post hoc tests between groups. # n = 
25: one missing data 
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4.3.2 Pre-pregnancy differences in relation to the current pregnancy 
outcome 
Seventy, out of the 143 women planning to conceive had livebirths. Of these 
one woman was lost to follow up, 5 pregnancies were complicated by PE 
and/or IUGR and 64 pregnancies were normal. There was no difference in the 
age (mean age of 32 years) or BMI between the women with normal 
pregnancy and those with PE/IUGR (26 ± 1 kg/m2 in normal versus 29 ± 2 
kg/m2 in the PE/IUGR group respectively). 
Differences in cardiovascular function (Table 4.4): On comparing the pre-
pregnancy cardiovascular function between women who developed 
uteroplacental insufficiency in the form of either PE or IUGR and those with 
normal pregnancy there were no significant differences between the brachial 
SBP, DBP and MAP. The central SBP was 8 ± 4 mm Hg higher in the 
PE/IUGR group compared to those with normal pregnancy, (P=0.06, Figure 
4.2).  
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Figure 4.2 Pre-pregnancy central SBP is higher in women with PE/IUGR (1= 
Normal pregnancy, 2= women who developed PE/IUGR in their current pregnancy) P 
= 0.06 by Mann-Whitney U test.  
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The pre-pregnancy HR was 10 ± 4 beats/minute lower in women who 
developed PE/IUGR compared to those with normal pregnancy, (P = 0.02, 
Figure 4.3).  
 
Figure 4.3 Pre-pregnancy HR is lower in women with PE/IUGR (1= Normal 
pregnancy, 2- women who developed PE/IUGR in their current pregnancy) *P = 0.02 
by Mann-Whitney U test.  
The pre-pregnancy PVR was higher by 219 ± 82 dynes.s-1.cm-5 in women who 
developed PE/IUGR compared to women with normal pregnancies, (P = 0.02, 
Figure 4.4). 
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Figure 4.4 Higher pre-pregnancy PVR in women with PE/IUGR (1= normotensive 
women, 2 = women who develop PE/IUGR) (*P = 0.02 by Mann-Whitney U test). 
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There was no significant difference between the CO, CI and SV between the 
two groups. There was no difference between AIx adjusted for age, height and 
HR prior to pregnancy between those who had normal pregnancy and had 
uteroplacental insufficiency. The unadjusted aPWV was higher is women who 
developed PE/IUGR compared to those with normal pregnancy (5.9 ± 0.6 
versus 5.3 ± 0.6 m/sec, P = 0.03) however there was no difference between 
aPWV adjusted for age and MAP (5.6 ± 0.6 versus 5.3 ± 0.6 m/sec, P = 0.3) 
Table 4.4 Differences in the pre-pregnancy cardiovascular parameters between 
women with normal pregnancy and those with utero-placental insufficiency 
Cardiovascular parameter 
 
Normal pregnancy 
(64) 
PE/IUGR 
(5) 
P 
Brachial SBP, mmHg 108 ± 9 114 ± 9 0.2 
Brachial DBP, mmHg 71 ± 7 77 ± 7 0.1 
Brachial PP, mmHg 37 ± 6  37 ± 3 0.9 
Central SBP, mmHg 99 ± 9 107 ± 9 0.06 
Central PP, mmHg 27 ± 5 29 ± 6 0.4 
PP amplification 1.4 ± 0.2 1.3 ± 0.2 0.1 
MAP, mmHg 85 ± 8 91 ± 8 0.1 
Heart rate, beats/min 68 ± 10 58 ± 9 0.02* 
CO, L/min 5.6 ± 1.0 5.0 ± 0.6 0.3 
CI, L/min/m
2
 3.2 ± 0.5 2.7 ± 0.5 0.08 
SV, ml 79 ± 12 83 ± 11 0.8 
PVR, dynes.s
-1
.cm
-5
 1240 ± 224 1459 ± 172 0.02* 
Unadjusted AIx, % 20 ± 9 27 ± 10 0.08 
AIxa, % 20 ± 9 24 ± 4 0.3 
Unadjusted aPWV, m/sec 5.3 ± 0.6 5.9 ± 0.6 0.03* 
aPWVb , m/sec 5.3 ± 0.6 5.6 ± 0.6 0.3 
 
Data are means ± S.D. a = adjusted for age, height and heart rate. b = adjusted for 
age and MAP. (SBP= Systolic blood pressure, DBP= Diastolic blood pressure, PP= 
pulse pressure, MAP=Mean arterial pressure, CO=cardiac output, SV= stroke volume, 
PVR= peripheral vascular resistance). *P < 0.05 is significant by Mann-Whitney U test.  
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Differences in pre-pregnancy blood biochemistry in relation to pregnancy 
outcome in the current pregnancy: We did not find any difference in the pre-
pregnancy blood glucose, lipid profile or platelet aggregation between the 
normal pregnancies and those who had PE/IUGR. However, the number is too 
small to establish statistical significance. 
Table 4.5 Differences in the pre-pregnancy blood biochemistry and platelet 
aggregometry between women with normal pregnancy and those with utero-
placental insufficiency 
 Normal pregnancy  
(64) 
PE/IUGR            
(5) 
P
* 
Total cholesterol, mmol/L 4.7 ± 0.8 4.2 ± 0.4 0.09 
Triglyceride, mmol/L 0.9 ± 0.8 0.7 ± 0.1 0.8 
HDL, mmol/L 1.6 ± 0.3 1.4 ± 0.4 0.2 
LDL, mmol/L 2.9 ± 0.7 2.5 ± 0.2 0.2 
Cholesterol:HDL ratio 3.1 ± 0.7 3.1 ± 0.7 0.8 
Plasma Glucose, mmol/L 4.4 ± 0.3 4.3 ± 0.5 0.6 
HbA1c, mmol/L 34.8 ± 0.4 34.8 ± 1.1 0.9 
Creatinine, µmol/L 67 ± 9 63 ± 9 0.5 
eGFR, ml/min/1.73m
2
 96 ± 2 103 ± 11 0.7 
AUC with 10µl ADP  65 ± 21 75 ± 24 0.2 
AUC with 5µl ADP 59 ± 20 68 ± 30 0.3 
AUC with 2µl ADP 45 ± 23 40 ± 27 0.6 
AUC with 1µl ADP 31 ± 19 38 ± 20 0.3 
AUC with1µl Low ADP 16 ± 10 19 ± 11 0.3 
 
HDL: High-density lipoprotein, LDL: Low density lipoprotein, HbA1c: Hemoglobin A1c, 
eGFR: estimated glomerular filteration rate, AUC: Area under the curve on 
aggregometry, ADP: Adenosine diphosphate. P <0.05 is significant by Mann- Whitney 
U test 
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4.4 Discussion    
Women with previous PE/IUGR had higher DBP, central SBP, MAP, PVR and 
lower PP amplification compared to both controls and women with RM as has 
been shown before with no difference between cholesterol, triglycerides, 
glucose or platelet function contrary to what has been shown before.163 
In contrast to women with previous PE/IUGR, women with previous 
unexplained RM had no difference in the cardiovascular function compared to 
normal controls. The women with RM had higher LDL cholesterol compared to 
nulliparous controls and those with PE/IUGR had higher total cholesterol:HDL 
ratio compared to multiparous controls. We found no difference in the adjusted 
AIx or aPWV between women with PE/IUGR and normal controls consistent 
with previous studies.141,163 Women with previous PE/IUGR, in contrast to 
those with RM also had a strong family history of CVD compared to controls. 
This finding in PE/IUGR is consistent with previous studies,238 although does 
not establish cause or effect.  
On comparing the pre-pregnancy cardiovascular function in relation to 
development of utero-placental insufficiency in the current pregnancy, we 
found that the women who developed either PE or IUGR had higher PVR and 
lower HR with higher central SBP. There was no significant difference in 
brachial SBP, DBP, MAP, CO or CI between the groups. We did not find any 
difference in pre-pregnancy aortic stiffness between the women with normal 
pregnancy and those with PE/IUGR when the AIx was adjusted for age, height 
and HR, and the aPWV was adjusted for age and MAP.  
4.5 Conclusion 
Women with previous PE/IUGR had higher BP and PVR compared to normal 
multiparous or nulliparous women. Women with unexplained RM had no 
difference in their cardiovascular function. Pre-pregnancy HR was lower with 
higher PVR in women who subsequently developed either PE and/or IUGR in 
their current pregnancy. This highlights the importance of future prospective 
studies of maternal cardiovascular function from prior to conception in order to 
account for the pre-existing abnormalities in cardiovascular function and 
enable assessment of exact physiological maladaptation during pregnancy. 
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CHAPTER 5: CARDIOVASCULAR, METABOLIC AND 
PLATELET CHANGES IN NORMAL PREGNANCIES 
 
 
 
Summary points: 
Timing in pregnancy Maximum change in cardiovascular function  
Early pregnancy (6 weeks)  HR 
 Brachial and central BP, MAP, PVR, AIx 
 Platelet aggregation 
First trimester (10-12 weeks)  eGFR, HDL cholesterol 
Second trimester (23-24 weeks)  HR 
 CO 
 Brachial and central BP, MAP, PVR, AIx and 
aPWV 
Third trimester (33-34 weeks)  HR 
 Brachial and central BP, MAP, PVR, AIx 
 CO 
Postpartum SBP lower and AIx higher compared to pre-
pregnancy values 
 
 
 
 
 
 
 
 
 
This chapter is based on: 
Mahendru AA, Everett TR, Wilkinson IB, Lees CC, McEniery CM.  Maternal 
cardiovascular changes from pre-pregnancy to very early pregnancy. J Hypertens. 
2012 Nov; 30(11):2168-72 
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5.1 Introduction 
Normal pregnancy is associated with profound cardiovascular changes in BP, 
CO and HR, beginning as early as 5 to 6 weeks in pregnancy.24-26 Recognition 
of changes in normal pregnancies has highlighted that pregnancies 
complicated by uteroplacental insufficiency may be associated with abnormal 
cardiovascular adaptation.19  
The existing information on cardiovascular and metabolic changes in normal 
pregnancy is mostly from cross-sectional studies or longitudinal studies using 
either first trimester or postpartum measurements as baseline values. There is 
lack of longitudinal studies describing changes in pulse wave reflection, 
central BP and aortic stiffness from a pre-pregnancy baseline. The extent of 
cardiovascular changes may be underestimated by using late first trimester 
‘baseline’ if these parameters have already altered by later first trimester and if 
the changes persist in the postpartum period. 
The objective of this study was to investigate prospective changes in maternal 
cardiovascular haemodynamics during normal pregnancy in nulliparous 
women and those with previous normal pregnancy, from prior to pregnancy 
until the postpartum period along with changes in metabolic, renal function 
and platelet aggregation in first trimester.  
5.2 Methods  
Cardiovascular function was assessed by measurements of brachial and 
central BP, HR, CO, SV, peripheral vascular resistance (PVR), augmentation 
index (AIx), carotid-femoral pulse wave velocity (aPWV) prior to pregnancy, 
very early in pregnancy, second trimester, third trimester and 3 to 4 months 
postpartum in the 54 women in control group with normal pregnancies. The 
metabolic changes in lipids including total cholesterol, triglycerides, HDL 
cholesterol, LDL cholesterol and Cholesterol/HDL ratio were assessed from 
prior to pregnancy to late first trimester and then reassessed 3 to 4 months 
postpartum. The platelet function was assessed prior to pregnancy, very early 
in pregnancy and 3 to 4 months postpartum. Details of the cardiovascular 
tests, blood biochemistry and platelet function test are described in chapter 2. 
The timings of cardiovascular, metabolic and platelet tests are described in the 
figure below. 
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Figure 5.1 Timing of cardiovascular assessments (middle), blood biochemistry 
tests (3) and platelet tests (3) described as median [IQR] 
Longitudinal data on cardiovascular assessment, blood biochemistry and 
platelet aggregation data were analyzed using repeated measures ANOVA 
with the Bonferroni post-hoc test for pair wise comparisons. Out of the total 54 
cases, early pregnancy measurements were missing in one case, second and 
third trimester measurements were missing in two cases and postpartum 
measurements in other two cases. For the cases where the cardiovascular 
data was missing, this was entirely at random and by chance and therefore, 
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new data values was imputed at that time point by calculating the estimated 
value using the mean difference of changes at that time in the pregnancy.233 
The differences between the pre-pregnancy and postpartum values were 
assessed using paired student t- test for normally distributed data and Mann-
Whitney U-test for non-normally distributed data. The AIx and carotid-femoral 
(aortic) aPWV at various times were compared using ANOVA – generalized 
linear model univariate analysis using age, height and heart rate as covariates 
for AIx and MAP as a covariate for aPWV. A value of P<0.05 was considered 
to be statistically significant. All P values were two-tailed. 
5.3 Results  
5.3.1 Demographics (Table 5.1) 
The multiparous women were older than the nulliparous women (33years 
compared to 31 years, P = 0.04). Most of the women were Caucasian. There 
was no difference in the height, weight or body mass index (BMI) between the 
nulliparous and multiparous women.  
Table 5.1: Demographic data of 54 women with normal pregnancies 
 Nulliparous (33) Multiparous (21) 
Age, years 
 
31  ± 3* 33 ± 5* 
Ethnicity, Caucasian 
 
29/33 (89%) 20/21 (95%) 
 
Height, meters 
 
1.64 ± 0.07 1.67 ± 0.08 
Weight, Kg 
 
67 ± 12 71 ± 13 
BMI, Kg/meters
2
 
 
25 ± 5 26 ± 4 
  
*Data are mean ± SD. *P<0.05 is significant by independent sample t-test 
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5.3.2 Timing of pre-pregnancy tests 
The pre-pregnancy visits were performed in both follicular and luteal phases of 
the cycle at a median of 14 days. There was no difference in pre-pregnancy to 
early pregnancy changes in maternal haemodynamics between the follicular 
or luteal phase of the menstrual cycle (Table 5.2). The timing of pre-pregnancy 
cardiovascular tests is reported as median days of the menstrual cycle. 
Table 5.2 Pre to early pregnancy changes in maternal haemodynamics 
described from follicular phase to early pregnancy and luteal phase to early 
pregnancy 
Cardiovascular parameter Follicular phase to 
early pregnancy 
difference 
 (n=30) 
Luteal phase to 
early pregnancy 
difference 
(n=26) 
P 
HR, beats/min 3 ± 6 3 ± 8 0.7 
Brachial SBP, mm Hg 6 ± 6 3 ± 8 0.2 
Brachial DBP, mm Hg 7 ± 5 5 ± 7 0.4 
MAP, mm Hg 8 ± 5 5 ± 8 0.2 
Central SBP, mm Hg 8 ± 6 5 ± 8 0.1 
CO, Litres/min 0.2 ± 0.7 0.2 ± 1.1 0.8 
SV, Litres 0.1 ± 11.8 3.3 ± 15.1 0.8 
PVR, dynes.s
-1
.cm
-5
 134 ± 144 61 ± 338 0.3 
AIx, % 8 ± 6 5 ± 8 0.1 
aPWV, m/sec 0.1 ± 0.6 0.1 ± 0.5 0.9 
 
*Data are means ± SD 
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5.3.3 Longitudinal cardiovascular changes in normal pregnancies 
(excluding three pregnancies with PE/IUGR) (Table 5.3)  
Blood pressure: There was a significant reduction in brachial SBP (4 ± 7 mm 
Hg), DBP (6 ± 6 mm Hg), MAP (6 ± 7 mm Hg) and central SBP (7 ± 7 mm Hg) 
from pre-pregnancy to early pregnancy (Table 5.3, Figure 5.2a). Further 
reduction of brachial SBP, DBP, MAP and central SBP occurred from first to 
second trimester but to a lesser extent than that from pre pregnancy to early 
pregnancy. All BP increased in the third trimester but were still below the 
baseline pre-pregnancy values. Postpartum, the brachial and central SBP 
were still significantly lower than the pre-pregnancy level by 4 ± 8 mm of Hg 
(P< 0.001, Figure 5.2b) at 16 weeks postpartum. Follow up did not continue 
beyond 16 weeks. 
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Figure 5.2a Changes in brachial, central SBP, DBP and MAP from pre-pregnancy 
to postpartum period. (T2 = second trimester and T3 = third trimester. The red box 
highlights the timing of significant changes in BP from pre pregnancy to early 
pregnancy) 
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Figure 5.2b Persistence of reduced brachial SBP and central SBP in the 
postpartum period. * P < 0.05 is significant by paired student t- test. 
*P<0.001 
*P=0.008 
*P<0.001 
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CO and SV: The CO increased by 0.6 ± 1.0 L/min from the pre-pregnancy 
period to the second trimester with minimum change from pre-pregnancy 
period to very early in first trimester. It decreased slightly but non-significantly 
in the third trimester and fell to the pre-pregnancy baseline in the postpartum 
period. There was no significant change in SV during pregnancy, however SV 
was higher in the postpartum period compared to the third trimester (83ml 
versus 77ml, P=0.03). The increase in CO in second trimester was probably 
due to an increase in HR. 
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Figure 5.3 Changes in CO and SV during normal pregnancy. Significant increase 
was seen in CO in the second trimester. (T2 = second trimester and T3 = third 
trimester) 
↑CO (**P = 0.001) 
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Heart Rate: There was a continuous increase in HR throughout pregnancy 
until the third trimester with a total increase of 13 ± 11bpm (overall 20% 
increase in the HR). The heart rate fell after delivery and with a decrease in 
HR from third trimester back to pre-pregnancy values in the postpartum 
period. 
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Figure 5.4 Changes in heart rate from prior to pregnancy to the postpartum 
period. HR increased throughout pregnancy. (T2 = second trimester and T3 = third 
trimester) 
**P=0.02 
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Pulse wave analysis (AIx): There was a significant reduction in both 
unadjusted AIx and AIx adjusted for heart rate from prior to pregnancy to early 
pregnancy (P=0.003), with further reduction in second trimester. However, 
most of the reduction in AIx (70% of the maximum reduction) occurred very 
early in pregnancy (Figure 5.5a). AIx increased in the third trimester and 
postpartum period with AIx in the postpartum period being significantly higher 
than the pre-pregnancy baseline (P = 0.01, Figure 5.5b). 
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Figure 5.5a Changes in AIx from prior to pregnancy to the postpartum period 
(T2 = second trimester and T3 = third trimester) 
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Figure 5.5b Higher AIx (Unadjusted and adjusted) in the postpartum period 
compared to the pre-pregnancy period. * P < 0.05 is significant by paired student t- 
test. 
*P =0.001 
*P =0.01 
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Aortic Pulse wave velocity (aPWV):  There was no change in aortic pulse 
wave velocity in the early pregnancy period. There was a trend towards 
reduction of aPWV from second to third trimester. This reduction in the aPWV 
was not statistically significant. It remained lower in third trimester and was 
followed by an increase after delivery to nearly the pre-pregnancy values. 
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Figure 5.6 Changes in aortic pulse wave velocity from prior to pregnancy to 
postpartum period. 
Peripheral vascular resistance: Peripheral vascular resistance reduced in very 
early pregnancy and further more in second trimester. The PVR reached its 
nadir in the second trimester and then continued to increase in the third 
trimester and postpartum period and reached to the value similar to the pre-
pregnancy baseline in the postpartum period.  
600
800
1000
1200
1400
1600
Pre-pregnancy Early pregnancy T2 T3 Postpartum
P
V
R
, 
d
y
n
e
s
.s
-1
.c
m
-5
P =0.09
* P =0.03
** P < 0.001
* P = 0.03
** P= 0.001
 
Figure 5.7 Changes in the PVR from a pre-pregnancy baseline to postpartum 
period 
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Table 5.3 Longitudinal changes in cardiovascular function in 54 normal 
pregnancies 
Parameter Pre-
pregnancy 
Early 
pregnancy 
Second 
trimester 
(T2) 
Third 
trimester 
(T3) 
 
Postpartum 
HR, beats/min 68 ± 10* 71 ± 10* 76 ± 10 * 80 ± 10* 68 ± 8* 
Brachial SBP, mm 
Hg 
108 ± 9* 104 ± 7* 103 ± 7  105 ± 8 104 ± 8* 
Brachial DBP, mm 
Hg 
71 ± 7* 65 ± 6* 63 ± 5* 68 ± 6* 69 ± 6 
MAP, mm Hg 84 ± 8* 78 ± 6* 76 ± 5* 81 ± 6* 82 ± 7 
Central SBP, mm 
Hg 
99 ± 9* 92 ± 7* 90 ± 6 93 ± 7* 96 ± 7  
CO, L/min 5.6 ± 1.0* 5.8 ± 1.2 6.2 ± 1.0* 6.1 ± 1.0 5.6 ± 1.0 
CI, L/min/m
2
 3.2 ± 0.6 3.3 ± 0.7 3.5 ± 0.5 3.3 ± 0.5 3.2 ± 0.5 
SV, ml 79 ± 12 78 ± 18 80 ± 12 77 ± 13* 83 ± 18* 
Unadjusted AIx, % 19 ± 10 12 ± 9* 9 ± 9* 12 ± 9 23 ± 6* 
Adjusted AIx,
 
% 18 ± 8* 12 ± 8* 10 ± 8* 14 ± 9 22 ± 8* 
Unadjusted aPWV, 
m/sec 
5.2 ± 0.6 5.1 ± 0.6 4.8 ± 0.5 4.9 ± 0.5 5.1 ± 0.6 
Adjusted aPWV, 
m/sec 
5.1 ± 0.7 5.2 ± 0.7 4.9 ± 0.7 4.9 ± 0.7 5.0 ± 0.7 
PVR, dynes.s
-1
.cm
-5
 1229 ± 232* 1129 ± 291 999 ± 181* 1081 ± 201* 1207 ± 227* 
 
Data are means ± S.D. HR= heart rate, SBP= Systolic blood pressure, DBP= Diastolic 
blood pressure, MAP=Mean arterial pressure, CO=cardiac output, SV= stroke volume, 
PVR= peripheral vascular resistance), *P<0.05 by repeat measures univariate 
analysis for overall significance and significance of difference between each visit in 
relation to the previous value calculated by post-hoc Bonferroni correction. 
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5.3.4 Changes in renal function from pre-pregnancy to postpartum 
period (n=51) (Table 5.4)  
There was significant decrease in serum creatinine (P <0.001) associated with 
an increase in eGFR (P <0.001) at the end of first trimester (Figure 5.8). The 
postpartum values were similar to the pre-pregnancy values. 
Table 5.4 Changes in renal functions from pre-pregnancy to first trimester and 
postpartum 
Renal function test Pre-
pregnancy 
First 
trimester 
Postpartum *P 
Creatinine, µmol/L 67 ± 9* 53 ± 8* 69 ± 11* <0.001 
eGFR, ml/min/1.73m
2
 98 ± 17*  127 ± 25* 95 ± 20* <0.001 
Sodium, mmol/L 138 ± 2 137 ± 2* 140 ± 2* <0.001* 
Potassium, mmol/L 3.9 ± 0.3* 4.0 ± 0.4 4.1 ± 0.4* 0.002 
 
*P<0.05 is significant by repeat measures analysis and significance of difference is 
between each visit in relation to the previous value calculated by post-hoc Bonferroni 
correction. 
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Figure 5.8 Estimated glomerular filtration rate (eGFR) increased significantly by 
late first trimester. (*P<0.05 is significant by paired t-test between the pre-pregnancy 
and first trimester values) 
*P<0.001 
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5.3.5 Metabolic changes from pre-pregnancy to postpartum period (n=46)  
Serum HDL increased, serum LDL and total cholesterol:HDL ratio decreased 
in the late first trimester in the 46 cases where tests were performed as per 
protocol (Figure 5.8). There was no difference between the pre-pregnancy and 
postpartum values of the lipid profile (Table 5.5). There was no change in 
plasma glucose in the first trimester.  
Table 5.5 Changes in lipid profile from pre-pregnancy to first trimester and 
postpartum 
 Pre-
pregnancy 
First 
trimester 
Postpartum P 
Total cholesterol, mmol/L 4.7 ± 0.9 4.7 ± 0.8 4.6 ± 0.9 NS 
Triglyceride, mmol/L 1.0 ± 0.9 1.0 ± 0.4 0.9 ± 0.7 NS 
HDL, mmol/L 1.6 ± 0.4* 1.8 ± 0.4* 1.6 ± 0.4* <0.001* 
LDL, mmol/L 2.8 ± 0.7* 2.4 ± 0.7* 2.7 ± 0.7* <0.001* 
Total cholesterol:HDL ratio 3.0 ± 0.6 2.6 ± 0.5* 2.9 ± 0.7* <0.001* 
Plasma Glucose, mmol/L 4.3 ± 0.4 4.3 ± 0.6 4.3 ± 0.6 NS 
 
*P<0.05 is significant by repeat measures analysis and significance of difference is 
between each visit in relation to the previous value calculated by post-hoc Bonferroni 
correction 
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Figure 5.9 HDL increased in the first trimester and LDL decreased when 
compared to pre-pregnancy values. (*P<0.05 is significant by paired t-test between 
the pre-pregnancy and first trimester values) 
*P=0.001 
*P=0.001 
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5.3.6 Changes in platelet aggregation during normal pregnancy (n=48) 
There was increased platelet aggregation at higher doses of 10µl ADP and 5µl 
ADP in early pregnancy (P=0.002 and P=0.004 respectively, Figure 5.10) 
compared to at lower doses of 2µl ADP and below (Table 5.5). There was no 
difference between the pre-pregnancy and postpartum values. 
Table 5.6 Changes in platelet aggregation at different concentrations of ADP 
 Pre-
pregnancy 
Early 
pregnancy 
Postpartum 
 
P 
Time from phlebotomy, minutes 15[13-21] 17[12-24] 22[17-25]  
AUC with 10µl ADP 64 ± 21* 73 ± 18* 70 ± 21 0.02* 
AUC with 5µl ADP 59 ± 20* 66 ± 21* 65 ± 23 0.08 
AUC with 2µl ADP 44 ± 22 49 ± 24 49 ± 26 0.2 
AUC with 1µl ADP 32 ± 21 37 ± 22 38 ± 23 0.1 
AUC with 1µlLow ADP 16 ± 11* 22 ± 13* 22 ± 15 0.01* 
 
*P<0.05 is significant by repeat measures analysis and significance of difference is 
between each visit in relation to the previous value calculated by post-hoc Bonferroni 
correction 
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Figure 5.10 Significant platelet aggregation was seen in very early pregnancy 
compared to pre-pregnancy values. *P<0.05 is significant by paired t-test 
*P=0.002 
*P=0.004 
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5.4 Discussion 
The major novel finding was a significant reduction in central, brachial BP, AIx 
and PVR very early in pregnancy at about 6 weeks gestation in relation to the 
pre-pregnancy baseline values. This is similar to observations from previous 
smaller longitudinal studies beginning from prior to pregnancy.24-26 This 
reduction was followed by a significant increase in the CO from the pre-
pregnancy baseline by 23-24 weeks along with an increase in HR throughout 
pregnancy with non-significant changes in SV. The initial changes in BP, PVR 
and HR were associated with a significant increase in eGFR by the end of first 
trimester, consistent to previous studies,146 suggesting that these changes 
were associated with volume expansion. The initial increase in CO could be 
explained by an increase in HR, however, persistent increase in preload due 
to volume expansion would explain the increase in SV and reduction in the 
aortic stiffness related to changes in structural properties of heart and aorta.  
The brachial and central SBP were still lower than the pre-pregnancy value, 
whereas the AIx was higher at 3 to 4 months postpartum. Therefore, it is likely 
that longitudinal studies of cardiovascular changes in pregnancy 
underestimate the pregnancy changes using postpartum ‘baseline’ values. 
The higher AIx in the postpartum period could be due to higher SV in the 
postpartum period. Hence, it is instructive to report comprehensive 
haemodynamic changes rather than cardiovascular parameters in isolation in 
order to understand the pathophysiology of cardiovascular function in normal 
and complicated pregnancies. 
We reported a significant increase in HDL cholesterol at the end of first 
trimester along with a significant reduction in LDL cholesterol, a reduction in 
the cholesterol:HDL ratio with all values returning to pre-pregnancy baseline in 
the post-partum period. Changes in total cholesterol and triglycerides are 
perhaps more significant in the latter part of pregnancy in association with fetal 
growth and may be influenced by hormonal changes at the feto-maternal 
interface later in pregnancy. Therefore, we did not find a significant change in 
total cholesterol or triglycerides in first trimester. The return to a pre-pregnancy 
baseline supports the hypotheses of pregnancy being a transient atherogenic 
event. 
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We reported increased platelet aggregation in very early pregnancy using 
platelet aggregometry consistent with previous studies suggesting platelet 
activation during pregnancy.184 The changes in BP, systemic vascular 
resistance and blood flow very early in pregnancy may be responsible for the 
platelet aggregation.  
5.5 Conclusion  
This is the first prospective study to report longitudinal changes in maternal 
cardiovascular function during pregnancy including central BP, AIx and aPWV, 
along with brachial BP, CO and PVR, renal function, lipid profile and platelet 
activation from prior to pregnancy up to the postpartum period. We found 
significant reduction in central, brachial BP, AIx and PVR very early in 
pregnancy at about 6 weeks gestation and an associated increase in eGFR by 
the end of first trimester. This was followed by a maximum increase in the CO 
from the pre-pregnancy baseline by 23-24 weeks along with an increase in HR 
throughout pregnancy. The metabolic function and platelet activation being 
similar in the pre-pregnancy and post-partum period may suggest thereby that 
a normal pregnancy may not have residual atherogenic effect on a woman’s 
cardiovascular system. Significant changes in the cardiovascular system in 
very early pregnancy together with the persistence of changes in the BP in the 
postpartum partum period suggest that cardiovascular changes from a late 
first trimester or postpartum ‘baseline’ may not give reliable estimates of 
pregnancy related changes. This highlights the value of conducting future 
longitudinal studies from prior to pregnancy in order to establish the exact 
extent and timing of changes during normal pregnancies and pregnancy 
complications. 
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CHAPTER 6: PREGNANCY CHANGES IN MATERNAL 
CARDIOVASCULAR, METABOLIC AND PLATELET 
FUNCTION IN WOMEN WITH PREGNANCY 
COMPLICATIONS 
 
 
 
Summary points: 
 Similar trends were observed in cardiovascular changes in HR, CO, PVR and 
arterial stiffness in all normal pregnancies. 
 An increase in BP was noted in second trimester in women with previous 
PE/IUGR and all those women who had PE and/or IUGR in their current 
pregnancy. 
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6.1 Introduction  
Nulliparous women are at higher risk of developing PE. Whereas normal 
pregnancy reduces the risk of development of PE in the subsequent 
pregnancy, women with previous PE/IUGR have a higher risk of recurrence of 
uteroplacental insufficiency in their subsequent pregnancy.195 Women with 
previous PE have impaired vascular compliance and increased vascular 
resistance in subsequent pregnancy.239 Recurrent PE/IUGR are associated 
with impaired cardiovascular adaptation in a subsequent pregnancy in the 
form of reduced plasma volume expansion, a lack of increase in the CO and 
an increase in the systemic vascular resistance in the second trimester.240,241  
Pregnancies complicated by IUGR are associated with impaired volume 
expansion and impaired diastolic function very early in pregnancy,19 whereas 
higher CO in late first trimester,27 impaired cardiovascular function236 and 
higher arterial stiffness in second trimester140 are associated with PE. 
In women with RM, there is thought to be higher resistance in the uterine 
blood flow prior to pregnancy and in very early pregnancy irrespective of the 
presence of anticardiolipin antibodies.242,243 RM is believed to be associated 
with long-term cardiovascular dysfunction; however, the cardiovascular 
changes in subsequent pregnancies in women with RM have not been 
described before. 
The objective of this chapter is to describe the longitudinal cardiovascular, 
metabolic and platelet changes in the pregnancies in women with previous 
PE/IUGR, those with RM and those women who had uteroplacental 
insufficiency in their current pregnancy. The study is not powered to compare 
the cardiovascular changes between the groups. 
6.2 Methods 
The cardiovascular parameters in all the normal pregnancies in women with 
previous RM or PE/IUGR are described as means ± standard deviation (SD). 
There were six normal pregnancies in women with previous RM and four 
normal pregnancies in women with previous PE/IUGR. Due to limited numbers 
repeated measures univariate analysis within the subgroups to determine the 
statistical significance of differences between the parameters in different 
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trimesters was not possible. The longitudinal trends of cardiovascular changes 
in these two groups have been described in graphs instead. The differences in 
the trends of cardiovascular changes between the groups were assessed 
using Kruskal Wallis test.  
Amongst the 70 pregnancies, there were five cases with uteroplacental 
insufficiency in the form of PE/IUGR. The trends of cardiovascular changes 
from pre-pregnancy to early pregnancy, early pregnancy to second trimester, 
second to third trimester and third trimester to postpartum have been 
described using descriptive statistics in tables. The differences in the trends 
were compared between the 64 normal pregnancies and the five cases with 
uteroplacental insufficiency using Mann-Whitney U test. A P value of < 0.05 
was considered as significant.  
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6.3 Results 
6.3.1 Longitudinal changes in subsequent normal pregnancies in women 
with previous preeclampsia/intrauterine growth restriction 
Amongst the women with previous PE/IUGR there were 6 viable pregnancies. 
Four out of the six pregnancies were normal. One woman had PE with IUGR 
and another one with IUGR. The cardiovascular changes in the four women 
with previous PE/IUGR who had normal pregnancies during the study are 
described in the Table 6.1.  
Table 6.1 Longitudinal changes in cardiovascular function in 4 normal 
pregnancies in women with previous PE/IUGR 
Parameter Pre-
pregnancy  
(1) 
Early 
pregnancy 
 (2) 
 
Second 
trimester  
(3) 
Third 
trimester  
(4) 
Postpartum 
(5) 
HR, beats/min 73 ± 17 81 ± 10 82 ± 12  84 ± 13 66 ± 11  
Brachial SBP, mm 
Hg 
114 ± 7 105 ± 5 107 ± 5  106 ± 8 100 ± 7 
Brachial DBP, mm 
Hg 
79 ± 9 68 ± 5  68 ± 4  70 ± 4  68 ± 8 
MAP, mm Hg 93 ± 9 82 ± 5  82 ± 4  83 ± 5  81 ± 8 
Central SBP, mm 
Hg 
106 ± 7 94 ± 6 95 ± 4 95 ± 6  88 ± 9  
CO, L/min 5.7 ± 0.5 6.2 ± 1.0 6.3 ± 0.8 5.8 ± 0.5 5.5 ± 1.2 
CI, L/min/m
2
 3.3 ± 0.2 3.6 ± 0.6 3.5 ± 0.6 3.1 ± 0.4 3.1 ± 0.6 
SV, mL 76 ± 18 74 ± 19 76 ± 13 66 ± 10 81 ± 21 
Unadjusted AIx, % 23 ± 3 14 ± 7 10 ± 9  14 ± 11 31 ± 5  
Adjusted AIx, % 22 ± 3 15 ± 4  11 ± 3 16 ± 3  28 ± 4  
Unadjusted aPWV, 
m/sec 
5.5 ± 0.6 5.0 ± 0.5 4.9 ± 0.4  4.8 ± 0.3 4.9 ± 0.3 
Adjusted aPWV, 
m/sec 
5.5 ± 0.6 5.0 ± 0.5 4.9 ± 0.4  4.8 ± 0.3 4.9 ± 0.3 
PVR, dynes.s
-1
.cm
-5
 1317 ± 243 1077 ± 200 1048 ± 103  1161 ± 148 1255 ± 477 
 
Data are means ± S.D. HR= heart rate, SBP= Systolic blood pressure, DBP= Diastolic 
blood pressure, MAP=Mean arterial pressure, CO=cardiac output, SV= stroke volume, 
PVR= peripheral vascular resistance 
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6.3.2 Longitudinal changes in subsequent normal pregnancies in women 
with previous recurrent miscarriage 
All the six pregnancies in the RM group were normal. The descriptive statistics 
of the changes in the various cardiovascular parameters from pre-pregnancy 
to postpartum are described in Table 6.2.  
Table 6.2 Cardiovascular changes in normal pregnancies in women with RM 
Parameter Pre-
pregnancy  
(1) 
Early 
pregnancy 
 (2) 
Second 
trimester  
(3) 
Third 
trimester  
(4) 
Postpartum 
(5) 
HR, beats/min 65 ± 3 75 ± 7 77 ± 1  86 ± 10 68 ± 12  
Brachial SBP, mm 
Hg 
103 ± 5 100 ± 6 98 ± 7 100 ± 5 102 ± 6 
Brachial DBP, 
mm Hg 
71 ± 3 66 ± 7  61 ± 4  67 ± 6 67 ± 5 
MAP, mm Hg 83 ± 3 78 ± 8  74 ± 3  78 ± 6  81 ± 5 
Central SBP, mm 
Hg 
96 ± 4 90 ± 6 87 ± 6 89 ± 4  96 ± 7 
CO, L/min 4.8 ± 0.3 6.2 ± 1.3 7.6 ± 1.2 5.6 ± 0.8 6.1 ± 0.8 
CI,  2.6 ± 0.4 3.4 ± 0.6 4.0 ± 0.7 2.9 ± 0.4 3.3 ± 0.3 
SV, Litres 71 ± 9 81 ± 14 95 ± 22 68 ± 11 93 ± 10 
Unadjusted AIx, 
% 
24 ± 12 16 ± 11 12 ± 9  10 ± 4 27 ± 11  
Adjusted AIx, % 24 ± 12 13 ± 11  13 ± 9 7 ± 4 28 ± 11  
Unadjusted 
aPWV, m/sec 
5.1 ± 0.5 5.3 ± 0.6 4.8 ± 0.6 4.5 ± 0.5 4.9 ± 0.6 
Adjusted aPWV, 
m/sec 
5.2 ± 0.5 5.3 ± 0.6 4.9 ± 0.5  5.0 ± 0.5 4.9 ± 0.6 
PVR, dynes.s
-
1
.cm
-5
 
1401 ± 115 1045 ± 282 789 ± 133  1126 ± 138 1071 ± 151 
 
Data are means ± S.D. HR= heart rate, SBP= Systolic blood pressure, DBP= Diastolic 
blood pressure, MAP=Mean arterial pressure, CO=cardiac output, SV= stroke volume, 
PVR= peripheral vascular resistance  
 
6.3.3 Comparison of trends in cardiovascular changes in all normal 
pregnancies (Total 64 pregnancies in nulliparous women, women with 
previous healthy pregnancies, previous preeclampsia/intrauterine growth 
restriction or recurrent miscarriage) 
Changes in BP: In general there was a reduction in brachial and central SBP, 
brachial DBP and MAP in all normal pregnancies in very early pregnancy 
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(Trends of these changes in BP have been shown in Figures 6.1 (A, B, C and 
D). This was followed by a further non-significant fall of the BP in the second 
trimester in women in the control group and in those with previous RM. 
However, in contrast the BP either remained unchanged or increased in the 
second trimester in women with previous PE/IUGR. The differences in the 
changes in BP were not significantly different between the three groups with 
limited numbers of pregnancies within the groups. 
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A) Brachial SBP 
-♦- Normal group 
-■- Normal pregnancies in 
previous RM 
-▲- Normal pregnancies in 
previous PE/IUGR 
 
B) Brachial DBP 
C) MAP 
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Figure 6.1 Longitudinal changes in A) brachial SBP, B) brachial DBP, C) MAP 
and D) central SBP in normal pregnancies. Normal pregnancies in the control 
group (black--♦--), normal pregnancies in women with previous RM (red--■--) and 
normal pregnancies in women with previous PE/IUGR group (blue--▲--)  
 
Changes in CO, SV and HR: There was an increase in CO (Figure 6.2) 
associated with an increase in HR (Figure 6.3), beginning very early in 
pregnancy and significant by second trimester, also associated with an 
increase in the SV in the second trimester (Figure 6.4). The increase in CO 
and SV was more marked in women with RM compared to the control group 
(P = 0.02) as shown in the figures 6.5 and 6.7. There was marked increase in 
HR in all groups throughout pregnancy (Figure 6.6).  
3.5
4.5
5.5
6.5
7.5
8.5
9.5
C
O
, 
L
/m
in
 
Figure 6.2 Longitudinal changes in CO in all normal pregnancies. Normal 
pregnancies in the control group (black--♦--), normal pregnancies in women with 
previous RM (red--■--) and normal pregnancies in women with previous PE/IUGR 
group (blue--▲--). *P <0.05 is significant by Kruskal Wallis test between the groups. 
 
D) Central SBP 
*P =0.02 
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Figure 6.3 Longitudinal changes in heart rate in all normal pregnancies (Normal 
control group = black--♦--, women with previous RM = red--■-- and those with previous 
PE/IUGR = blue--▲--). 
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Figure 6.4 Longitudinal changes in stroke volume in normal pregnancies. 
(Normal control group = black--♦--, women with previous RM = red--■-- and those with 
previous PE/IUGR = blue--▲--). 
 
CHAPTER 6: CARDIOVASCULAR CHANGES IN PREGNANCY COMPLICATIONS 
 
 126 
Changes in PVR: There was a significant reduction in the PVR beginning from 
very early in pregnancy in all three groups. The early pregnancy drop in PVR 
was significant in the women with RM compared to the normal controls and 
PE/IUGR group (P =0.04). It continued to decrease to reach nadir in the 
second trimester in both control group and women with RM, but not in women 
with PE/IUGR, where it did not decrease significantly in the second trimester 
(Figure 6.5).  
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Figure 6.5 Longitudinal changes in the PVR in normal pregnancies in all groups. 
*P <0.05 is significant by Kruskal Wallis test between the groups 
 
AIx and aPWV: The adjusted AIx reduced significantly during pregnancy in all 
groups and remained higher than pre-pregnancy values in the postpartum 
period (Figure 6.6). 
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Figure 6.6 Longitudinal changes in adjusted AIx in normal pregnancies in the 
control group (black--♦--), women with previous RM (red--■--) and those with previous 
PE/IUGR (blue-▲--) 
*P=0.04 
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The aPWV adjusted for MAP reduced between second and third trimester in 
the control group however the reduction was not statistically significant. A 
similar trend was observed in normal pregnancies in the RM group, however, 
in the PE/IUGR group, aPWV reduced in very early pregnancy. 
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Figure 6.7 Longitudinal trends in aPWV in normal pregnancies in all 
groups (Control group (black-♦-), women with RM (red-■-) and those with 
PE/IUGR (blue-▲-) 
 
Differences in pre-pregnancy to first trimester lipid changes: There was no 
difference in the trend of first trimester increase in HDL cholesterol between all 
the groups. 
Differences in pre-pregnancy to first trimester changes in renal function: There 
was no difference in the increase in estimated GFR in late first trimester 
between all normal pregnancies. 
Differences in pre-pregnancy to early pregnancy platelet aggregation: There 
was no difference between the pre-pregnancy to early pregnancy increase in 
platelet aggregation between the groups with normal pregnancies (mean 
difference in AUC with 10µl ADP of 7.9 ± 21 in controls, 9.4 ± 14 in women 
with PE/IUGR and 2.0 ± 15 in women with RM). 
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6.3.4 Longitudinal changes in current pregnancies complicated by 
preeclampsia and/or intrauterine growth restriction 
The absolute values of the cardiovascular parameters in the 5 pregnancies 
complicated by PE/IUGR have been described below in Table 6.3.  
Table 6.3 Absolute values of the cardiovascular parameters in pregnancies 
complicated by PE/IUGR (n=5) 
Parameter Pre-
pregnancy  
Early 
pregnancy 
Second 
trimester  
Third 
trimester 
Postpartum  
HR, beats/min 59 ± 10 72 ± 11 70 ± 6 72 ± 10 63 ± 8  
Brachial SBP, 
mm Hg 
115 ± 9 107 ± 5 111 ± 10 118 ± 4 111 ± 3 
Brachial DBP, 
mm Hg 
79 ± 7 66 ± 9  72 ± 4  75 ± 2 76 ± 3 
MAP, mm Hg 93 ± 8 80 ± 6  85 ± 4  90 ± 2  89 ± 2 
Central SBP, 
mm Hg 
108 ± 10 94 ± 4 98 ± 5 105 ± 3  103 ± 4 
CO, L/min 5.0 ± 0.7 5.6 ± 0.2 6.5 ± 1.3 6.3 ± 0.9 5.9 ± 0.2 
CI, L/min/m
2
 2.7 ± 0.5 3.0 ± 0.3 3.4 ± 0.5 3.2 ± 0.2 3.1 ± 0.3 
SV, ml 78 ± 4 83 ± 21 96 ± 13 84 ± 5 91 ± 7 
Unadjusted AIx, 
% 
26 ± 11 13 ± 13 14 ± 7  14 ± 12 23 ± 9  
Adjusted AIx, % 23 ± 10 16 ± 13  14 ± 6 18 ± 12 25 ± 11  
Unadjusted 
aPWV, m/sec 
5.7 ± 0.6 5.4 ± 0.5 5.3 ± 0.6 5.1 ± 0.1 5.5 ± 0.5 
Adjusted aPWV, 
m/sec 
5.7 ± 0.6 5.6 ± 0.5 5.2 ± 0.6  5.0 ± 0.1 5.3 ± 0.5 
PVR, dynes.s
-
1
.cm
-5
 
1503 ± 162 1157 ± 91 1078 ± 171 1171 ± 201 1218 ± 64 
 
Data are means ± S.D. HR= heart rate, SBP= Systolic blood pressure, DBP= Diastolic 
blood pressure, MAP=Mean arterial pressure, CO=cardiac output, SV= stroke volume, 
PVR= peripheral vascular resistance.  
 
Changes in BP in pregnancies complicated by PE/IUGR: Women who 
developed PE/IUGR during their index pregnancy in the study had a higher 
pre-pregnancy BP than women with normal pregnancies. These women had a 
significant reduction in the BP in very early pregnancy. However, unlike the 
further drop in BP from early pregnancy to second trimester seen in normal 
pregnancies, there was an increase in brachial DBP by 5 ± 7 mm Hg, in MAP 
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by 5 ± 5 mm Hg and in central SBP by 4 ± 5 mm Hg in the second trimester, 
followed by a further greater increase in the third trimester in women who 
developed PE/IUGR. (Figures 6.8 A, B and C) 
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Figure 6.8 Changes in BP: A) Brachial DBP, B) MAP and C) Central SBP in 
normal pregnancies and pregnancies associated with PE/IUGR.T2= second 
trimester, T3= third trimester. *P<0.05 is significant by Mann-Whitney U test for 
differences between the mean change in BP at different time points in pregnancy 
between normal pregnancy and those with PE/IUGR. 
P =0.05 
* P = 0.02 
A) Brachial DBP 
B) MAP 
C) Central SBP 
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Other cardiovascular changes: The trends of changes in CO, HR, SV, pulse 
wave analysis, aPWV and PVR were similar in the normal pregnancies and 
the pregnancies with PE/IUGR.  
Differences in pre-pregnancy to first trimester lipid changes: There was no 
difference between the first trimester increase in lipids (HDL) between normal 
pregnancies and those with PE/IUGR. 
Differences in pre-pregnancy to first trimester changes in renal function: There 
was no difference in the increase in estimated GFR between all normal 
pregnancies. 
Differences in pre-pregnancy to early pregnancy platelet aggregation: The 
platelet aggregation was higher in women with PE/IUGR (mean difference in 
AUC for aggregation between pre-pregnancy to early pregnancy with 10µl of 
ADP being 11 ± 22 and with 5µl of ADP being 16 ± 20) than in women with 
normal pregnancies (7 ± 20 with 10µl of ADP and 5 ± 16 with 5µl of ADP). 
However, this difference was not statistically significant. 
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 6.4 Discussion  
We found that the cardiovascular changes in early pregnancy were similar in 
all normal pregnancies. Women with previous PE/IUGR had a higher pre-
pregnancy BP and had a significant reduction in the BP in early pregnancy, 
however, in the second trimester instead of a decrease in BP as noted in all 
women in the normal group and women with previous unexplained RM; the 
brachial DBP, central SBP and MAP were found to increase. This finding 
supports that the theory of maternal cardiovascular maladaptation may be 
related to pre-existing higher BP in women with previous PE/IUGR. There was 
no difference in the cardiovascular adaptation in normal pregnancies between 
women with previous unexplained RM and women with previous normal 
pregnancies. We did not find any significant differences in the trends in renal 
function, platelet aggregation or first trimester changes in lipids between 
women with previous PE/IUGR, RM or normal pregnancies. There are no 
previous studies of platelet aggregation or lipids changes in relation to 
previous history of PE/IUGR or unexplained RM to compare our findings. 
In the women who developed PE/IUGR in their current pregnancy, there was a 
trend of an increase rather than decrease in BP, in particular of the MAP in the 
second trimester. Although, limited by numbers to make any conclusions and 
a heterogeneous outcome group i.e. combination of PE and/or IUGR, the 
findings are consistent with those of a previous large cohort study of BP 
changes.162  
6.5 Conclusion 
An increase rather than a decrease in BP was observed in the second 
trimester in women with previous PE/IUGR and those who developed 
uteroplacental insufficiency in their current pregnancy. Apart from the changes 
in BP, similar cardiovascular changes were observed in all women with normal 
pregnancies including nulliparous women, those with previous normal 
pregnancies, unexplained RM and previous PE/IUGR.  
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Summary points: 
 Implantation timing was a key determinant of fetal size at 10-14 weeks and 
influenced gestational age assessment but did not influence first, second or 
third trimester fetal growth, placentation, or birth weight z-score. 
 Second to third trimester fetal growth, uterine artery Doppler PI and a 
maximum second trimester CO increase were significantly correlated with 
birth weight z-score. 
 
 
 
 
 
 
 
 
 
 
This chapter is based on: 
Mahendru AA, Daemen A, Everett TR, Wilkinson IB, McEniery CM, Abdallah Y, 
Timmerman D, Bourne T, Lees CC. Impact of ovulation and implantation timing on 
first trimester crown-rump length and gestational age. Ultrasound Obstet Gynecol. 
2012 Dec; 40(6):630-5 
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7.1 Introduction 
Normal implantation is crucial for the establishment of a successful pregnancy. 
Impaired embryo-endometrial interaction and abnormal implantation are likely 
to be pivotal in the disease process of recurrent miscarriage.1 This hypothesis 
is supported by an increased incidence of early pregnancy loss in cases with 
delayed implantation.6 Impaired trophoblastic invasion of the spiral arterioles is 
believed to be responsible for PE and IUGR. Since the process of spiral artery 
remodeling begins along with trophoblastic differentiation around the time of 
implantation, it is possible that abnormal implantation underlies the 
pathogenesis of PE and fetal growth restriction.  However, the events 
surrounding implantation in natural human conception are unclear. We 
hypothesize that both early and late pregnancy complications could be due to 
the same underlying pathology: namely impaired embryo-endometrial 
interaction around the time of implantation and impaired endometrial 
preparation as evidenced by delayed implantation. We test this hypothesis by 
observing the relationship between ovulation to implantation timing (O-I 
interval) in relation to previous history of healthy pregnancy, recurrent 
miscarriage and PE/IUGR. We explore the relationship of O-I interval with 
early pregnancy loss, placental function using uterine artery Doppler, fetal 
growth in the first, second and third trimester and birth weight in a cohort of 
women who conceived naturally. 
The timing of implantation may also have an impact on gestational age 
assessment (GA) and may influence embryonic and fetal growth. GA itself is a 
determinant of perinatal outcome.244 GA is established based on 
measurement of fetal crown-rump length (CRL) at 10-14 weeks.245 We 
hypothesize that variation in fetal CRL at 10-14 weeks could be attributed to 
variation in the ovulation to implantation (O-I) interval and that differences in 
O-I interval may correlate to birth weight and GA at delivery.  
Pregnancies complicated by fetal growth restriction are associated with 
abnormal cardiovascular adaptation very early in pregnancy. We explore this 
hypothesis by investigating the relationship between fetal growth and birth 
weight of the neonate with the cardiovascular adaptation during pregnancy. 
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7.2 Methods 
101 women became pregnant out of the 143 initially recruited in the study. The 
differences in the demographics and menstrual cycle characteristics such as 
ovulation day, implantation day and ovulation implantation timing, were 
investigated using Kruskal- Wallis test between groups of women with 
previous RM, PE/IUGR and those with previous healthy pregnancies. The 
differences in ovulation, implantation timing and menstrual cycle data were 
also investigated in all pregnancies in relation to the current pregnancy 
outcome. 
Ultrasound scans were performed at 6-7, 8-9 weeks, and 10-14 weeks of 
gestation from LMP in all women as described in the chapter 2 to establish 
first trimester growth rate. CRL growth rate (mm/day) was calculated by 
dividing change in CRL by change in gestational age. In the case of 3 scans, 
the average was taken from the growth rate between scan 1 and 2 and the 
growth rate from scan 2 to 3.246  
Fetal size at 10-14 weeks was determined by the CRL measurement at 10-14 
weeks and CRL z-score at the 10-14 week scan was calculated as:  
CRL z-score = Measured CRL – expected CRL/standard deviation 
The expected CRL was based on the CRL values derived by Robinson and 
Fleming80,216 for a GA derived from ovulation timing. The relationship between 
implantation day, O-I interval, first-trimester growth and fetal size i.e. CRL z-
score at 10-14 weeks was investigated in the 56 women with viable 
pregnancies, where complete data was available regarding ovulation timing, 
implantation timing and O-I interval.  
GA was estimated by LMP (GALMP), adjusted from ovulation timing (GAOV) and 
implantation timing (GAIMP). GAOV was derived by subtracting 14 days from the 
predicted ovulation date (LH +1) to the effective LMP, as is convention for 
pregnancy dating. GAIMP was derived by adding the difference between the 
observed implantation day and the median implantation day (which was day 
27 in this study) if the observed implantation day was earlier than day 27. 
Similarly we subtracted the difference if the observed implantation day was 
later than day 27. Bland-Altman plots were constructed to compare the GA 
CHAPTER 7: OVULATION IMPLANTATION TIMING, FETAL GROWTH AND 
PREGNANCY OUTCOME 
 
 135 
predicted by CRL (GACRL), GAOV and GAIMP. The 95% confidence intervals (CI) 
were calculated of the differences between the GA estimated by single CRL 
measurement and that estimated based on adjustments for ovulation and 
implantation timing. 
The second to third trimester growth rates were derived from differences 
between second and third trimester AC measurements divided by the 
differences in GA between the scans in days. AC measurements were used in 
growth rate estimation because they correlate better with birth weight. The 
relationship between second, third trimester growth assessed using serial 
growth scans, length of gestation at delivery, birthweight and O-I interval was 
investigated using linear correlation. The first, second and third trimester 
growth rates were then compared to cardiovascular changes in the pregnancy. 
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7.3 Results 
7.3.1 Clinical characteristics and menstrual cycle data in all pregnancies 
The age, ethnicity in all the women who became pregnant is described in table 
7.1 in relation to their previous obstetric history. Women with previous 
PE/IUGR were significantly older compared to the nulliparous women. There 
was no significant difference between the time to conceive in the women with 
previous healthy pregnancies, those with RM or previous PE/IUGR (median of 
4 months versus 6 months in RM and PE/IUGR group, P = 0.5). There was no 
significant difference between the ovulation or implantation days between the 
groups of women in relation to their previous obstetric history, however, the O-
I interval was longer in the women with previous RM (13 days compared to 11 
days in those with previous healthy pregnancies and previous PE/IUGR 
respectively, P =0.03). 
Table 7.1 Characteristics of all pregnant women and menstrual cycle details in 
relation to their previous obstetric history 
 
 
Characteristics 
 
 
Nulliparous 
51 
Previous 
healthy 
pregnancies 
25 
 
Recurrent 
Miscarriage 
17 
 
Previous 
PE/IUGR 
8 
 
 
P
*
 
Age, years 31 (28-33) 34 (31-35) 35 (32-39) 37 (36-38) 0.001* 
Time to conceive, 
months 
5 (3-8) 4 (2-7) 6 (4-11) 6 (2-11) 0.6 
Ovulation day, 
days 
16 (14-19) 15 (14-20) 16 (15-18) 15 (14-18) 0.9 
Implantation day, 
days 
27 (25-31) 28 (26-33) 29 (26-32) 27 (26-29) 0.5 
O-I interval, days 11 (10-12) 11 (10-12) 13 (11-15) 11 (9-12) 0.03* 
 
O-I interval = ovulation to implantation interval. *P <0.05 is significant by Kruskal 
Wallis test for comparison between the ovulation day, implantation day and O-I 
interval women with previous healthy pregnancies in comparison to those with 
previous RM and PE/IUGR 
 
CHAPTER 7: OVULATION IMPLANTATION TIMING, FETAL GROWTH AND 
PREGNANCY OUTCOME 
 
 137 
7.3.2 Menstrual cycle data in relation to the current pregnancy outcome 
in all pregnancies 
Miscarriages less than 6 weeks had a delayed implantation day (31 versus 27 
and 25 days in viable pregnancies and those with miscarriages at > 6 weeks 
respectively, P =0.004) and a prolonged O-I interval (14 days versus 11 days 
in both: pregnancies viable at >10 weeks and in miscarriages greater than 6 
weeks) (Table 7.2). 
Table 7.2: Menstrual cycle data of all pregnancies described in relation to the 
current pregnancy outcome 
 
Days 
Viable 
pregnancies at > 
10 weeks 
Miscarriage 
<6wks 
(*n=13) 
Miscarriage 
>6wks 
(*n=12) 
 
P
†
 
Ovulation day 
 
16 (11 to39) 15 (14 to 23) 14 (12 to 20) 0.2 
Menstrual cycle 
length, days 
28 (21 to 60) 
 
30 (27 to 47) 
 
28 (25 to 35) 
 
0.2 
Implantation day 27 (23 to 44) 
 
31 (26 to 37) 
 
25 (23 to 32) 0.004* 
O-I interval, days 11 (9 to 20) 
 
14 (11 to 17) 
 
11 (9 to 13) <0.001* 
 
O-I interval = Ovulation to implantation interval, *
 
P <0.05 is significant using Kruskal-
Wallis Test. Complete information was available on ovulation day in 59/71 viable 
pregnancies, menstrual cycle length in 69/71 viable pregnancies, implantation day in 
58/71 viable pregnancies and O-I interval in 56/71 viable pregnancies.  
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7.3.3 Demographics and clinical characteristics of women with viable 
pregnancies 
Seventy-one out of the 101 pregnancies were viable at the end of first 
trimester. The median age, ethnicity and parity of the 71 women with viable 
pregnancies have been described in the table below. The O-I interval data 
was available for only 56 of the 71 pregnancies. One of these 56 was lost to 
follow up during the pregnancy and one of them had a termination of 
pregnancy (TOP) for chromosomal abnormality after the first trimester. 
Therefore, first trimester fetal growth, first trimester fetal crown rump length, 
second trimester growth, third trimester growth, birth weight and gestational 
age at delivery have been described in 54 cases with complete data on the O-I 
interval (described in Figure 7.1) 
 
Table 7.3 Demographics and clinical characteristics of the 71 women with viable 
pregnancies 
 
Characteristics  Participants (n=71) 
Age, years 32  (29-35) 
Ethnicity 
White  
Black 
Asian 
Others 
 
65 (91.6)  
2 (2.8)  
2 (2.8)  
2 (2.8)  
Parity 
Nulliparous 
Multiparous 
 
37 (52)  
34 (48)  
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Figure 7.1 Flow chart of pregnancies with complete data on the O-I (Ovulation 
implantation) interval, first, second and third trimester growth 
101 pregnancies 
71 pregnancies viable pregnancies after 
10weeks 
29 Early Pregnancy Loss 
13 Miscarriages <6weeks 
12 Miscarriages >6weeks 
4 Ectopic pregnancies  
Data analyzed for following 
56 with complete information on O-I interval 
 
 
15 Missing ovulation and /or implantation data 
Amenorrhea so did not start using the LH kits (1)
 *
 
Did not use the LH tests as per protocol or did not detect an LH 
surge (12)
 *
 
Did not use pregnancy tests per protocol (13)
 * 
*
Categories are not mutually exclusive 
 
 
1 Lost to follow-up 
Trying to conceive 143 
First trimester growth and O-I interval: 
Three first trimester scans: 45 
Two first trimester scans: 11/ (Too early for CRL at first scan) 
 
Second trimester growth and O-I interval: 51/54 
(3 Had only one scan) 
Third trimester growth and O-I interval: 53/54 
 
TOP for abnormal karyotype 15 weeks: 1 
Lost to follow up as moved area: 1 
Delivery outcome: 54 
1 Delivered at 28 weeks 
(Missing data for third trimester) 
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7.3.4 Ovulation and implantation in relation to fetal growth, size, 
placental function, GA and birth weight 
O-I interval and first trimester growth: We did not find any significant 
relationship between first trimester CRL growth rate and O-I interval 
(Spearman’s correlation coefficient rho ‘’ = 0.1, P = 0.7). First trimester 
growth rate was not related to the difference between observed and expected 
CRL based on GALMP (= 0.2, P = 0.1). However, there was a significant 
relationship between CRL growth rate and the difference between observed 
and expected CRL based on GAOV ( = 0.4, P = 0.003, Figure 7.2) and that 
between observed and expected CRL based on GAIMP ( = 0.5, P < 0.001, 
Figure 7.3).  
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Correlation between first trimester growth rate and Z-score CRL 
based on GA
OV
 ( = 0.4, P = 0.003) 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 Correlation between first trimester growth rate and Z-score CRL 
based on GA
IMP 
( = 0.5, P < 0.001) 
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O-I interval and Z-score CRL at 10-14 weeks: CRL Z-score at the 10-14 week 
scan shows a negative relationship with the O-I interval ( = -0.431, P = 
0.0009, Figure7.4). In a multiple regression model, O-I interval correlated best 
with the Z-score CRL (based on GA by ovulation) at 10-14 weeks (R2 = 8.9, P 
<0.001), followed by first trimester growth rate (R2 = 2.2, P=0.04, Figure 7.4) 
 
 
Figure 7.4 Scatter plot of crown-rump length (CRL) Z-score at 10-14 
weeks showing the inverse relationship between CRL Z-score and the 
ovulation implantation (O-I) interval ( = -0.431, P = 0.0009) 
 
O-I interval and GA estimation at 10-14 weeks: The difference between GACRL 
and GAOV showed a similar inverse relationship with O-I interval ( = -0.430 P 
= 0.0009; Figure 7.5). 
 
Figure 7.5 Scatterplot of difference between GA observed by CRL (GA
CRL
) and 
GA derived from the ovulation day (GA
OV
). The smaller the O-I interval, the 
greater the difference between GACRL and GAOV (ρ = -0.430, P = 0.0009) 
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GA is routinely assigned from fetal CRL measurement at 10-14 weeks. Since 
this study showed that implantation timing is better related to the fetal size at 
10-14 weeks and to the difference in GA derived by fetal size at 10-14 weeks, 
we explored the impact of ovulation timing and implantation timing on GA 
assessment. The differences between GACRL and GALMP, GACRL and GAOV and 
that between GACRL and GAIMP were determined in comparison with the GA 
derived from LMP using Bland-Altman plots. The mean difference between 
GACRL and GALMP was -0.8 days (95% LOA, -11.8 to 10.1 days) (Figure 7.6), 
that between GACRL and GAOV was 1.3 days (95% LOA, -3.8 TO 6.4 days) 
(Figure 7.7) and that between GACRL and GAIMP was 0.4 days (95% LOA, -4.0 
to -4.9 days) (Figure 7.8). 
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Figure 7.6 Bland-Altman plot, showing comparison of gestational age (GA) 
estimated from crown-rump length measurement at 10-14 weeks’ gestation 
(GA
CRL
) with GA based on the last menstrual period (GA
LMP
). The bold line in the 
middle of the graph represents the mean difference (with 95% CI shown (_._._.) and 
dashed lines (_ _ _) at the either end represent 95% limits of agreement (± 1.96 SD) 
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Figure 7.7 A) Bland-Altman plot showing comparison of gestational age (GA) 
estimated from crown-rump length measurement at 10-14 weeks’ gestation 
(GA
CRL
) with GA adjusted by ovulation day (GA
OV
). B) Bland-Altman plot 
showing comparison of gestational age (GA) estimated from crown-rump length 
measurement at 10-14 weeks’ gestation (GA
CRL
) with GA adjusted by 
implantation day (GA
IMP
). The bold line in the middle represents the mean difference 
(with 95% CI shown (_._._.) and dashed lines at the far ends (_ _ _) represent 95% 
limits of agreement (± 1.96 SD) 
A 
B 
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O-I interval and placental function (Uterine artery Doppler at 23-24 weeks): 
The O-I interval did not correlate to the median uterine artery pulsatility index 
(PI) (median PI: 0.82[0.75-0.97], ρ = 0.2, P = 0.2).  
O-I interval and late pregnancy growth rate, birth weight and GA at delivery: 
The O-I interval did not correlate to the combined second and third trimester 
AC growth rate ( = 0.09, P = 0.5), but did correlate with borderline 
significance to the second to third trimester growth rate ( = 0.3, P = 0.05). 
The O-I interval did not correlate to the z-score birth weight at delivery ( = 
0.2, P = 0.2; Figure 7.8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8 No relationship between z-score birth weight adjusted for GA and O-I 
interval ( = 0.2, P = 0.2) 
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However, O-I interval was inversely correlated to the difference in the length of 
gestation derived by LMP and derived from implantation day at the time of 
delivery i.e. longer the O-I interval, the greater the difference between the 
length of gestation based on LMP and implantation timing ( = 0.3, P = 0.04, 
Figure 7.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9 The difference in the length of gestation by LMP and implantation 
timing is correlated to the O-I interval ( = 0.3, P = 0.04). The bold lines represent 
the mean and 95% CI. 
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7.3.5 Factors affecting birth weight at delivery 
Maternal demographics: We found no correlation between maternal age and 
parity with either fetal CRL at 10-14 weeks ( = 0.1, P = 0.6 and  = 0.1, P 
=0.3) or with z-score birth weight ( = 0.2, P = 0.1 and  = 0.2, P = 0.2). 
Maternal weight gain in pregnancy from pre-pregnancy to late third trimester: 
median of 11kg [8-14kg] was significantly correlated with z-score birth weight 
( = 0.3, P = 0.02). 
Birth weight and first trimester embryonic growth, fetal size at 10-14 weeks: 
There was no correlation between mean first trimester growth rate of 1.8 [1.7-
1.9] mm/day and second to third trimester growth rate of fetal AC of 1.6 [1.4-
1.7] mm/day (ρ = 0.130, P =0.3). The first trimester CRL z-score at 10-14 
weeks did not correlate with second to third trimester fetal AC growth rate ( 
=-0.083, P =0.6). The first trimester growth rate did not correlate with the z-
score birthweight ( = 2, P = 0.2) nor did the CRL z-score at 10-14 weeks ( = 
0.1, P= 0.3). 
Placental function and 23-24 weeks uterine artery Doppler: The mean uterine 
artery PI (0.88 ± 0.3) was inversely related to birth weight z-score (Pearson’s 
correlation coefficient r = -0.3, P= 0.03), however was not related first trimester 
CRL growth rate (r = 0.06, P= 0.6), CRL z-score at 10-14 weeks (r =-0.1, P = 
0.5) and growth rate of AC from second to third trimester (r = -0.045, P = 0.7).  
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Second and third trimester growth rates: The second to third trimester fetal AC 
growth rate and fetal EFW growth rates were linearly correlated to the z-score 
birth weight at delivery ( =0.598, P <0.001 and  =0.758, P<0.001 
respectively, Figure 7.10) respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10 An increase in second to third trimester EFW growth rate is 
correlated with an increase in z-score birth weight ( =0.758, P<0.001). The bold 
lines represent the mean and 95% CI. 
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7.3.5 Cardiovascular changes in relation to fetal size and fetal growth 
The details of cardiovascular changes in pregnancy have been described in 
the chapter 5. A maximum increase was seen in the HR from prior to 
pregnancy to third trimester of 13 ± 11 beats/min. There was a significant 
decrease of BP from pre-pregnancy to first trimester followed by a further 
reduction in the second trimester. The maximum increase in CO was in the 
second trimester. The maximum increase in CO from pre-pregnancy to 
second trimester was significantly correlated to the z-score birth weight ( = 
0.3, P = 0.04, Figure 7.11), but not to the second to third trimester growth rate 
( = 0.2, P = 0.2) or to the EFW in second trimester. 
The maximum increase in HR during pregnancy did not correlate with second 
to third trimester growth rate of AC (r = 0.144, P= 0.3) or with the z-score birth 
weight (r= 0.120, P =0.3). The maximum decrease in BP from pre-pregnancy 
to second trimester did not correlate with second to third trimester growth rate 
of AC (Decrease in MAP: r=0.14, 0.3 and decrease in CSBP: r = -0.14, P 
=0.3). Neither the maximum decrease in the MAP or CSBP from pre-
pregnancy to second trimester correlated to the z-score birth weight ( = -
0.123, P = 0.3 &  = -0.079, P = 0.5), nor did a maximum decrease in the PVR 
from pre-pregnancy to early pregnancy (r =0.03, P= 0.8). We did not find any 
correlation between changes in AIx or aortic stiffness and birth weight or fetal 
growth rate. 
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7.4 Discussion 
This is the first prospective study describing the ovulation and implantation 
timing in relation to the ultrasound measurements of embryonic growth in the 
first trimester, variations in GA assessments and length of gestation, fetal 
growth in late pregnancy and maternal cardiovascular changes in natural 
conception.  
7.4.1 Ovulation-implantation interval, growth and fetal size 
The major novel finding was that O-I interval was a major determinant of fetal 
size at 10-14 weeks. An early implanting embryo (short O-I interval) was larger 
than expected and a later implanting embryo (long O-I interval) was smaller 
than expected by almost exactly the number of days of variance about the 
median O-I interval. The O-I interval did not correlate with the first, second or 
third trimester growth, nor with the z-score birth weight. However, the O-I 
interval correlated with the difference in the length of LMP derived gestation 
versus implantation timing based length of gestation. The median ovulation 
timing in this study was 16 days as opposed to the assumption of day 14 
ovulation made by Robinson and Fleming’s CRL charts that are routinely used 
for dating.80 It is therefore, plausible that it is likely that where ovulation 
occurred later on day 16, there will be a systematic over-estimation of post-
implantation gestation. This could explain the observed 1.3 days 
overestimation from GACRL as shown in Figure 7.7(A).  
We did not find a significant correlation between first trimester growth rate and 
z-score CRL based on LMP at 10-14 weeks. However, the CRL growth rate 
was related to the z-score CRL adjusted for ovulation and implantation timing, 
meaning thereby, that the first trimester CRL at 10-14 weeks depends on the 
implantation timing and subsequent embryonic growth. Contrary to what has 
been shown before,86-88 we did not find any correlation between first trimester 
CRL measurement, first trimester growth and birth weight. These previous 
studies assumed a single first trimester CRL measurement as representative 
of first trimester growth. Although this study has limited numbers to make any 
conclusions, it is possible that the fetal birth weight is rather dependent on 
later pregnancy fetal growth. 
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 7.4.2 Cardiovascular changes, growth and fetal size 
The factors that affected birth weight significantly were total weight gain in 
pregnancy, uterine artery doppler PI, second to third trimester fetal growth and 
the maximum increase in CO in the second trimester. Uterine artery doppler PI 
is an indirect indicator of uteroplacental blood flow and therefore, lower 
resistance may suggested better perfusion of the uteroplacental bed and 
therefore, lead to better fetal growth. 
Interestingly, of all the cardiovascular changes, maximum increase in CO from 
pre-pregnancy to second trimester was significantly associated with birth 
weight. It was however, not related to either the second trimester EFW or to 
second to third trimester fetal growth. It is plausible that it is the changes in 
CO that are dependent on the uteroplacental flow eventually affect the birth 
weight independent of fetal growth.  
7. 5 Conclusion 
Fetal size at 10-14 weeks was dependent on the implantation timing and 
therefore O-I interval influenced GA assessment. However, the implantation 
timing did not impact on first trimester embryonic growth, placentation and 
uterine artery Doppler, late pregnancy fetal growth or birth weight. Birth weight 
was influenced by maternal weight gain in pregnancy, placental function, 
second to third trimester growth and changes in maternal CO to improve the 
uteroplacental flow.   
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Summary of findings: 
 It is feasible to conduct and complete a prospective cohort study from prior to 
conception, combining measures of ovulation and implantation with measures 
of fetal size, cardiovascular changes and pregnancy outcomes in naturally 
conceived pregnancies. 
 Pre-pregnancy BP and PVR are higher in women with previous PE and/or 
IUGR. 
 Normal pregnancies are characterized by an increase in HR during 
pregnancy, an early pregnancy and second trimester fall in BP, AIx and PVR 
along with second trimester increase in CO when compared to pre-pregnancy 
values. 
 All normal pregnancies in nulliparous women, women with previous healthy 
pregnancies and those with unexplained RM were characterized by similar 
cardiovascular changes. 
 A second trimester increase in BP was observed in pregnancies associated 
with PE/IUGR and in normal subsequent pregnancies in women with previous 
PE/IUGR. 
 Women with previous unexplained RM had delayed implantation in 
subsequent pregnancies. 
 Delayed implantation was associated with an early pregnancy loss less than 
6weeks gestation. 
 Implantation timing was the key determinant of fetal size at 10-14 weeks and 
influenced GA assessment but did not influence first, second or third trimester 
fetal growth, placentation or birth weight z-score. 
 Second trimester increase in CO correlated with the birth weight z-score. 
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8.1 Background  
Early risk prediction and diagnosis, increased surveillance and early delivery 
remain the management options for PE. Although it is known that women with 
PE have abnormal cardiovascular function134 and increased risk of CVD in 
long term,29,100 the exact mechanism of cardiovascular maladaptation in PE 
and long-term CVD is not known. It has been proposed that events around 
human implantation determine trophoblastic invasion and placentation and 
may therefore be important in predicting events preceding uteroplacental 
insufficiency in very early pregnancy. However, due to the inability to perform 
in vivo studies at the trophoblast-decidual interface, complete understanding 
of the events around implantation and their relationship with cardiovascular 
changes in pregnancy remain unclear.110,112 
Only a prospective study from prior to pregnancy and in very early pregnancy 
may help in understanding the ‘cause and effect’ relationship, improve 
screening for PE and may lead to development of new interventions in the pre-
pregnancy period to prevent PE.34 An improved understanding of changes in 
the post partum period may also enable us to understand mechanisms of 
cardiovascular disease and prevention of CVD by controlling postpartum risks 
and early treatment opportunities. Most of the available data on cardiovascular 
changes in pregnancies: both normal and those with PE/IUGR consists of 
cross-sectional studies. Recruitment to prospective studies from prior to 
pregnancy can be challenging compounded with an increased incidence of 
pregnancy loss,36 “drop out rate”37 and requirement of large number of normal 
pregnancies in view of the rarity of occurrence of pregnancy complications 
such as PE/IUGR.  
8.2 Feasibility of a prospective cohort study  
This was a prospective cohort feasibility study combining pre-pregnancy to 
postpartum changes in cardiovascular function in relation to implantation 
events, fetal growth and pregnancy outcomes. This study was conducted in a 
single centre in Addenbrooke’s Hospital. One hundred and forty three women 
planning to conceive were recruited over a period of 11months from July 2010 
to June 2011. There were 101 pregnancies: 25 pregnancies miscarried; there 
were 4 ectopic pregnancies, 70 live births and one TOP after 12 weeks for 
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abnormal chromosomes. The incidence of PE and/or IUGR was 33% (2/6) in 
women with previous PE/IUGR and 4% (3/70) in nulliparous women. 
This study shows that it is feasible to recruit women who are planning to 
conceive, conduct pre-pregnancy cardiovascular assessments and follow 
them up during pregnancy at various time points for cardiovascular 
assessments and fetal growth. Based on the current data, approximately half 
the women recruited will have healthy ongoing pregnancies. About 7 to 14% 
participants did not complete the entire study protocol for cardiovascular or 
blood tests and complete data for O-I interval, embryonic and fetal growth and 
cardiovascular changes was available in 63% cases. This information 
regarding conception rates, pregnancy loss rate, incidence of pregnancy 
complications and missing data, would allow the design of a prospective study 
from prior to conception, powered for pregnancy complications such as PE.  
The availability of ovulation and pregnancy test kits, extra early and late 
pregnancy scans and extensive advertising enabled good recruitment to this 
study. The flexibility of research visits, a single person dedicated for study 
recruitment, performing the scans and cardiovascular tests with good rapport 
and communication with the participants enabled good follow up and 
completeness of data in the study. A recent large Chinese pre-conception 
cohort study has also shown the feasibility of pre-pregnancy recruitment and 
pregnancy follow up for BP measurements along with biochemical markers of 
placentation in large numbers.234 The challenges were recruiting women who 
had previous PE/IUGR because it was not only difficult to identify them, but 
also to identify those who were trying to conceive again. Those women who 
experienced early pregnancy loss also required additional support and 
counseling. The completeness of data after delivery required good rapport and 
communication with the participants in order to get delivery details from other 
hospitals. Arranging postpartum follow up was challenging due to difficulties in 
contacting these participants and then arranging the visit with a 3 to 4 month 
old baby. 
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8.3 Pre-pregnancy cardiovascular function in relation to previous 
pregnancy outcome 
In this study, women with PE/IUGR began a subsequent pregnancy with 
higher BP (DBP, central SBP, and MAP), lower pulse pressure (PP) 
amplification and PVR compared to women with previous healthy 
pregnancies, consistent with findings of the previous studies.163 However, this 
does not prove the ‘cause and effect’ relationship because the higher BP and 
PVR may be a result of a previous pregnancy. The limitations of this study are 
the small numbers in these groups, selection bias in the women with 
PE/IUGR- as these women were self-selected and there may have been a 
selection bias towards more severe and earlier onset disease. Although this is 
a small cohort, the number is consistent with the recruitment protocols of 
previous studies.163  
On the other hand, there was no difference in the cardiovascular function, 
lipid, cholesterol, renal function and platelet aggregation in women with 
unexplained RM and those with previous normal pregnancies. RM has been 
associated with an increased risk of CVD in epidemiological studies but most 
studies of CVD and RM include women with antiphospholipid syndrome,32,190 
which is a common cause of RM and, in itself can lead to endothelial 
dysfunction and hypertension. There is limited data regarding detailed 
cardiovascular function in women with RM and the link between 
cardiovascular dysfunction and long term CVD remains unexplored. No 
prospective data on cardiovascular function and arterial stiffness in women 
with RM is available to compare against our findings. 
Although, PE/IUGR and RM may all have underlying abnormal implantation, 
their link to cardiovascular dysfunction remains uncertain. While it is plausible 
that underlying maternal vascular disease predisposes to development of PE 
and CVD later in life, RM in itself may not be associated with pre-existing 
vascular disease or have an immediate deleterious effect on maternal 
cardiovascular function. Oestrogen is believed to have a protective effect on 
vascular endothelium247 and pregnancy duration influences the length of time 
a women is exposed to oestrogen with the highest exposure being at the end 
of a full-term pregnancy. It has been previously hypothesized that the shorter 
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duration of exposure to lower levels of oestrogen in women with RM may 
predispose them to CVD which manifests later in life.248 
However, in the absence of pre-pregnancy and prospective data on these 
women the ‘cause and effect’ relationship cannot be explored. This 
emphasizes the importance of a larger prospective pre-pregnancy cohort 
study. 
8.4 Pre-pregnancy cardiovascular function in relation to current 
pregnancy outcome 
There were only five pregnancies with PE and/or IUGR in this study. We 
therefore, combined early and late onset disease in all women irrespective of 
their previous history into a group of uteroplacental insufficiency. Those 
women who developed either PE or IUGR had higher pre-pregnancy central 
SBP and PVR, implying the presence of vascular dysfunction prior to 
pregnancy. These women also had a lower HR, which may suggest a lower 
plasma volume reserve prior to pregnancy. There was no significant difference 
in BP, CO, AIx or aPWV or in metabolic function, renal function or platelet 
aggregation in comparison with those with normal pregnancies. 
This study does not have the power to answer the questions on pre-pregnancy 
cardiovascular dysfunction in women who subsequently develop PE and 
especially early-onset disease, which is more likely to be associated with long-
term cardiovascular dysfunction. 
Nevertheless, although it is known that arterial stiffness is higher in the 
disease phase of PE, there are no data regarding pre-pregnancy arterial 
stiffness or cardiovascular function in women who develop PE.172 It is 
plausible that arterial stiffness is higher as a result of the cardiovascular 
dysfunction during PE but may perhaps be normal prior to and after the 
pregnancy. On the other hand, there may be some cardiovascular dysfunction 
in the form of higher central SBP even before pregnancy. Again only a 
prospective study powered for the outcomes of PE may be able to answer this 
question and may enable assessment of the cardiovascular maladaptation 
during pregnancy. 
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8.5 Cardiovascular, metabolic and platelet changes in normal 
pregnancies 
There were significant changes in BP, HR, CO, AIx, renal function and platelet 
aggregation during pregnancy, beginning from very early in pregnancy.  
The significant reductions in brachial SBP, DBP and MAP very early in 
pregnancy were consistent with those reported in previous, albeit smaller, 
prospective studies.24-26 The mid-pregnancy decrease in brachial BP had been 
questioned by a longitudinal study beginning from 14 to 16 weeks of 
pregnancy,249 however, it is likely that the most significant reductions in BP 
were missed due to the relatively late ‘baseline’ used in this study. We 
observed a further decrease in the BP at 23-24 weeks consistent with what 
has been shown previously. We also observed a greater reduction of central 
versus brachial SBP in very early pregnancy, which confirms and extends 
previous cross-sectional studies demonstrating that the central SBP is lower in 
pregnant than non-pregnant women.126,127 Interestingly, all BP measurements 
were lower in the postpartum period compared to the pre-pregnancy values 
however, only the SBPs were significantly lower at 3 to 4 months postpartum 
compared to the pre-pregnancy values. Therefore, using postpartum values as 
baseline may lead to underestimation of pregnancy related changes in BP. 
We observed a significant increase in HR throughout pregnancy beginning 
from very early in pregnancy until the third trimester, with return of the HR to 
baseline at about 3 to 4 months postpartum, consistent with previous 
studies.24 There was a significant increase in the CO at 23-24weeks rather 
than in very early pregnancy despite a significant increase in the HR in very 
early pregnancy, followed by a non-significant drop in the third trimester. This 
is in contrast to previous studies where CO increases significantly in early 
pregnancy and an increase in CO and SV is also seen in the third trimester in 
normal pregnancies.24,112 The early pregnancy measurements were performed 
before 8 weeks when the SV increases and this may explain the lack of early 
pregnancy increase in the CO in this study. Alternatively, this could be 
because the Innocor technique uses a gas re-breathing method which may be 
affected by changes in the respiratory function during pregnancy. The later 
increase in CO could be due to structural changes in the heart secondary to 
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exposure to an increased preload in the first trimester. Since 
echocardiography was not performed in this study, we are unable to explain 
cardiac structural changes during normal pregnancies. 
AIx decreased significantly very early in pregnancy followed by a further 
smaller decrease in the second trimester. This reduction has been 
underestimated in previous studies beginning from late first-trimester.127,128 
Interestingly, the AIx was found to be higher than pre-pregnancy values at 3 to 
4 months postpartum. This may be because of higher SV in the postpartum 
period. Since cardiovascular parameters are interdependent on each other, 
only comprehensive understanding of all cardiovascular parameters can 
establish the pathophysiology of cardiovascular changes. 
We observed a reduction in aPWV between the second and third trimester 
consistent with previous studies, demonstrating an increase in aortic 
compliance during pregnancy.139,144 The later onset of changes in aortic 
stiffness may be because structural changes in the aorta are secondary to 
continued exposure to higher preload in the earlier part of pregnancy.  
The eGFR increased significantly by the late first trimester suggesting the 
renal vasodilatation and volume expansion. The increase in HDL cholesterol 
and decrease in LDL cholesterol in late first trimester with no significant 
changes in total cholesterol or triglycerides was contrary to what has been 
shown previously.177 It is possible that changes in cholesterol perhaps occur 
later in pregnancy as a result of the fetal effects on maternal metabolism. This 
has been shown previously in studies of lipids and cholesterol in the second 
and third trimester.183 Platelet aggregation was elevated only at higher 
concentration of ADP in early pregnancy, suggesting that pregnancy induced 
changes probably start very early in pregnancy alongside the haemodynamic 
and blood flow changes, even before placental function begins. 
An understanding of the cardiovascular changes in normal pregnancies is a 
key to understanding the pathophysiology of cardiovascular changes in 
pregnancies associated with uteroplacental insufficiency. So far, few 
prospective cohort studies with limited numbers from pre-pregnancy to the 
postpartum period including very early pregnancy measurements have 
assessed cardiovascular, metabolic or haematological changes in normal 
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pregnancy. The role of normal pregnancy in ‘programming’ and modifying the 
pre-existing cardiovascular, metabolic and platelet function has not been 
explored so far. Previous studies have used either late first trimester or 
postpartum values as ‘baseline’, whereas, we have demonstrated that 
significant changes would have already occurred before the first trimester and 
some of them would persist postpartum. Recently a Chinese pre-pregnancy 
cohort study has recruited a large number of women prior to pregnancy and is 
the largest prospective study from prior to pregnancy. It does not include 
measurements in very early pregnancy, nor does it include data on 
comprehensive cardiovascular function including central BP, AIx, aortic 
stiffness or cardiac output and their results are yet to be reported.234  
This is the first prospective study from pre-pregnancy to postpartum period 
including early pregnancy measurements of comprehensive maternal 
cardiovascular, renal, metabolic and platelet changes in pregnancy including 
central BP, AIx and aortic stiffness. We have shown that it is feasible but also 
important to evaluate comprehensive changes from prior to pregnancy, in very 
early pregnancy and postpartum in all future pregnancy studies of maternal 
cardiovascular function. 
8.6 Cardiovascular, metabolic and platelet changes in women with 
pregnancy complications 
8.6.1 Previous history of preeclampsia/intrauterine growth restriction/ or 
recurrent miscarriage 
Similar cardiovascular changes in HR, CO, PVR, arterial stiffness, renal 
function, lipid changes and platelet activation were noted in normal 
pregnancies in all groups of women irrespective of their previous obstetric 
history. Women with previous PE/IUGR already began with a higher pre-
pregnancy ‘baseline’ BP and it appeared that the only difference in the 
pregnancy adaptation was an increase rather than a decrease in DBP and 
MAP in the second trimester. Although we cannot conclude based on the 
small numbers in this study, we hypothesize that in the women with previous 
PE/IUGR, there is cardiovascular maladaptation even in subsequent normal 
pregnancy. 
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8.6.2 Preeclampsia and/or intrauterine growth restriction in index 
pregnancy 
We observed an increase rather than a decrease in the mid trimester BP in 
women who developed uteroplacental insufficiency in their current pregnancy, 
evident by either early or late onset PE/IUGR . There was no difference in 
other cardiovascular parameters, which may be due to limited numbers in the 
study. 
We also observed higher platelet aggregation in early pregnancy in women 
with PE/IUGR compared to those with normal pregnancies using higher 
concentrations of ADP. However, this difference was not statistically 
significant. If this is true it may imply that platelet dysfunction in PE or 
uteroplacental insufficiency may occur very early in pregnancy lead to 
impaired placentation at the time of trophoblastic invasion in late first trimester. 
These findings emphasize the importance of a large prospective study 
incorporating all the cardiovascular parameters and involving larger number of 
pregnancies with PE/IUGR.  
8.7 Ovulation, implantation timing, fetal growth, cardiovascular 
changes and pregnancy outcome 
Implantation timing was the key determinant of fetal size at the 10-14 weeks 
scan and influenced GA assessment. This study reported an 11 day range of 
ovulation to implantation timing using digital home ovulation and pregancy test 
kits. Women with a previous history of RM had a median implantation day 13 
compared to day 11 in all other groups implying the possibility of impaired 
implantation as a cause of their recurrent pregnancy failure. This is supported 
by recent data suggesting the role of impaired implantation in RM women.1 
Delayed implantation was associated with early pregnancy loss at less than 6 
weeks consistent with previous studies.6  
The novel finding of this study was the association of delayed implantation 
with a smaller CRL measurement at 10-14 weeks which would affect GA 
assessment. Not only this, the median ovulation day in this study was day 16 
as opposed to day 14 assumed by the Robsinson CRL charts.80 The 95% CI 
of differences between GACRL versus GALMP reduced from 21.9 days to 10.2 
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days by adjusting for ovulation and 8.9 days by adjusting for implantation day, 
thereby implying that the precision of GA estimation in a pregnancy by CRL, 
improves greatly by taking into account ovulation timing and furthermore, by 
accounting for the implantation date. Neither the implantation timing nor the 
CRL measurement at 10-14 weeks correlated with birthweight. 
First trimester growth also appeared to be independent of implantation timing 
and did not affect second or third trimester growth or birthweight z-score. 
However, this study has insufficent numbers to firmly draw these conclusions.  
None of the biological factors such as ovulation or implantation timing affected 
the later pregnancy fetal growth or placentation as demonstrated by uterine 
artery Doppler or birth weight z-score at delivery.  
Factors affecting birth weight included maternal weight gain in pregnancy, 
second to third trimester fetal growth, uterine artery doppler PI and an 
increase in CO in the second trimester compared to the pre-pregnancy values. 
None of the other cardiovascular changes appeared to correlate to birthweight 
z-score at delivery.  
This is the first study to investigate fetal growth and fetal size in relation to 
ovulation and implantation timing and highlights the importance of prospective 
studies from prior to conception in order to enable futhur discoveries about the 
processes around implantation  which might in future help clinicians to monitor 
and support the progress of healthy pregnancies.109 
8.8 Future studies 
This study shows not only that it is feasible to recruit, conduct and complete a 
study of cardiovascular function, measures of ovulation, implantation along 
with measures of fetal size but at the same time pre-pregnancy and early 
pregnancy period is very important. Future studies from preconception period 
may provide valuable insight into mechanisms of maternal and fetal disease. 
This might lead to newer developments in the prediction and prevention of 
pregnancy complications such as PE.  
Pregnancy is believed to be a unique condition where cardiovascular 
adaptation occurs in response to volume changes, changes in preload and 
afterload131 along with metabolic adaptation in order to optimize uteroplacental 
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perfusion for a successful pregnancy outcome. Pregnancy complications such 
as preeclampsia, fetal growth restriction or gestational diabetes are examples 
of cardiovascular maladaptation and are all associated with an increased 
future cardiovascular risk. 
Future studies might elucidate the changes that occur in fetal growth 
restriction, early and late onset preeclampsia separately as these conditions 
are often, possibly incorrectly considered together. Pre-pregnancy to 
postpartum changes in diabetic pregnancies are also not well described. 
Although in this study cardiovascular adaptation in normal pregnancy is 
relatively well described, the changes in lipids and renal function still need to 
be better delineated.  
Prospective studies of fetal growth will determine the relative contribution of 
implantation timing, first, second and third trimester growth velocity and 
cardiovascular risk factors in determination of birthweight. Even in assisted 
conception (where embryo transfer dates are known) very little is known about 
implantation timing.  
The above studies can most easily be performed in either nulliparous women 
or those with previously healthy pregnancies, however, consideration should 
be given for targeted studies recruiting women with previous pregnancy 
complications. In particular, those at higher risk of abnormal cardiovascular 
adaptation in relation to preeclampsia and fetal growth restriction.  
Further we have not addressed whether the maternal cardiovascular response 
to pregnancy is similar to cardiovascular adaptation to exercise. If the 
maternal response to exercise and pregnancy are similar, one might speculate 
that exercise or other sympathetic stimulation may be used in the pre-
pregnancy period to simulate the cardiovascular challenges of pregnancy. 
This could unmask and predict the occurrence of maladaptation in response to 
pregnancy. Various physiological parameters can affect measurements of 
cardiovascular parameters and therefore, 24 hour readings of these 
measurements may be more applicable. With the availability of newer non-
invasive techniques, it may be possible to use 24-hour ambulatory readings 
and measure various cardiovascular parameters more accurately in larger 
population studies.  
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Based on the observations of this study we propose sample size calculations 
to conduct a prospective pre-pregnancy study powered for PE. Assuming an 
incidence of PE of 5%, this means that for one woman developing PE, 40 
women must be recruited pre-pregnancy, of whom 30 will become pregnant 
and 20 will have viable pregnancies. The ratio of 40 recruited: 1 case of PE 
cardiovascular changes in a large number of healthy pregnancies need to be 
investigated for every one case of PE. Therefore in order to be able to have at 
least 50 women with PE/IUGR, 2000 women will have to be recruited (Figure 
8.1). 
 
 
CHAPTER 8: DISCUSSION AND FUTURE PROSPECT 
 
 163 
 
 
 
 
 
       
     
       
 
 
  
  
 
 
       
 
 
Figure 8.1 Pictorial representation of planning for recruitment of a prospective 
study 
40 women trying to conceive 
30 pregnancies 
20 viable pregnancies 
1 pregnancy with preeclampsia 
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